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ABSTRACT 
  
Several studies have found a positive correlation between hypertension and 
hyperhomocysteinemia.  Increasing evidence implicates oxidative stress as one of the initiating 
events closely linked to the homocysteine‟s ability to damage endothelium, subsequently causing 
vascular dysfunction.  We previously found that heparin protects cultured endothelial cells from 
free radical injury and oral heparin at 1 mg/kg/48h prevents venous thrombosis in a rat model in 
vivo.  Our objective was to study the protective effects of oral heparin in a rat model with 
elevated plasma homocysteine (Hcy) concentrations, and begin to elucidate whether the 
pathophysiological effects of Hcy are mediated through an oxidative mechanism causing 
endothelial dysfunction.   
Elevated plasma Hcy levels were induced by feeding male Wistar Kyoto rats a diet 
containing an additional 1.7% methionine for 8 weeks.  Groups included rats fed additional 
methionine, methionine plus oral heparin (1 mg/kg/48h by gastric feeding tube), and age-
matched controls fed normal rat chow.  At the end of 8 weeks of treatment, rats were 
anesthetized using 1.5% isoflurane in 100% oxygen.  Hemodynamics parameters were assessed 
by inserting a Millar Mikro Tip pressure transducer into the left ventricular chamber and the 
thoracic aorta.  Fasting plasma total Hcy levels were measured using a Hcy immunoassay kit 
with an Abbott IMx instrument.  Malondialdehyde (MDA) concentrations, a lipid peroxidation 
product and marker for oxidative stress, was measured by a spectrophotometric method in serum 
and tissue samples.  Glutathione (GSH) concentrations, an important antioxidant for low-level 
oxidative stress was measured by HPLC in plasma and tissues samples.  Lastly, tissue samples 
from each experimental group were stained with the TUNEL method to assess their respective 
percentage of apoptotic endothelial cells.  Results were expressed as mean ± S.E.  Unpaired 
Student‟s two-tailed t-test was employed to assess the difference between groups with p < 0.05 
considered significant.   
Plasma Hcy was significantly elevated after 8 weeks in the methionine (7.17  0.46 
mol/L) and methionine plus heparin treated rats (7.02  0.40 mol/L) compared to control (5.46 
 0.36 mol/L).  All measures of arterial pressure, systolic (SP) and diastolic pressure (DP) and 
mean arterial pressure (MAP), were significantly elevated in rats fed the methionine diet without 
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heparin (119.9 ± 3.9 mmHg; 90.3 ± 3.5 mmHg; 97.7  2.9 mmHg, respectively) compared to 
controls (107.8 ± 2.5 mmHg; 79.2  2.1 mmHg; 88.8  2.2 mmHg, respectively) but not 
compared to heparin (114.7 ± 3.3 mmHg; 83.4  2.4 mmHg; 93.8  2.7 mmHg, respectively).  
Left ventricular end diastolic pressure (LVEDP) was significantly elevated with the methionine 
diet without heparin (14.2  2.5 mmHg) but not with heparin treatment (8.4  1.9 mmHg) versus 
controls (7.1  1.1 mmHg).  Also, left ventricular systolic pressure (LVSP) was significantly 
elevated in the methionine fed rats after 8 weeks (122.6  3.2 mmHg) compared to controls 
(112.3.  2.9 mmHg).  Heparin treatment had no effect on LVSP (119.9  3.2 mmHg).  
Additionally, the results of this study showed that oral heparin treatment significantly 
decreased liver MDA concentrations (2.42  0.28 nmol/mg protein) compared to the methionine 
treated group (5.10  0.96 nmol/mg protein) and methionine treatment alone significantly 
reduced MDA concentrations in kidney tissue (1.59  0.12 nmol/mg protein) compared with 
controls (3.26  0.66 nmol/mg protein).  Methionine diet significantly decreased GSH 
concentrations in plasma (0.59  0.59 µmol/L) compared with controls (4.24  0.94 µmol/L) and 
oral heparin treatment significantly attenuated the decrease in GSH concentrations in left 
ventricle tissue samples (0.0229  0.0023 µmol/mg protein) compared with methionine treatment 
alone (0.0135  0.0016 µmol/mg protein).      
Elevated plasma homocysteine levels, induced by methionine diet feeding significantly 
increased the percent of apoptotic endothelial cells in the aortas (17.04 ± 3.74%) and superior 
mesenteric arteries (17.99 ± 1.90%) of WKY rats compared with control aortas and mesenteric 
arteries (6.08 ± 3.24%; 7.43 ±1.62%, respectively) and compared to oral heparin treated 
mesenteric arteries (7.31 ± 1.18%).   
The results of this study showed that elevated plasma levels of Hcy correlate with the 
development of hypertension, defined as significantly increased arterial pressure.  Oral heparin 
treatment prevented the significant increase in arterial pressures and LVEDP, decreased MDA 
concentrations and therefore the oxidative stress on the liver, attenuated the decrease caused by 
elevated plasma Hcy in left ventricle GSH concentrations, and significantly reduced the number 
of apoptotic endothelial cells in the superior mesenteric artery of high methionine fed rats.  We 
conclude that elevated levels of plasma Hcy contributes to the development of hypertension and 
furthermore towards the onset of heart failure likely through an oxidative mechanism and that 
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oral heparin reduces the overall oxidative stress in specific physiological environments, 
preventing Hcy mediated endothelial cell apoptosis. 
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1.0. REVIEW OF THE LITERATURE 
1.1. INTRODUCTION 
1.1.1. Blood Pressure 
Blood pressure (BP) is defined as the hydrostatic force of blood that exerts pressure 
against the walls of a blood vessel (Kablund, 2005).  Blood pressure is dynamically regulated 
and fundamentally required for life.  Arterial BP is pulsatile, in rhythm with the cardiac cycle.  
Arterial BP is expressed as systolic pressure which occurs during heart contraction and diastolic 
pressure during heart relaxation.  Mean arterial pressure (MAP) is considered to be the perfusion 
pressure that supplies blood to organ systems.  The MAP is not the arithmetic mean between 
systolic and diastolic pulse pressures.  It is the sum of the diastolic pressure and a third of the 
pulse pressure, which is equal to the systolic minus the diastolic pressure. 
                                                                                  
(1.1) 
 
Blood pressure can be understood by Ohm‟s law, in which the change in BP in a vessel is 
equal to the product of blood flow and vessel resistance.  As blood flow is typically laminar and 
is contained within a closed system, flow is related to cardiac output (CO).  For any given CO, 
the pressure generated by ventricular contraction is subject to resistance along its travel pathway.  
This is known as vascular resistance.  Total peripheral resistance (TPR) is the total vascular 
resistance in the systemic circulation, equal to the Mean Arterial Pressure (MAP) minus the 
Mean Venous Pressure (MVP) divided by CO. 
                                                                                 (1.2) 
 
The cardiovascular (CV) system intrinsically includes the heart and the vasculature, therefore 
defining arterial BP as the product of CO times total peripheral resistance (TPR). 
                                                                                                   (1.3) 
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1.1.1.1. Cardiac Output 
Cardiac output is the volume of blood ejected from the heart per unit of time.  Cardiac 
output on the left side of the heart is directly proportional to the volume ejected from and 
pressures generated by the left ventricle (LV).  This relationship is the same for the right side of 
the heart.  Equal CO from both the right and left sides of the heart is an indicator of CV health 
such that the stroke volume (SV) of blood entering the lungs for oxygenation is equal to the SV 
of blood ejected for tissue perfusion.  As per the formula for BP, increases in CO for any given 
TPR will increase BP, and vice versa.  The mathematical relationship for CO is the product of 
SV, the volume of blood ejected from one ventricle with each contraction, and heart rate (HR) 
the number of heart contractions per minute  
                                                                                                     (1.4) 
 
1.1.1.2. Heart Rate 
The sinoatrial (SA) node is the heart‟s pacemaker, initiating myocardial contraction and 
when functioning properly sets a HR in a healthy, relaxed adult at approximately 60 - 80 
beats/min (Thorin & Thorin-Trescases, 2009).  Heart rate is dynamic and changes in relation to 
body system demands.  The autonomic nervous system predominantly controls the regulation of 
HR.   
1.1.1.2.1. Autonomic Nervous System (ANS) Regulation 
The CV centre in the medulla oblongata is the epicenter for CV regulation.  The CV 
centre is capable of increasing or decreasing neural input to the SA node, atrioventricular (AV) 
node and myocardium, slowing or increasing the HR and influencing contractility. However, 
autonomic innervation does not set or undo the fundamental HR rhythm.   
Parasympathetic innervations that regulate HR are carried by cranial nerve X (Vagus 
nerve).  Axons from the vagus nerve terminate in the SA node, the AV node and atrial 
myocardium.  Acetylcholine is released from these axons, slowing the HR.  Since very few 
vagus axons terminate on the ventricles, this type of autonomic regulation likely has little effect 
on ventricular contractility.   
Sympathetic neurons, known as the cardiac accelerator nerves, extend out to the SA node, 
AV node and most of the myocardium.  Cardiac accelerator nerves release norepinephrine, and 
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both norepinephrine and epinephrine are released from the adrenal medulla into the circulation, 
both which increase the rate of spontaneous depolarization in the SA and AV nodes, increasing 
HR.  When either is bound to receptors on the myocardium, calcium ion cytosolic entry 
increases, enhancing contraction.  It is important to note that norepinephrine and epinephrine 
have different effects on HR and contractility dependent upon which receptor type they‟re bound 
to.  Alpha (α) adrenergic receptors predominantly trigger vascular smooth muscle contraction, 
which has no direct effect on HR or contractility (Wray, Nishiyama, & Richardson, 2009).  Beta 
(β) adrenergic receptors increase myocardium contraction through β1 receptor activation.  
Norepinephrine or epinephrine are defined with respect to β-adrenergic receptors, as positive 
chronotropic agents, increasing HR, and positive inotropic agents, increasing contractility (Chen-
Izu, et al., 2000).   
1.1.1.3. Stroke Volume 
The heart‟s primary function is a pump for blood, not a reservoir.  Blood that enters the 
heart is intended to be ejected within a few cardiac cycles to ensure continuous delivery of 
oxygenated blood to organs and tissues.  Stroke volume is defined as the volume of blood ejected 
from one or the other but not both ventricles during each contraction.  The three major factors 
that regulate SV are preload, afterload and contractility. 
1.1.1.3.1. Preload 
Preload is the amount of stretch placed onto the ventricular wall during diastole 
(relaxation) while it passively fills with blood from the atria before and after atrial contraction.  
Ventricular end diastolic volume (EDV) and end-diastolic pressure (EDP) is therefore 
proportional to preload.  An increase in the length-tension relationship of the myocardium, 
implies that the further the ventricle is stretched during filling, the greater the muscle length 
available for contraction, resulting in a larger potential force or pressure generated during 
ventricular systole.  This also means that the more the ventricle is filled during diastole, the 
greater the SV will be during systole.  This relationship is defined by ventricular pressure-
volume loops and the Frank-Starling Law of the Heart.  Preload is determined by venous return, 
atrial systolic pressures, HR and SV (Greenway & Lautt, 1986).   
1.1.1.3.1.1. Heart Rate 
Heart rate significantly affects the time available for ventricular diastole.  As the HR 
increases, so does the rate of blood ejection from the ventricles and the time allowed for 
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ventricular filling.  A shorter duration for filling corresponds to a lower EDV.  A lower EDV in 
response to increased HR is equal to decreased preload, changing the hemodynamics of the heart 
with respect to decreased ventricular systolic pressure and SV as per Frank-Starling‟s Law.   
1.1.1.3.2. Afterload 
Afterload is defined as the pressure achieved in the LV at maximum systolic elastance or 
stretch (Greenway & Lautt, 1986).  Changes in afterload are determined by TPR, aortic 
compliance, SV and by other factors causing impedance to blood flow (Greenway & Lautt, 
1986).  The pressure generated by the ventricles during systole must be higher than aortic 
pressure, as required to open the aortic valve and permit the ejection of blood.  Afterload is the 
force the heart has to overcome to eject blood, which with respect to pressure-volume loops, 
correspondingly increases pressures generated by the ventricle during systole.  However, despite 
this increase in ventricular systolic pressure, there is an overall decrease in SV and therefore an 
increase in end-systolic volume (ESV).  A decrease in SV is equal to a reduction in the ejection 
fraction of the ventricle, causing a subsequent increase in preload in the next contraction, as per 
the Frank-Starling Law. 
1.1.1.3.3. Contractility 
Contractility, the strength of contraction at any preload is the third factor that influences 
SV.  End diastolic volume or preload is the volume that fills the ventricle during ventricular 
diastole, and the ESV is the volume remaining in the ventricle after contraction.  Inotropic agents 
will increase (positive inotropy) or decrease (negative inotropy) the contraction of the ventricle, 
affecting the ejection of blood.  The ventricles normally retain a small volume of blood after 
contraction.  The force of ventricular contraction or amount of pressure generated by the 
myocardium can reduce or increase the end systolic volume.   
1.1.1.3.3.1. Inotropic Agents 
Positive inotropic agents such as norepinephrine and epinephrine, acting on β1-adrenergic 
receptors increase ventricular contractility, where given no change in preload, more powerful 
contractile forces generated in the ventricles are associated with more complete emptying.  
Maximum emptying of the ventricle would reduce ESV, which usually relates to a higher CO.   
All β-adrenergic agonists will exert a positive inotropic effect on the heart increasing 
both the force and velocity of contraction.  As well positive inotropic agents such as cardiac 
glycosides or digoxin act independently of adrenergic catecholamine activities.  Side effects of 
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prolonged positive inotropy or overdose of a positive inotropic agent include anorexia, nausea, 
and confusion, along with a HR below 60 beats per minute (Colucci, Wright, & Braunwald, 
1986).     
Negative inotropic agents such as varapamil, a myocardium selective calcium channel 
blocker drug, significantly reduce CO (Kondo & Shibata, 1984).  As this effect may be coupled 
with effects on smooth muscle in vessels and vasodilation, which would decrease TPR, the 
overall effect would be a measureable drop in BP.  The side effects of these medications are 
similar to hypotensive symptoms such as dizziness, headache and constipation (Hoffmeister, 
Hepp, & Seipel, 1987).   
1.1.1.3.3.2. Myocardial Indices of Contractility and Relaxation 
Indices that provide information about the rate of contractility and relaxation of the 
myocardium are useful when describing the behavior of cardiac muscle fibers during the cardiac 
cycle.   The index of myocardial contractility and relaxation is the change in ventricular pressure 
over time, + dP/dt or – dP/dt (P: pressure; t:time; d: delta/change) respectively.  These indicies 
may also be considered the rate of contractility and relaxation over time.  The rate of change in 
ventricular pressure during systole indicates myocardial responsiveness to contractile signals.  
Conversely, the rate of change in ventricular pressures immediately following ventricular 
systole, indicates how quickly isovolumetric relaxation takes place before ventricular filling next 
occurs.  
1.1.1.3.3.3. Venous Return 
The venous system is comprised of a network of highly collapsible and distensible blood 
vessels which transport deoxygenated blood under low pressure back to the heart from the 
extremities.  The venous system is called a capacitance system, as it acts as a reservoir for 
approximately 64% of total blood volume.  Venous return to the right atrium is driven by 
pressure gradients.  Most of the driving pressure exerted by cardiac contraction is lost by the 
time blood reaches the venous system, due mainly to the high resistance passage of blood 
through the arterioles.  The pressure in the right atrium is considered to be 0 mmHg, the residual 
pressure in the venous system (approximately 17 mmHg) is enough of a driving force to pump 
blood into the heart for re-circulation (Guyton, et al., 1957).  There are several factors which 
facilitate venous return including a cardiac-suction event, decreased pressure in the right atrium 
6 
 
and increases in venous pressures from the skeletal muscle pump which increase venous driving 
pressure gradients towards the heart.  Increased venous return increases SV, and thus CO. 
1.1.1.4. Total Peripheral Resistance 
The total peripheral resistance of the systemic circulation is the sum of all the resistances 
exerted by the systemic vasculature.  Vascular resistance opposes blood flow because of 
frictional forces between blood and the walls of the blood vessels.  The formula for BP indicates 
that increases in TPR will result in increased BP for a given CO.  Three factors contributing to 
blood flow resistance are explained by Poiseuille‟s Law and the following equation:  
                                                                                                                 (1.5) 
The equation describes how resistance to flow (R) is directly proportional to blood 
viscosity (η), vessel length (L) and internal vessel radius (r) (Sutera & Skalak, 1993).  Notably, 
the vessel radius is the most influential factor contributing to the resistance to flow. 
1.1.1.4.1. Blood Viscosity 
Blood viscosity may contribute to resistance to blood flow.  The major components of 
blood influencing viscosity are red and white blood cells, platelets and plasma proteins.  The 
viscosity of normal blood is approximately three times greater than water.  Changes to the 
normal composition of the blood, such as increased red blood cells (hematocrit) will 
correspondingly increase viscosity.  As the hematocrit rises to levels of 60 or 70%, from normal 
values of 38 to 48%,  blood viscosity increases by two to three times normal, causing significant 
resistance to its flow (Lenz, C. et al., 2008) (Purves, et al., 2004).  Increases to hematocrit are 
common in disorders such as polycythemia (Tefferi, 2003).  Conversely, anemia, low red blood 
cell percent can decrease blood viscosity, which has the potential to lead to heart failure due to a 
significant drop in BP and reduced blood flow and oxygen delivery to organ systems (Iyengar & 
Abraham, 2005).  Although, viscosity is a factor in the resistance of blood flow, outside of 
disease and illness, it is not a significant contributor to TPR. 
1.1.1.4.2. Vessel Length 
Resistance to blood flow increases with increasing vessel length as per Posieulle‟s Law.  
Considering the organization of the vascular tree, the length and radius of different vessels are 
responsible for the marked drop in BP seen as blood flows from the heart to the extremities.  
Microvascular rarefaction is classified as the disappearance of microvessels, including the 
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arterioles and capillaries.  The disappearance of vessels effectively decreases the length of 
resistance to blood flow.  Decreasing vessel length should correspondingly decrease TPR.  
However the opposite is true as the resistance to blood flow increases as there are fewer 
pathways available for the same volume of blood.  This idea has been observed in several 
studies, showing that microvascular rarefaction, increases TPR and the overall pattern of blood 
flow distribution in experimental animals which develop hypertension (Greene, et al., 1989).  
Vessel length is not considered a significant contributor to TPR.  
1.1.1.4.3. Vessel Radius 
Vessel radius is the most significant factor affecting the resistance to flow.  This dynamic 
can be understood by Poiseuille‟s Law, since resistance is inversely proportional to the 4th power 
of the radius.  Smaller lumen radius increases the friction between blood and the walls of the 
vessel, resulting in an overall increase in resistance to flow and correspondingly an increase in 
BP. The lumen of the aorta is relatively wide (1.25 cm radius) and highly elastic to absorb the 
high pressures generated by the LV during systole (Lang, et al., 1994).  Decreasing lumen size, 
restricts blood flow from the aorta to the large arterial branches (0.2 cm radius).  Flow is again 
opposed when blood travels to the arterioles (30 µm radius) and again to the capillaries (3.5 µm 
radius)  (Zamir, 1977).  But given the large number of capillaries in comparison to arterioles, the 
velocity of blood flow slows, however the resistance to flow does not increase proportionally.   
The cross-sectional area of each type of vessel is inversely related to the velocity of blood 
flow.  The cross-sectional area of a blood vessel increases with each branching of that vessel, 
meaning that blood flow velocity decreases where cross-sectional area is the greatest.  The 
velocity of blood flow is the slowest in the capillaries.  Blood vessel length and radius both 
contribute to cross-sectional area.  Zamir (1977) showed that there is greater than a 1000 fold 
increase in cross-sectional area between the aorta and the capillaries, 3 – 5 cm2 compared to 
4500 – 6000 cm2 respectively.  Ultimately, because of their highly muscularized structure, 
arterioles are able to significantly alter their vessel radius, and are therefore considered the major 
resistance vessel, and determinant of TPR, making vascular smooth muscle contractility an 
important factor in BP control.   
1.1.1.4.3.1. Vasoconstriction and Vasodilation 
The most significant resistance vessels in the vascular tree are the arterioles, which have 
highly muscular, well-innervated walls.   Relative to the low resistance of the arteries, arteriole 
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radii resistance is responsible for reducing mean arterial BP from 93 mmHg to approximately 37 
mmHg prior to entering the capillaries (Zamir, 1977).  The radii of arterioles are susceptible to 
both vasoconstriction, vessel narrowing, and vasodilation, vessel widening.  This function allows 
the arterioles to modulate vascular tone and blood flow resistance by utilizing their precapillary 
sphincters to variably distribute blood flow to various organ systems depending upon metabolic 
needs and regulate arterial BPs.    
1.1.2. Blood Pressure Regulation 
Various organ systems play a role in the regulation of CO and TPR and therefore BP.  In 
Figure 1 below, several major feedback loops highlight the importance of CO or TPR in 
regulation of arterial pressure.  The feedback loops will be discussed as follows: (1) 
baroreceptors located in the aortic arch and the carotid sinus can detect overall changes in arterial 
pressures and respond accordingly through the ANS by activating either its sympathetic or 
parasympathetic divisions, (2) the chemoreceptor system of the peripheral nervous system will 
respond to ischemia when BP falls and act through the sympathetic nervous system (SNS) to 
control arterial pressure, (3) ischemia detected by chemoreceptors in the central nervous system 
(CNS) will respond through the SNS to control arterial pressure, (4) the renal-fluid output system 
acts through changes in total body volume to control arterial pressure, (5) the anti-diuretic 
hormone (ADH) and thirst control centre cause changes in blood volume to regulate BP, (6) 
aldosterone also acts by changing blood volume to control arterial pressure, (7) the renin-
angiotensin system controls TPR to induce changes to arterial pressure, (8) capillary pressure and 
filtration system acts by redistributing body fluid between the blood and interstitial fluid to help 
control BP, (9) the volume of blood in the vasculature acts through changes in venous 
capacitance to alter venous return and CO and therefore arterial pressure. 
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Figure 1  Factors of arterial blood pressure control.  (Guyton, et al., 1974), with Permission from 
Wolters Kluwer Health 
 
1.1.2.1. Baroreceptors  
Located within the carotid sinus and in the aortic arch, baroreceptors respond quickly to 
changes in BP.  They are stretch-sensitive mechanoreceptors which transmit neural impulses, 
firing most frequently in response to increased stretch/BP.  The negative feedback response 
system utilizes both the SNS through innervations to the heart and vasculature and the 
parasympathetic nervous system (PNS) via the vagus nerve.  Reduced stretch of the 
baroreceptors increases SNS stimulation and decreases PNS stimulation, causing increased TPR 
and CO via: (1) increasing the contractility of the heart through β1-adrenergic receptor 
stimulation; (2) increases HR via the activation of cardiac accelerator nerves in the medulla and 
(3) causes vasoconstriction through the activation of α1-adrenergic receptors.  When BP is raised 
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back to its homeostatic set-point the cycle is reversed activating the PNS and reducing the SNS, 
resulting in vagus nerve mediated decrease to HR, decreasing both CO and BP.  In hypertension, 
baroreceptor resetting is commonly incomplete (Lohmeier, 2001).  Additionally, baroreceptors 
have been shown to suppress renal sympathetic nerve activity which promotes sodium excretion 
and further BP compensation in hypertension (Malpas & Barrett, 2002).     
1.1.2.2. Peripheral Chemoreceptors 
Peripheral chemoreceptors located in the carotid and aortic bodies and also preganglionic 
chemoreceptors in the thorax and abdomen, are essential for detecting changes in the partial 
pressure of arterial blood oxygen and for initiating homeostatic reflexes which are critical for 
responding to hypoxia.  Chemoreceptors are sensitive and respond to changes in blood oxygen 
and carbon dioxide concentrations/partial pressures and blood pH.  Low blood oxygen partial 
pressures can result from a myriad of physiological and pathological changes.  Regardless of the 
initiating change, a decrease in blood oxygen results in tissue ischemia causing tissue death and 
dysfunction.  Interestingly, Fukuda et al. (1987) demonstrated that spontaneously hypertensive 
rats have an enhanced chemoreceptor response to hypoxia as compared with normotensive rats.  
Furthermore, Habeck (1991) reported that only patients with essential hypertension and not renal 
hypertension exhibit the same increase in receptor response.  Three different SNS actions which 
increase BP are intrinsic to the chemoreceptor response to low blood oxygen or high carbon 
dioxide partial pressures: (1) stimulation of respiratory centers in the medulla oblongata which 
increases pulmonary ventilation, reciprocating an increase in venous return and CO, modestly 
increasing BP; (2) increased TPR via SNS activation of α1-adrenergic receptors and lastly (3) 
mild tachycardia and increases in contractility caused by SNS β1-adgrenergic receptor 
stimulation.   
1.1.2.3. CNS Chemoreceptors 
Blood flow to the CNS is essential for life.  As such, chemoreceptor responses to CNS 
ischemia are fast.  Centrally located chemoreceptors in the CNS respond primarily to increases in 
the partial pressure of carbon dioxide, or hypercapnia.  When these receptors detect hypercapnia, 
the vasomotor area of the medulla oblongata is stimulated sending nerve impulses through the 
spinal cord directly onto the walls of resistance vessels causing vasoconstriction, elevating TPR 
and BP.  Guyenet et al. (2010) also indicate that the SNS response to hypercapnia includes a 
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wake-promoting and interoceptive awareness in awake individuals elicited through further 
noradrenergic and serotonergic influences.  
1.1.2.4. Renal Fluid Output          
Changes in blood fluid volume have a profound effect on BP as it is directly proportional 
to the amount of fluid exerting pressure on blood vessel walls.  The renal system is the most 
important regulator of body fluid volumes.  This type of BP regulation is a relatively slow 
mechanism for BP control.  Increases in blood hydrostatic pressure, filters water from the blood 
through the glomerulus into the renal tubules and eventually into the collecting duct for 
elimination from the body.  Patients are diagnosed with acute renal failure when this system 
fails, marked by decreased urine output, hypertension and increased mortality (Liangos et al., 
2005).  The most effective renal regulation is accomplished by the secretion and actions of anti-
diuretic hormone (ADH) and aldosterone. 
1.1.2.5. Anti-diuretic Hormone (ADH) 
Anti-diuretic hormone is secreted in response to lowered BP and compensates by 
increasing blood volume and to some extent TPR.  Osmoreceptors detect changes in the 
osmolarity of blood, the relative ratio of plasma proteins in blood, that when elevated, indicate 
low blood volume stimulating the release of ADH from the posterior pituitary gland.  ADH acts 
in three different ways to increase BP: (1) controls the re-absorption of water and urea in the 
distal tubules and collecting duct, increasing the amount of water in the blood while 
concentrating and decreasing urine volumes; (2) stimulates thirst and therefore increases fluid 
intake and correspondingly fluid volume; and (3) causes vasoconstriction through arginine 
vasopressin receptor responses which have been shown to produce endothelin and increase 
vascular smooth muscle intracellular Ca
2+
 concentrations (Ikeda, Kohno, & Takeda, 1995).   
1.1.2.6. Aldosterone 
Aldosterone is secreted from the cortex of the adrenal gland and regulates BP by 
increasing blood volume through the renal system.   Its overall effect is to increase the 
reabsorption of Na
+
 and water in the distal tubules and collecting duct of the kidney and promote 
the secretion of K
+
 ultimately increasing BP via changes in overall blood volume.  Various 
neural, hormonal and ionic signals trigger aldosterone release from the adrenal cortex.  
Aldosterone secretion is primarily driven by K
+
 plasma concentrations, which are believed to 
cause membrane depolarization opening volatage-gated channels in the zona glomerulosa of the 
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adrenal gland (Boulkroun, et al., 2010).  Angiotensin II (Ang II) is another primary factor of 
aldosterone release, acting directly on the adrenal cortex (Williams & Dluhy, 1972).  
Furthermore, Ang II increases the release of adrenocorticotropic hormone (ACTH) from the 
anterior pituitary which in turn promotes aldosterone synthesis (Brown, Strott, & Liddle, 1972).  
When water and sodium are reabsorbed in the kidney tubules, circulating volumes increase 
appearing as increased juxtaglomerular apparatus perfusion.  This type of detection by the 
juxtaglomerulus apparatus inhibits further renin release from the kidneys shutting down the 
renin-angiotensin system and also further aldosterone release.  Baroreceptor have also been 
implicated as an inhibitor of aldosterone secretion ultimately via ACTH inhibition (Giannattasio, 
et al., 1989).  Lastly, again through the renin-angiotensin systems (RAS), the SNS also 
modulates aldosterone release.    
1.1.2.7. Renin-angiotensin System (RAS) 
The primary responses of the RAS are to cause arteriolar vasoconstriction, thus 
increasing TPR, and reabsorbing sodium and water thus increasing blood volume.   The system 
is primarily activated by a decline in arterial BP.  The main bioactive agent of the system is Ang 
II, which is formed through a cascade of biochemical events initiated by the release of renin from 
the kidneys.  When perfusion to the juxtaglomerular apparatus decreases the kidneys release 
renin.  Angiotensinogen is synthesized in the liver and is converted into Angiotensin I through 
the renin dependent action on angiotensinogen.  Angiotensin II is then converted from 
angiotensin I by angiotensin-converting enzyme (ACE) located on endothelial cells, primarily in 
lung capillaries.  Ang II is a potent vasoconstrictor of arterioles by potentiating the release of 
norepinephrine on post-ganglionic adrenergic fibers, amplifying α-adrenoreceptor-mediated 
vasoconstriction (Mancia, et al., 2006).  As previously discussed, Ang II regulates the release of 
aldosterone and ADH, and is therefore indirectly responsible for promoting water resorption in 
the kidney. 
1.1.2.8. Capillary Pressure 
Blood pressure increases are reflected throughout the vascular system such that increased 
arterial pressure will also cause an increase in capillary pressures.  The hydrostatic pressure of 
blood inside the capillaries forces water into interstitial spaces defined by the Starling equation 
which defines the forces across the semipermeable wall of the capillaries.  Filtration through the 
capillaries can be markedly increased by immune mediated release of vasoactive agents, such as 
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histamine, that increase its relative permeability, and changes to capillary and interstitial oncotic 
pressure and lymphatic flow.  Edema, is a symptom of excessive capillary filtration, where large 
amounts of water are filtered from the blood into the interstitium where it pools and causes 
recognizable tissue stretching/swelling.  
1.1.2.9. Vascular Volume  
Changes to blood volume affect both venous return and correspondingly CO as a 
reflection of increases in mean circulatory filling pressures.  However, when the system is 
stressed and blood volumes are expanded for a prolonged period of time, the filling pressure and 
CO will eventually return to normal and relax (Prather, Taylor, & Guyton, 1969).  Prather et al. 
(1969) showed that elevated blood volume for over two hours failed to maintain elevated CO and 
mean circulatory filling pressures.  The veins accommodate increased volume by relaxation of 
smooth muscle.   
1.1.3. Measuring Blood Pressure 
Blood pressure measurement is one of the most definitive clinical parameters researchers 
and medical professionals can use to diagnose and predict CVD morbidity.  It is imperative that 
BP measurements are accurate, as it is a very complex hemodynamic variable that ultimately can 
have far reaching implications when it comes to the treatment of hypertension.  For instance, if a 
measurement is erroneously low, a patient may be denied drug treatment to prevent future heart 
attack or stroke, and conversely if the measurement is too high the patient may be placed 
unnecessarily on lifelong BP lowering treatments (O'Brien, Beevers, & Lip, 2001).  The 
oscillometic method is considered a non-invasive technique for measuring BP.  This method 
allows the examiner to measure systolic and diastolic BP, by observing the oscillations of blood 
flow, (i.e. pulse) relative to inflation pressures of an external cuff.  Other methods of BP 
measurement include direct or invasive procedures such as using implanted arterial pressure 
catheters or radiotelemetry, giving the advantage of receiving beat-by-beat waveforms of BP in 
anesthetized or conscious subjects.   
1.1.3.1. Oscillatory Method 
In clinical practice, the oscillatory method uses a pressure cuff and gauge, commonly 
referred to as a sphygmomanometer, placed onto a subject‟s arm, which is inflated initially to a 
pressure in excess of the systolic arterial pressure in the brachial artery.  For animal 
experimentation, non-invasive BP sensor technologies include photoplethysmography, 
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piezoplethysmography and Volume Pressure Recording, which use a variation of the 
sphygmomanometer which is commonly called an occlusion tail-cuff (Bunag, 1973).  The 
oscillatory method is based on the transmission and recognition of Korotkoff sounds generated 
by blood flow in the artery (Jorde & Williams, 1986).  When the cuff pressure exceeds systolic 
pressure, blood flow is impeded in the artery in contact with the cuff and no sound is heard.  The 
pressure of the cuff is then slowly released until the cuff pressure and Korotkoff sounds begin to 
oscillate with the cycle of blood flow in the brachial or tail artery (Kurtz, et al., 2005).  The point 
of maximum oscillation, provides the subject‟s mean intra-arterial pressure, and systolic and 
diastolic BP are then estimated from an empirically derived algorithm (Kayrak, et al., 2010).  
Benefits of using the oscillatory method include the relatively low cost of the equipment; that the 
subjects can be conscious, surgery or anesthesia are not required, and relatively no chance of 
injury, infection or death associated with the procedure.     
1.1.3.1.1. Errors in Oscillatory Blood Pressure Measurements 
Blood pressure measurements provided by manual or semiautomatic instruments, may 
vary considerably from a subject‟s „true' BP due to short-term BP perturbations and incorrect or 
skewed calibration techniques (Hansen & Staber, 2006).  Anxiety and/or stress are a significant 
source of error when taking BP cuff measurements.  White-coat hypertension describes elevated 
BP measurements seen in up to 25% of subjects examined by health professionals, attributed to 
the anxiety caused by the exam (Jhalani, et al., 2005).  Anxiety is linked to activity in the 
amygdala, nuclei located in medial temporal lobes of the brain (Rosen & Schulkin, 1998).  The 
amygdala can send direct nerve impulses to the hypothalamus for the activation of the SNS 
(Karrow, 2006).  As discussed previously, the SNS can both directly increase CO and TPR when 
activated.  Therefore it is obvious that anxiety and stress are often associated symptomatically 
with increased BP.  However, this source of error can be lessened by acclimatizing the subject 
prior to measurement.  For rodents, it is suggested that the rodent is placed in a comfortable 
holder, preferably with a darkened nose to limit the animals‟ view, and to use a warming blanket 
and comfortable room temperature to encourage blood flow and overall reduce animal stress 
(Kurtz, Griffin, Bidani, & Davisson, 2005).    
1.1.3.2. Intra-Arterial Blood Pressure Catheters 
Intra-arterial BP catheters provide real-time BP measurements.  This type of 
measurement is commonly used in intensive-care patient management where BP and blood gas 
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measurement in real-time is critical to patient survival (Daily, 1995).  However, the placement of 
the catheters can be painful in a conscious subject, and with any invasive technique there is the 
risk of infection, thrombosis and potential arterial bleeding if a catheter is dislodged.  Intra-
arterial catheters provide flexibility in experimental investigation, as they can be manipulated in 
their placement to measure other hemodynamic parameters including atrial, ventricular and 
venous pressures.  A complication of using intra-arterial catheters in experimentation is that 
anesthesia is required which can depress CV and respiratory function.     
1.1.3.2.1. Anesthesia and Intra-Arterial Blood Pressure Measurement 
Central systolic BP, measured by aortic catheterization, as opposed to brachial BP 
measurements, may provide measurement of cardiac afterload and preload and therefore is an 
important tool in assessing CV pathology and in determining CVD risk (Hope, et al., 2005).  In 
choosing an anesthetic for catheter implantation, researchers choose those with minimal 
respiratory and CV effects.  Volatile anesthetics can change the rhythm, rate and depth of 
breathing at clinically relevant concentrations (Karanovic, et al., 2009).  Heart rate changes in 
response to periodic changes in lung volume, may be used as a measure of PNS function 
(Mehlsen, et al., 1987).  Isoflurane depresses both the SNS and PNS equally (Kato, et al., 1992).  
Isoflurane is also known to increase HR and decrease TPR (Eger, 1984).  The older volatile 
anesthetics such as halothane, have little or no effect on vascular tone, whereas isoflurane 
directly limits coronary vasodilator reserves in coronary resistance vessels (Ciofolo & Reiz, 
1999).  These older anesthetics have been discontinued for several reasons including their known 
ability to cause myocardial depression, and hepatotoxicity as seen with halothane (Dale & 
Brown, 1987).  Isoflurane is not metabolized like halothane and does not cause the same 
pronounced toxic effects.  Additionally, myocardial contractility is stable with isoflurane, 
making it the inhalation anesthetic of choice for many surgical operations (Dale & Brown, 1987).  
1.1.4. Hypertension 
Hypertension is a medical condition where BP is chronically elevated above set levels of 
140 mmHg systolic and 90 mmHg diastolic BP (Carretero & Oparil, 2000).  When the word 
hypertension is used without a qualifier it is defined as the systemic elevation of arterial BP.   
Hypertension is considered a symptom of CVD and chronic hypertension is a major risk factor 
for other types of CVD including myocardial infarction (MI) and cerebrovascular accident 
(stroke) (Bale, 2010). 
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1.1.4.1. Epidemiology of Hypertension 
Kearney et al. reported that hypertension affected approximately 1 billion people 
worldwide in 2000, likely an underestimation, and that by 2025 this number will increase to 
nearly 1.56 billion (Kearney, et al., 2005).   The prevalence of hypertension in a population is 
related to several factors reported by Carretero et al.: (1) race, with the highest occurrence found 
in African American populations (32.4%) followed by Caucasian (23.3%) and Mexican 
American populations (22.6%); (2) age, since systolic BP rises throughout life in industrialized 
countries; (3) geographic patterns, for instance, hypertension is most prevalent in the 
southeastern United States; (4) gender, the development of hypertension is more commonly 
diagnosed in men, discounting the effect of menopause on this trend; and lastly (5) 
socioeconomic status, which is inversely related to the prevalence, morbidity, and mortality rates 
of hypertension (Carretero & Oparil, 2000).  Given the global prevalence of hypertension it is 
disheartening to know that data published recently in the Framingham Heart Study, indicates that 
even in individuals with normal BP at age of 55, there is still a 90% risk of developing 
hypertension at some point in their life (Sundström & Vasan, 2005).  
1.1.4.2. Pathophysiology of Hypertension 
Hypertension is a serious risk factor for CVD.  There continues to be uncertainty about 
the exact pathophysiology of hypertension.  There are several known etiologies for hypertension 
including renal and/or adrenal disease, classified as secondary hypertension.  Essential 
hypertension describes a rise in BP from unknown etiologies.  Interrelated factors may 
contribute, with potential synergism, to increase arterial BP.   
1.1.4.3. Risk Factors for the Development of Hypertension 
1.1.4.3.1. Essential Hypertension 
Essential hypertension remains a major modifiable risk factor for CVD.  Its cause has not 
yet been elucidated and may be due to unknown genetic variations and many non-hereditary 
factors (Muda, et al., 2005).  Healthy lifestyle habits such as maintaining a normal body weight, 
not smoking, moderate alcohol intake, regular exercise, and healthy diet are individually and 
jointly associated with a lower lifetime risk of CVD (Djousse, Driver, & Gaziano, 2009).     
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1.1.4.3.1.1. Race/Ethnicity 
It is estimated by segregation analysis that up to 45% of individual differences in BP can 
be accounted for by ethnicity (Luft, 2002).   One cause of hypertension has been linked to a gene 
responsible for the proteolytic cleavage of angiotensinogen into angiotensin II, one of the most 
active vasoconstrictive agents (Watt, et al., 1992).  African Americans are shown to be the 
predominant carriers of an AGT gene polymorphism which is directly correlated with an 
increased risk of developing hypertension (Kumar, et al., 2005).  Racial genetic differences have 
also been identified in ion-transport mechanisms, salt-sensitivities and calcium homeostasis 
(Douglas, Thibonnier, & Wright, 1996). 
1.1.4.3.1.2. Family History and Epidemiology 
Hypertension is about twice as common in a person with a hypertensive parent, and 
epidemiological studies suggest that family genetics account for 30% of a populations‟ BP 
(Beevers, 2001).  Hyperinsulinemia was significantly associated with a family history of 
hypertension in healthy children compared to having a family history of other CVD risk factors 
(Rodríguez-Moran, et al., 2010).   
1.1.4.3.1.3. Insulin Resistance (Type I Diabetes) 
The prevalence of insulin resistance (IR) in hypertensive individuals is high, and has been 
shown to be a more predominant risk factor for hypertension in ethnic than Caucasian 
populations, with and without type 2 diabetes (Huang, et al., 2010).    Insulin resistance, resulting 
in hyperinsulinemia, has been associated with decreased peripheral blood flow and experimental 
models indicate that IR promotes fibroblastic myocardial growth, increasing left ventricular wall 
thickness (Lind, et al., 1995).  Left ventricular (LV) hypertrophy is a hallmark symptom of 
prolonged hypertension.  Hypertensive patients with LV hypertrophy have been found to have 
associated IR and impaired insulin-mediated glucose uptake and non-oxidative glucose 
metabolic capacity (Paolisso, et al., 1995).  Impaired insulin-induced endothelial NO production 
is common during IR, considered to be a non-hereditary risk factors for hypertension as caused 
by obesity, type 2 diabetes and the metabolic syndrome  (Mustafa, 2009).   
1.1.4.3.1.4. Smoking 
Smoking is considered an important modifiable risk factor for the development of arterial 
hypertension according to the European Society of Hypertension and the European Society of 
Cardiology on the management of hypertension (2007).  It is estimated that there are currently 
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3.2 million men and 2.7 million women who smoke in Canada, with rates highest in Quebec and 
lowest in British Columbia (Lee, et al., 2009).  Many studies have well doumented an association 
between chronic obstructive pulmonary disease (COPD) and CVD  (Holguin, et al., 2005).  The 
common thread between these two diseases is smoking.  The Lung Health Study has shown that 
age, smoking, gender, marital status, higher diastolic BP, and impaired pulmonary function are 
strong risk factors for both COPD and correspondingly CVD (Finklestein, Cha, & Scharf, 2009).  
Long-term exposure to cigarette smoke is shown to impair endothelium-dependent vascular 
reactivity, induce the proliferation of poorly differentiated smooth muscle cells (SMC) in 
pulmonary vessels leading to intimal hyperplasia, and reduce the expression of endothelium 
derived vasodilators such as nitric oxide (NO) (Barbera, et al., 2001).  Increased arterial 
resistance due to SMC proliferation and endothelial dysfunction are hallmarks of hypertension.  
Smoking is one of the most obvious risk factors in the development of hypertension. 
1.1.4.3.1.5. Obesity 
       The prevalence of hypertension, based on population studies, is about 20% in normal 
weight individuals and more than 50% in obese individuals  (Bo, et al., 2009).  In obese subjects, 
vascular dysfunction, which may include impaired endothelial-dependent vasodilation, decreased 
arterial compliance and increased inflammatory markers, are detectable prior to the onset of 
hypertension (Freedman, et al., 2005).  Increased epicardial and visceral adipose deposits have 
been associated with early hypertension, modulating both mineralocorticoid secretion and 
sympathetic nervous activity through the secretion of adipokines, contributing to increased BP 
(Natale, et al., 2009).  Dyslipidemia can further trigger endothelial dysfunction exacerbating the 
development of hypertension (Sima, Stancu, & Simionescu, 2009).  Obesity is also associated 
with microalbuminuria.  Microalbuminuria is defined as the urinary albumin excretion of 30-300 
mg/24 hours, which is considered a risk factor for hypertension, and has also been associated 
with endothelial dysfunction (Thoenes, et al., 2007).  Thoenes et al. (2009) showed that patients 
with abdominal obesity, had many specific CV risk factors and markers, including elevated BP, 
blood glucose, and insulin levels.  Increases in BP and abdominal obesity have been positively 
associated with increased body weight and alcohol consumption (Suter, Maire, & Vetter, 1995). 
1.1.4.3.1.6. High Alcohol Intake 
Many epidemiological studies have demonstrated a linear relationship between alcohol 
consumption and BP or hypertension, regardless of age, race, gender or the type of alcohol 
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(MacMahon, 1987).  MacMahon (1987) showed that systolic and distolic BP increased by 3-4 
mmHg and 1-2 mmHg respectively per three drinks per day.  Alcohol has both vasodilalatory 
and vasocontrictive actions dependent on plasma concentrations.  High alcohol concentration has 
been shown to augment catacholamine and vasopressin vasoconstriction, and inhbits 
endothelium-dependent vasodilation  (Brizzolara, Morris, & Burnstock, 1994).  At low 
concentrations, alcohol may increase the release of NO and inhibit norepinephrine-induced 
vasocontriction  (Puddey, et al., 2001).  Acetylaldehyde, a metabolite of alcohol is also a known 
vasodilator and is commonly associated with facial flush and hangover headache following 
injestion.  Alcohol has also been shown to have marked cardiac effects.  In hypertensive patients, 
CO and HR significantly increased after alcohol consumption  (Kawano, et al., 1992).  The SNS 
is activated by alcohol, increasing catacholamines and suppressing the baroreceptor reflex 
(Kawano, 2002) (Abdel-Rahman, Dar, & Wooles, 1985).  Alcohol also acts on the endocrine 
system, increasing the risk for the development of hypertension by increasing plasma renin 
activity, and stimulating the release of ACTH, plasma cortisol and aldosterone (Howes & Reid, 
1986).  Urinary excretion is known to increase after consuming alcohol.  Detrimentally, 
increased urinary output of magnesium and calcium are shown in habitual drinkers, possibly 
contributing to BP elevation and possible arrythmias (Hsieh, et al., 1992).  In conclusion, 
excessive alcohol consumption has profound and far reaching effects on the CV system. 
1.1.4.3.1.7. Excessive Sodium Intake       
The renin-angiotensin-aldosterone system is perhaps the most important regulator of 
sodium, which stimulates its re-absorption in the kidney.  Sodium accounts for the majority of 
the body‟s extracellular fluid (ECF) osmotic activity.    When sodium is at above normal 
concentrations in the ECF, it brings with it water, thereby increasing total hydrostatic pressures.  
Since blood plasma is a component of the ECF, increases in hydrostatic pressures will ultimately 
define BP.  Therefore, increased ECF sodium will correspondingly increase BP.  Salt-sensitivity 
will exacerbate sodium as a risk factor for hypertension.  The factors that predispose BP salt-
sensitivity are chronic kidney disease, obesity, age, African-American ethnicity and diabetes 
(Cianciaruso, Bellizzi, & Minutolo, 1996) (Anderson, Fedorova, & Morrell, 2008) (Sarafidis & 
Bakris, 2007).  Essential hypertension, as a manifestation of sodium toxicity in susceptible 
individuals, is prevented by limiting salt intake to less than 2 g per day (Freis, 1976).  Salt intake 
has been shown to lead to left ventricular hypertrophy (LVH) without significantly elevating BP 
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(Yuan & Leenen, 1991).  Yu et al. discovered that increased salt intake elevated BP, potentially 
due to its other deleterious effects, which included cardiac, vascular, and renal fibrosis and 
hypertrophy (Yu, et al., 1998).  The proposed mechanism for salt-induced tissue fibrosis is 
increased cytokine expression, such as TGF-β1 (Yu, et al., 1998).  
1.1.4.3.1.8. Sedentary Lifestyles 
Many epidemiological and exercise studies give evidence that increased physical activity, 
of adequate duration, intensity and volume, can lower BP significantly, on its own and in 
conjunction with pharmacological therapy (Kokkinos, Narayan, & Papademetriou, 2001).  Other 
population studies report that the relative risk for developing hypertension in persons with a 
sedentary lifestyle, is increased with a 35% to 70% higher BP at rest compared to those whom 
are physically active (Blair, Goodyear, Gibbons, & Cooper, 1984).  The underlying mechanism 
responsible for exercise regulation of BP is still unknown.  Kokkinos et al. reported a 12% 
reduction in left ventricular mass, after 16 weeks of physical exercise in hypertensive 
individuals, leading to improved CO (Kokkinos, Narayan, & Colleran, 1995).  Reductions in 
SNS activity, including a decrease in norepinephrine plasma concentrations and therefore 
reduced TPR also follow exercise (Floras, et al., 1989). 
1.1.4.3.1.9. Vitamin D Deficiency 
The third National Health and Nutrition Examination Survey (NHANES III) reported, 
even after adjustments for age, gender, ethnicity and physical activity, that there is a significant 
inverse association between metabolised serum vitamin D concentration and BP.  Vitamin D 
deficiency impairs calcium and phosphorus homeostasis.  Vitamin D is also thought to have an 
important role in the maintenance of the heart, vascular smooth muscle (VSM), endothelium, 
stomach, pancreas, brain, skin, gonads and immune system (Holick, 2004).  Vitamin D 
deficiency is associated with obesity and IR (Parikh, et al., 2004), increased vascular resistance 
and increased carotid intima-media thickness (Duprez, et al., 1993) (Targher, Bertolini, & 
Padovani, 2006). Potential biological mechanisms which may explain the correlation of vitamin 
D deficiency to the development of hypertension include vitamin D‟s ability to suppress renin 
biosynthesis (Li, et al., 2004) and elevate parathyroid hormone, which increases the risk of 
arterial calcification (Watson, Abrolat, & Malone, 1997). 
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1.1.4.3.1.10. Low Birth Weight  
Embryonic-fetal development that results in low birth weight (LBW) is associated with 
reduced nephron endowment, hypertension and renal disease in adulthood (Barker, Osmond, & 
Law, 1989).  Perinatal programming controls nephrogenesis during 34-36 weeks gestational age 
(Ingelfinger, 2008).  Infants born prior to 36 weeks gestational age are at a high risk of LBW.  
Twin studies reveal that the association between LBW and renal dysfunction is more associated 
with fetoplacental factors than genetic factors (Gielen, et al., 2005).  Moreover, factors that 
reduce the movement of nutrients via the placenta such as smoking and preeclampsia, 
additionally increase the risk of LBW (Puddu, et al., 2009).  Studies have shown that 
normotensive humans have on average 1,429,000 nephrons compared to 702,000 in hypertensive 
individuals (Puddu, et al., 2009).  Approximately 10% of very LBW infants develop 
hypertension after 6 to 12 years (Rodriguez-Soriano, Aguirre, Oliveros, & Vallo, 2005).  Lower 
nephron numbers results in reduced filtration area, glomerular volume and impaired tubular 
function (Puddu, et al., 2009), indicating impaired renal BP regulation.  Other studies report a 
marked associated with LBW and reduced nephron number, with evidence of a higher 
compensatory glomerular volume (Hughson, et al., 2003).   
1.1.4.3.1.11. Elevated Plasma Renin 
Renin is the rate-limiting enzyme in the RAS, which as previously discussed, has an 
established role in regulating blood volume, arterial BP as well as cardiac and vascular function.  
Renin release ultimately regulates the formation of Ang II, which when acting through its 
receptor AT1 increases arterial tone, renal sodium reabsorption, aldosterone secretion and 
sympathetic neurotransmission (Staessen, Li, & Richart, 2006).  RAS over-activation is therefore 
considered to be a major factor in the pathogenesis of hypertension (Maiba & Feldman, 2003).  
Other deleterious effects of Ang II activation of AT1 receptors that increase the risk of 
developing hypertension include oxidative stress and unregulated cellular growth causing 
endothelial dysfunction and vascular and ventricular hypertrophy (Brasier, Recino, & Eledrisi, 
2002).     
1.1.4.3.1.12. Type II Diabetes (Insulin Resistance) 
Insulin resistance is a condition where insulin loses its effectiveness at reducing blood 
sugar, by facilitating glucose uptake and storage in muscle and adipose tissue.  Several studies 
have confirmed that approximately 50-70% of normal weight patients with essential 
22 
 
hypertension have reduced insulin sensitivity (Bao, Srinivasan, & Berenson, 1996) (Ferranini, 
Buzzigoli, & Bonadonna, 1987)(Srinivasan, et al., 1996).  Insulin resistance may lead to the 
development of hypertension due to altered peripheral resistance, increased SNS activation and 
increased sodium retention (Scherrer & Sartori, 1997)(Hopkins, et al., 1996).  Endothelin-1 (ET-
1), a potent vasoconstrictor, is often elevated in obese individuals (Muller-Wieland, et al., 1998).  
Endothelin elevation compounded with insulin mediated endothelial dysfunction, demonstrated 
by decreased endothelium-dependent nitric-oxide vasodilatory action, results in increased BP 
(DeFronzo, 2010).  Furthermore, elevated plasma levels of epinephrine and norepinephrine have 
been observed in obese patients, especially those with arterial hypertension (Weidmann, et al., 
1993). 
1.1.4.3.1.13. Homocysteine 
There is an increasing body of evidence that suggests that hyperhomocysteinemia (hHcy), 
or elevated plasma concentrations of homocysteine (Hcy), is a modifiable risk factor for the 
development of essential hypertension.  Oxidative stress has been proposed as the primary 
pathophysiological mechanism through which Hcy contributes to the development of 
hypertension.  Homocysteine increases oxidative stress (Voutilainen, et al., 1999), reduces the 
bioavailability of NO (Zhang, et al., 2000), stimulates VSM cell proliferation and decreases the 
ratio of elastin to collagen in the vascular wall (van Guldener & Stehouwer, 2000).  All of these 
properties of hHcy implicate increased vasoconstriction and vascular resistance, as the features 
of Hcy derived hypertension. 
1.1.4.3.2. Secondary Hypertension 
Secondary hypertension differs from essential hypertension as it is attributed to an 
underlying, identifiable cause.  Some common causes of secondary hypertension often include 
diseases, of the renal or endocrine systems, medications or toxicants induced hypertension.  
Special conditions such as sleep apnea and pregnancy can cause the development of 
hypertension. 
1.1.4.3.2.1. Kidney Disease 
Hypertension is a classic symptom of chronic kidney disease (CKD).  The loss of kidney 
function results in a decline in glomerular filtration rate and therefore a reduced ability to 
regulate body fluids and correspondingly BP.  Conditions arising from CKD include: activation 
of the RAS and SNS, increases in peripheral vascular resistance and BP (Johnson, Alpers, & 
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Yoshimura, 1992) (Converse, Jacobsen, & Toto, 1992); reactive oxygen species (ROS) 
inactivation of NO and subsequent endothelial dysfunction (Mallamaci, Tripepi, & Maas, 2004); 
and sodium overload dependent expansion of extracellular fluid volume causing VSM cell 
hypertrophy and accelerated damage to kidney tubules and microcirculation (Gu, Anand, & 
Shek, 1998).  Hypertension, in patients with CKD, is almost inevitable, so treatment of the 
condition aims for a target BP of 130/80 mm Hg, with minimal use of pharmaceuticals such as 
non-steroidal anti-inflammatories (NSAIDs), cyclooxygenase (COX) inhibitors and 
amphetamines, known to markedly worsen BP control (Chobanian, Bakris, & Black, 2003). 
1.1.4.3.2.2. Adrenal Disease 
The adrenal gland is located superior to the kidneys.  The cortex of the adrenal gland is 
responsible for the synthesis of corticosteroid hormones including: aldosterone, cortisol and 
testosterone.  The adrenal medulla is the body‟s main source for circulating epinephrine and 
norepinephrine.  When diseased, the synthesis of hormones and catacholamines from the adrenal 
gland is compromised resulting in either an over- or under-abundance of circulating levels.  
Hyperaldosteronism, is characterized by over-synthesis and secretion of aldosterone, despite high 
salt and volume retention, which can be predictive of hypertension (Wei, Whaley-Connell, & 
Habibi, 2009).  Cushing‟s syndrome is another adrenal disease characterized by the over-
secretion of cortisol, also associated with the development of hypertension. 
1.1.4.3.2.3. Hyperaldosteronism 
Elevated levels of aldosterone have been reported in hypertensive patients and 
hypertensive animal studies (Douma, Petidis, & Doumas, 2008).  Elevated aldosterone levels 
have the following effects leading to the development of hypertension: increased left ventricular 
mass (Schunkert, Hense, & Muscholl, 1997); endothelial dysfunction indicated by decreasing 
NO bioavailability, as a consequence of reactive oxygen species generation (Schiffrin, 2006); 
activated RAS in the brain, increasing sympathetic vascular tone (Yu, Wei, & Zhang, 2008); 
increased salt appetite and sodium intake through activation of centers in the amygdala further 
promoting BP elevation (Gomez-Sanchez, 2004).   
1.1.4.3.2.4. Cushing‟s Syndrome 
Hypertension is a common symptom of Cushing‟s syndrome, developed in correlation 
with increased levels of circulating cortisol.  Cortisol activates the RAS, yet renin concentrations 
are generally normal in individuals with Cushing‟s syndrome (Suzuki, Handa, & Kondo, 1982).  
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Activation of RAS by cortisol appears to be mediated by increased AT1 receptors for Ang II in 
both peripheral tissues and the brain (Sato, Suzuki, & Murakami, 1994).  Evidence also indicates 
that cortisol increases β-adrenergic receptor sensitivity to catecholamines, increasing vascular 
tone (Sakaue & Hoffman, 1991).  Glucocorticoids, such as cortisol, are also implicated in the 
elevation of cytosolic Ca
2+
, due to the downregulation of the Na
+
/Ca
2+
 exchanger in VSM cells, 
causing subsequent vasoconstriction (Smith & Smith, 1994).   
1.1.4.3.2.5. Medications 
Side effects of medication may also contribute secondary hypertension.  Several major 
classes and types of medications have a risk of increasing BP, in specific risk groups, such as the 
elderly, and those with pre-existing kidney disease or hypertension. NSAIDs and COX inhibitors 
block the synthesis of prostaglandins, increase BP in susceptible individuals by about 5 mm Hg 
(de Leeuw, 1996).  The inhibition of prostaglandin synthesis is associated with vasoconstrictor 
and antinatriuretic effects (Brater, 1999).  NSAIDs also inhibit the detoxification and elimination 
of aldosterone, increasing basal levels and consequently increasing BP (Knights, Mangoni, & 
Minors, 2006).   
Cyclosporine, a calcineurin immunosuppresor, used in organ transplant patients to 
prevent rejection, causes afferent arteriolar constriction and tubulointerstitial fibrosis (Andoh & 
Bennett, 1998).  Both of these effects increase BP and decrease glomerular filtration rate leading 
to hypertension.  In vitro, cyclosporine produces ROS, most notably superoxide and hydrogen 
peroxide (Lopez-Ongil, Hernandez-Perera, & Navarro-Antolin, 1998).  The effects of 
cyclosporine that are causal to the pathogenesis of hypertension have been effectively eliminated 
with antioxidant therapy, suggesting that ROS are the mediator of the drug‟s toxicity (Andoh, et 
al., 1997).  
Erythropoietin (EPO) increases BP in normotensive, healthy subjects as well as CKD 
patients (Krapf & Hulter, 2009).  Erythropoietin dependent increases to BP are considered 
independent of the hematocrit increase.  More recent evidence from animal and human studies 
suggests that EPO increases platelet cytosolic calcium, required for VSM contraction (Vaziri, 
Zhou, & Naqvi, 1996) (Tepel, Wischniowski, & Zidek, 1992).  Ni et al. (1998) demonstrated that 
calcium channel blockers attenuate BP increases in EPO treated rats, supporting the theory of 
Varziri et al. (1996) and Tepel et al. (1992).  Moreover, evidence also indicates that EPO may 
induce hypertension through the release of ET-1 and the vasoconstrictive prostanoid thomboxane 
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(Bode-Boger, Boger, Kuhn, Radermacher, & Frolich, 1996), and by decreasing endothelial nitric 
oxide synthase (eNOS) expression in cultured human endothelial cells (Wang & Vaziri, 1999).   
Monoamine oxidase inhibitors (MAOIs) are widely used for the treatment of psychiatric 
disorders including depression, despite long-standing concerns over their hypertensive effects 
(Rabkin, Quitkin, & McGrath, 1985).  MAOIs alone are not considered risk factors for 
hypertension, but when used in combination with other medications and some types of food, they 
are likely partially responsible for hypertensive crisis, described as diastolic BP of 120 mmHg 
(Cook & Katritsis, 1990).   Diastolic pressure of this magnitude in humans carries a considerable 
risk for organ damage.  Patients using MAOIs are required to follow a strict dietary regime, 
including avoidance of foods containing tyramine, and are monitored closely for adverse drug 
interactions if taking other medications such as sympathomimetics, ephedrines and opioids.  Nies 
(1984) indicated that 15% - 45% of MAOIs, in concert with the intake of tyramine or 
contraindicated medications, are converted into amphetamines such as serotonin, dopamine and 
norepinephrine, all known to increase both CO and BP.   
1.1.4.3.2.6. Obstructive Sleep Apnea/Hypopnea 
Obstructive sleep apnea/hypopnea (OSAH) syndrome is characterized by repeated 
episodes of apnea (suspension of normal breathing) and hypopnea (very shallow breathing) 
during sleep (Duran-Cantolla, et al., 2009).  Brooks et al. (1997) demonstrated in an in vivo 
canine model that intermittent airway occlusion resulted in small night-time BP increases, 
gradually leading to sustained daytime hypertension.  Duran-Cantolla et al. (2009) summarized 
that in OSAH patients, a combination of intermittent hypoxemia, RAS and chemoreceptor 
stimulation as well as sympathetic activation, are potential mechanisms in the pathogenesis of 
OSAH dependent hypertension.   
1.1.4.3.2.7. Preeclampsia 
Preeclampsia classically presents itself at approximately 20 weeks gestation with the 
characteristic features of systolic BP of ≥ 140 mmHg and diastolic BP of ≥ 90 mmHg (ACOG 
Committee on Obstetric Practice, 2002).  The amount of literature available describing the 
pathogenesis of preeclampsia is overwhelming.  However, there are several common features 
that hallmark the significant physiological differences between pregnant women with normal 
BPs and those whom develop preeclampsia.   The placenta is the focal point to the pathogenesis 
of the disease.  Increased oxidative stress, marked by higher levels of lipid peroxidation, 
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superoxide (O2
-
) and isoprostanes has been shown to cause placental atherosis (Roberts & Hubel, 
2004).  Perturbation to the natural killer cell/human leukocyte antigen-C axis causes a marked 
immune reaction shown to inhibit cell migration into the placenta hindering normal development 
(Lockwood, et al., 2006).  Placental malformation leads to the release of antiangiogenic factors 
such as soluble fms-like tyrosine kinase-1 and endoglin, both known mediators of endothelial 
dysfunction (Maynard, et al., 2003) (Venkatesha, et al., 2006).  Other culprits identified in the 
pathogenesis of preeclampsia include decreased levels of vascular endothelial growth factor and 
placental growth factor hindering normal placental development (Zhou et al., 2002).  All of the 
aforementioned factors contribute to abnormal placentation which further contribute to reduced 
placental perfusion, vascular dysfunction, capillary damage and potential vasospasms, conditions 
predictive for the development of hypertension. 
1.1.4.3.2.8. Toxicants 
Heavy metal exposure is an identifiable risk factor for secondary hypertension.  Mercury 
and cadmium have the most profound effect on the CV system.  Mercury is a known promoter of 
oxidative stress as per its Fenton type reactions with sulfhydryl groups.  Mercury induced 
oxidative stress has been demonstrated to include increased hydrogen peroxide production and 
glutathione depletion (Lund, et al., 1993).  The vascular consequences of mercury exposure and 
subsequent oxidative stress include: inflammation, thrombosis, VSM cell proliferation and 
migration, and endothelial dysfunction (Houston, 2007).  Even more convincing are 
epidemiological studies on mercury miners whom have significantly increased systolic BP that is 
46% higher than age matched controls, and correlated directly with lipid peroxidation and overall 
vascular oxidative stress (Kobal, et al., 2004). 
Cadmium has been shown in animal studies to cause widespread CV toxicity including 
aorta and coronary artery atherosclerosis, reductions in CO, cardiac conduction system 
abnormalities, increased BP and renal tubular dysfunction characterized by proteinuria and 
chronic renal insufficiencies (Hallenbeck, 1984) (Revis, et al., 1981).  The proposed mechansism 
that leads to cadmium induced hypertension includes increases in catecholamines, sodium 
retention, increased intracelluar calcium and alterations in Na
+
/K
+
 ATPase (Kristensen, 1989). 
1.1.5. Reactive Oxygen Species and Hypertension 
Reactive oxygen species are reactive intermediates of molecular oxygen (O2) 
metabolism.  Most ROS species are chemically reactive because they lack a full complement of 
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paired electrons in their outer valence shell.  Examples of ROS include superoxide radical (O2
-
) 
and the hydroxyl radical (OH
·
).  These types of ROS are commonly referred to as oxygen free 
radicals, because of their free, unpaired valence electron.  Unpaired outer valence electrons are 
always in search of a bonding mate with whom to share electrons thus completing and stabilizing 
this outer electron shell.   Therefore, when ROS come into contact with biological tissues or free 
molecules they will attack that source of electrons and strip or share electrons with them to 
ensure electron pairing in their outer valence shell, destabilizing or damaging the substance they 
contact.  Other ROS which have a full complement of paired electrons in their outer shell include 
hydrogen peroxide (H2O2) and hypochlorous acid (HOCl).  Both H2O2 and HOCl are considered 
reactive, as they can easily convert back into a radical form, as O2
-
 or OH
·
.  Many ROS exist, and 
they contribute to the development of CVD including hypertension, atherosclerosis, restenosis 
and diabetic vascular complications (Griendling, et al. 2000) (Touyz & Schiffrin, 2004) 
(Landmesser & Harrison, 2001).  The hypothesis of hypertension by ROS is based upon theories 
of vascular remodelling and dysfunction which to varying degrees is influenced by ROS (Touyz 
& Schiffrin, 2004).  Intengan and Schiffrin (2001) described that in hypertension, small arteries 
undergo structural remodelling due to events such as increased cell growth and migration, and 
include the deposition of extracellular matrix and inflammation.   
1.1.5.1. Formation of reactive oxygen species 
Oxygen is unique in that is freely accepts electrons generated by physiological oxidative 
metabolism within cells, and is known to produce ROS including O2
-
, OH
·
 and H2O2 (Auten & 
Davis, 2009).  Other well known ROS that play a role in the pathogenesis of CVD include 
peroxynitrite (ONOO
-
), singlet oxygen (
1
O2), and peroxyl radicals (ROO
·
) (Winterbourn & 
Hampton, 2008).  There are many endogenous sources of ROS as well as physiological processes 
that can result in ROS production including the uncoupling of the electron transport chain in 
mitochondria, involving normal activity of several enzyme systems such as the cytochrome P450 
monooxygenase system (Auten & Davis, 2009).   
1.1.5.1.1. Superoxide Radical (O2
-
) 
Superoxide is a main product of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase activity and is the primary oxidant that escapes the mitochondrial electron transport 
chain (Winterbourn & Hampton, 2008).  Within the internal mitochondrial membrane, O2
-
 may 
be generated during normal physiological respiration.  The reaction involves the reduction of O2 
28 
 
by the addition of four electrons to produce water.  Further chemical reduction of O2
-
 can form 
H2O2 and OH
·
.  Superoxide radical is highly reactive with thiols such as glutathione, 
homocysteine and sulphates (Winterbourne, 1994), but also with catecholamines and vitamin C 
(Warren & Ward, 1986).  The superoxide radical can be considered an omnipotent ROS, such 
that on its own it can cause significant oxidant injury to the vasculature.  Additionally O2
-
 is 
converted into the extremely toxic OH
·
 through Haber-Weiss reactions.  The O2
-
 is a hydrophilic 
molecule due to its negative charge, and is therefore only able to act locally through internal 
signalling or paracrine effects. 
1.1.5.1.2. Hydroxyl Radical (OH·) 
Produced by the Haber-Weiss or Fenton reactions, O2
-
 and H2O2, in the presence of 
transition metals such as iron, can form the OH
·
.  The OH
·
 is considered a highly toxic ROS.  It 
can readily react with membrane lipids causing the formation of even more complex radicals 
through the process of lipid peroxidation (Auten & Davis, 2009).  The OH
·
 can easily modify 
deoxyribonucleic acid (DNA), including base and sugar lesions, DNA protein crosslinks as well 
as strand breaks (Miyamoto, et al., 2007) .  Those ROS with the ability to modify or damage 
DNA are likely candidates involved in triggering cellular apoptosis, further contributing to 
overall cell death.  Lipid peroxidation of cell membranes irreversibly damages cells therefore, 
OH
·
 is considered a prime culprit in the pathogenesis of CVD such as hypertension and 
atherosclerosis.   
1.1.5.1.3. Peroxynitrite (ONOO·) 
In human neutrophils and endothelial cells, superoxide has been shown to react with NO 
to form ONOO
·
 (Carrera, et al. 1994) (Kooy & JA, 1994).  Additionally, ONOO
·
 can be 
protonated to form peroxynitrous acid, another highly reactive and oxidative species, however, 
having a very short half life, it yields yet again OH
·
 and nitric dioxide (NO2
-
) (Radi et al. 2000).  
Peroxynitrite is also a known inducer of lipid peroxidation, indicated by malondialdehyde 
production and conjugated diene formation (Radi, et al., 1991).  Moore et al. (1995) 
demonstrated that when low-density lipoproteins (LDL) are exposed to ONOO
-
, lipid 
peroxidation was promoted, increasing the formation of F2-isoprostanes and conversion of the 
lipoproteins to even more negatively charged moieties.  The oxidative hypothesis for 
atherosclerosis is based upon the oxidation of LDLs, implicating peroxynitrite as a potential 
therapeutic target.    
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1.1.5.1.4. Nitric Oxide (NO) 
Nitric oxide is considered a key determinant of vascular homeostasis, as it plays a role in 
vasodilation and endothelium membrane stability (Leopold & Loscalzo, 2009).  Nitric oxide can 
be produced by eNOS in the endothelium, and stimulated macrophages, strongly correlating its 
production with inflammation, and therefore many forms of CVD such as atherosclerosis (Cohen 
& Tong, 2010).  Recently, endothelial and neuronal NO synthase isoforms expression has been 
shown in cardiomyocytes (Barouch, et al., 2002).  However, Damy et al. (2003 & 2004) showed 
that changes to the expression of these isoforms are found in CVD conditions such as myocardial 
infarction and heart failure.  In the vasculature, Padmaja and Huie (1993) demonstrated that NO 
derived reactive nitrogen species react with amino acids, lipid and thiols resulting in various 
modifications.  Sun and Murphy (2010) claim that the nitrosylation of proteins may be 
cardioprotective, by inhibiting changes to the overall protein structure and function, preventing 
further, irreversible oxidative/nitrosative modification on thiol groups.  
1.1.5.1.5. Singlet Oxygen (1O2) 
Singlet molecular oxygen is a strong oxidant that is highly reactive towards electron rich 
organic molecules including proteins, lipids and nucleic acids (Cadet, et al. 2000).  Singlet 
oxygen has been implicated in the toxic effects of ultraviolet (UV) solar radiation exposure, and 
plays a role in the apoptosis cell signalling cascade (Ryter & Tyrrell, 1998).  In biological 
systems, 
1
O2 generation has mainly been attributed to photochemical reactions.  Other chemical 
reactions that may produce 
1
O2 are those associated with lipid peroxidation, phagocytosis, and 
the catalytic mechanisms of peroxidases (Kiryu, et al., 1999).      
1.1.5.1.6. Hydrogen Peroxide (H2O2) 
Hydrogen peroxide is a strong oxidant which is constantly being formed from the 
mitochondria as well as from enzymatic reactions.  Dismutation of O2
-
 generates H2O2, which by 
Fenton reactions in the presence of transition metals, can produce the highly reactive OH
· 
(Miyamoto, et al., 2007).  The formation of H2O2 from O2
-
 is important biologically because this 
dismutation provides lipophilicity to the ROS, making it free to cross cell membranes expanding 
its range of action.  Hydrogen peroxide is also known to react with hypochorous acid (HOCl) to 
yield 
1
O2, (Held, Halko, & Hurst, 1978).  The anti-oxidants glutathione peroxidase and catalase 
are both able to catalyze the conversion of H2O2 into water and molecular oxygen, demonstrated 
by the reaction:  
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H2O2 → H2O + O2.                                                                                                    (1.6) 
 
1.1.5.1.7. Peroxyl Radicals (ROO·) 
Peroxyl radicals are formed during a cascade of events that are initiated through lipid 
peroxidation.  When activated, lipoxygenase and cyclooxygenase form lipid hydroxides.  As the 
concentrations of lipid hydroxides rise, the hydroxides are cleaved to produce the ROO
·
, known 
to attack all types of biological molecules including cholesterol, carbohydrates, fatty acids, and 
proteins (Spiteller, 2006).  Peroxyl radical formation has been associated with inflammatory and 
neurodegenerative diseases such as Alzheimer‟s Disease and atherosclerosis (Spiteller, 2006)    
1.1.5.2. Endogenous Sources of Reactive Oxygen Species 
Reactive oxygen species are produced under physiological and pathophysiolgical 
conditions.  ROS are considered toxic and therefore pathophysiological when the balance 
between their generation and subsequent detoxification is lost. 
1.1.5.2.1. Mitochondria 
 In the mitochondrial respiratory electron transport chain, a small amount of O2
-
 is 
produced by NADH reductase and cytochrome C reductase (Puddu et al. 2008).  Li et al. (1999) 
described that the rate of ROS generation from the mitochondria is modulated by the potential of 
the inner mitochondrial membrane, primarily regulated by calcium ion movement.  As 
previously described, excessive production of ROS from the mitochondria causes damage to 
lipids, proteins and also mitochondrial DNA (mtDNA), which is unprotected and close to the 
inner membrane, susceptible to ROS insult (Croteau & Bohr, 1997).  The synthesis of defective 
protein subunits of the mitochondrial respiratory chain can result from mtDNA damage, causing 
a vicious cycle of further oxidative stress and ROS generation (Wei, et al. 1998).  Rachek et al. 
(2006) showed that NO at high concentrations can damage mtDNA by stimulating 
overproduction of O2
-
, H2O2 and ONOO
·
.   
Oxidized LDL has also been shown to increase mitochondrial O2
-
 formation, potentially 
suggesting its role in the pathogenesis of atherosclerosis (Zmijewski, et al., 2005).  
Overproduction of ROS from the mitochondria is considered dysfunctional, and has been 
associated with hypertension as indicated in rat studies (De Cavanagh, et al., 2006).   
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1.1.5.2.2. Enzymes 
A major source of ROS production are physiological enzymes found in inflammatory 
cells and platelets.  Some of the most predominant enzyme sources of ROS in the vasculature 
include: NADPH oxidase, myeloperoxidase, xanthine oxidase, lipoxygenases, endothelial and 
inducible nitric oxide synthases (Leopold & Loscalzo, 2009).   
1.1.5.2.2.1. NADPH oxidases  
NADPH oxidases (Nox) have been identified as major sources of ROS in the vasculature.  
The Nox family has 7 catalytic homologues, four of which have been identified in the 
vasculature (Nox 1, Nox 2, Nox, 4 and Nox 5), all of which are expressed in endothelial cells, 
but only Nox 1, Nox 4 and Nox 5 are expressed in VSM cells (Lassegue & Griendling, 2010) 
(Lassegue & Clempus, 2003).  These enzymes produce superoxide via the transfer of electrons 
from NADPH to molecular oxygen through the following reaction:  
                                          (1.7) 
The Nox system is activated by many factors including G-protein coupled receptor 
agonists, cytokines, growth factors, shear stress and ischemia/reperfusion (Frey, Ushio-Fukai, & 
Malik, 2009).  Some of the consequences of Nox derived ROS as described by Frey et al. (2009) 
include endothelial dysfunction and increased endothelial permeability, inflammation, vascular 
remodelling, cell growth and migration, apoptosis and senescence, all known contributors in the 
pathogenesis of hypertension.   
1.1.5.2.2.2. Myeloperoxidase (MPO) 
Myeloperoxidase, expressed in neutrophils and monocytes, uses chloride as a substrate 
and H2O2 as a co-substrate for the formation of HOCl (Leopold & Loscalzo, 2009).  
Hypochlorous acid is a potent chlorinating oxidant, and MPO is the only known pathway that 
synthesizes this reactive chlorinating species in humans (Harrison & Schultz, 1976).  
Myeloperoxidase catalyzes the oxidation of NO
·
 to NO2
-
 in human plasma (Abu-Soud & Hazen, 
2000).  Furthermore, MPO activity is in part dependent upon NO
·
 activity, such that at low 
concentrations, NO
·
 reduces MPO into its active form, and at high concentrations, NO
·
 inhibits 
MPO by forming a nitrosyl-complex with the enzyme (Abu-Soud & Hazen, 2000).  The 
predominant effects of MPO generated HOCl is that it can oxidize thiols and thiol esters, mediate 
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the chlorination of amines and unsaturated lipids, and cause the oxidative bleaching of heme 
groups and iron-sulphur centres (Harrison & Schultz, 1976) (Albrich, McCarthy, & Hurst, 1981).   
1.1.5.2.2.3. Xanthine Oxidase 
Xanthine oxidase (XO) is expressed only by vascular endothelial cells, and exists in two 
isoforms, the dehydrogenase and oxidase (Linder, Rapola, & Raivio, 1999) (Stirpe & Della 
Corte, 1969).  Xanthine oxidase produces O2
-
 through the catalytic oxidation of hypoxanthine to 
xanthine and uric acid (Olson, et al., 1974).  Only the oxidase isoform generates O2
-
, and its 
activity is thought to be redox sensitive because under physiological conditions, the 
dehydrogenase isoform predominantes (Nishino, 1997).  However, Poss et al. (1996) described 
that in a hypoxic setting the oxidase isoform will predominate, therefore correlating ischemia 
with the ability of XO to produce ROS.   
Studies have indicated that XO is an important source of ROS that contribute to vascular 
oxidant stress.  For instance, Spiekermann et al. (2003) showed that XO inhibition improved 
impaired vasodilation and vascular reactivity in patients with known coronary artery disease and 
hypercholesterolemia.  There have also been specific genetic polymorphisms associated with the 
pathogenesis of CVD, including the A69901C variant of XO, which was identified in a study of 
953 hypertensive patients in Japan (Yang, et al., 2008).   
1.1.5.2.2.4. Lipoxygenases 
Lipoxygenases oxidatively modify biologically active lipids (Leopold & Loscalzo, 2009).  
The enzyme catalyzes the insertion of molecular oxygen into polyunsaturated fatty acids yielding 
eicosanoids, including leukotrienes, thromboxanes and through cyclooxygenase, prostaglandin 
(Samuelsson, et al., 1987).  During the transformation of prostaglandin to thromboxane, OH
-
 and 
O2
-
 are produced.  The OH
•
 is also produced from the lipoxygenase pathway associated with 
arachidonic acid metabolism (Kontos, Wei, & Povlishock, 1980).  Eicosanoids are mediators of 
inflammatory reactions and have vasoconstrictive and vasodilatory properties, important in the 
pathogenesis of hypertension and CVD.      
1.1.5.2.2.5. Endothelial Nitric Oxide Synthase (eNOS) 
Endothelial nitric oxide synthase uncoupling, is clinically relevant in the pathogenesis of 
hypertension, diabetes mellitus, hypercholesterolemia and atherosclerosis (Pritchard, et al., 
1995).  Endothelial nitric oxide synthase produces both NO
·
 and O2
-
 through several different 
pathways.  The production of NO
·
 occurs through electron transfer from NADPH, oxidizing L-
33 
 
arginine (Leopold & Loscalzo, 2009).  When either L-arginine or NADPH are not present in 
sufficient concentration, eNOS “uncouples” reducing O2 into O2
-
 (Vasquez-Vivar, et al., 1998).  
Also causing eNOS uncoupling and subsequent production of O2
-
 is the release of zinc from a 
zinc-thiolate moiety of eNOS by ONOO
-
 (Zou, Shi, & Cohen, 2002).   
1.1.5.2.2.6. Inducible Nitric Oxide Synthase (iNOS) 
The expression of iNOS is colocalized with oxidized lipids and protein derivatives found 
in atherosclerotic plaques (Niu, et al., 2001).  Within these plaques, iNOS is localized with 
macrophages and VSM cells (Luoma & Yla-Herttuala, 1999).  Just as with eNOS, iNOS 
uncoupling is thought to be responsible for the generation of ROS.  Leopold and Loscalzo (2009) 
reported that in a diabetic rat model, OH
·
 and ROO
·
 were generated by an uncoupled iNOS.   
1.1.5.2.3. Other Sources of Reactive Oxygen Species 
Reactive oxygen species can originate from various sources throughout the intra- and 
extracellular spaces.  Some small molecules such as thiols, flavins and catacholamines have been 
known to auto-oxidize and subsequently release oxidative intermediates, around the endoplasmic 
reticulum, nuclear membrane, and peroxisomes (Muller & Sies, 1987). 
1.1.5.3. Reactive Oxygen Species and Vascular Dysfunction 
The endothelium regulates vascular homeostasis and function through local mediators 
that regulate vascular tone, hemostasis and inflammation.  There is a mounting body of evidence 
that indicates that ROS production is directly related to the mechanisms of vascular/endothelial 
dysfunction.  A key feature of vascular dysfunction is vascular remodelling or reorganization of 
endothelial and/or VSM cells.  Furthermore, a dysfunctional vascular system can be diagnosed in 
relation to the bioavailability and actions of NO.  Nitric oxide is a potent vasodilator with a 
critical role in modulating vascular tone.  Nitric oxide is also antithrombotic since it inhibits 
platelet activity, but also vascular leukocyte adhesion and VSM cell proliferation (Nedeljkovic, 
Gokce, & Loscalzo, 2003).  In summary, the vascular effects of ROS include, impaired 
vasoreactivity and vascular remodelling. 
1.1.5.3.1. Vascular Remodelling 
Reactive oxygen species have been shown to regulate to some extent vascular function, 
through the modulation of cell growth, apoptosis, necrosis, cell migration, inflammation and 
extracellular matrix protein production (Xu & Touyz, 2006).  Rao and Berk (1992) indicated that 
both VSMC DNA synthesis and cell number increased in response to ROS.  VSM cell 
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proliferation and migration has also been shown to be induced by agonists such as angiotensin II, 
platelet-derived growth factor and thrombin (Sundaresan, et al., 1995) (Patterson, et al., 1999).  
In hypertension, Rao and Berk (1992) demonstrated that redox-sensitive growth processes lead 
to accelerated proliferation and hypertrophy of VSMC, corresponding to further vascular damage 
and remodelling.    
Reactive oxygen species have been shown to modulate vascular structure by increasing 
extra-cellular matrix protein deposition such as collagen and fibronectin (Touyz & Schiffrin, 
2004).   Specifically, O2
-
 and H2O2 have influence over vascular matrix metalloproteinases 
(MMP)-2 and MMP-9 which cause basement membrane and elastin degredation respectively 
(Rajagopalan, et al., 1996).  Further contributing to vascular remodelling are ROS sensitive 
inflammatory processes.   
Reactive oxygen species have been linked to the expression of proinflammatory 
molecules such as the monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-1, IL-6, and 
IL-8, cellular adhesion molecules such as vascular cell adhesion molecule and intercellular 
adhesion molecule-1, both encoded by endothelial cells and upregulated by cytokines including 
the interleukins (Muller, et al., 2000).  The recruitment of inflammatory molecules in concert 
with vascular oxidative stress increases endothelial permeability impairing endothelial function 
and exacerbating vascular damage, as seen in patients with essential hypertension (Kristal, et al., 
1998).   
Cell death by lipid peroxidation or apoptosis and subsequent cellular reorganization are 
further hallmarks of vascular remodelling.  Increased lipid peroxidation has been identified as a 
key mechanism for the development of CVD.  Subsequent to lipid peroxidation is the formation 
of highly reactive intermediates,  which alter cell function and generate bioactive compounds 
(Minuz, et al., 2006).   
Unsaturated fatty acids such as phopholipids located in cellular membranes, are highly 
susceptable to peroxidation by ROS.  Hydroxyl radicals are able to abstract a hydrogen atom 
from the fatty acid which then is modified into several reactive substances including aldehydes 
such as malondialdehyde, and hydrocarbons (Bergamini et al., 2004).  These reactive substances 
are now free to modify other structures.  Lipid peroxidation of the plasma and intracellular 
membranes cause destabilization, resulting in leakage of proteases and Ca
2+
 into the cytosol, 
further contributing to necrotic cell death (Vanlangenakker, et al., 2008). 
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Apoptosis is described as programmed cell death including the following identifiable 
chracteristics: membrane blebbing, DNA fragmentation and nuclear condensation.  Signals 
known to be either pro- or anti-apoptotic are regulated by a mitochondrial protein known as Bcl-
2 encoded by the B-cell lymphoma 2 gene (Kim, et al., 2006).  Dysfunctional mitochondria 
which can be pro-apoptotic are characterized by their altered transmembrane potential, producing 
ROS and mitochondrial membrane permeabilization (Gottlied, et al., 2003).  This interaction 
results in the release of small molecules, the most notable being cytochrome c, activating 
caspase-dependent apoptotic pathways (Sharpe, et al., 2004).  Reactive oxygen species such as 
H2O2 and ONOO
-
, in high concentration (>100 µmol/l), are pro-apoptotic causing the 
detachment and shedding of endothelial cells from the extracellular matrix (Li, et al., 1999).   
1.1.5.3.2. Impaired Vasoreactivity 
Impaired vasoreactivity in hypertension has been linked to decreased NO bioavailability 
(Touyz & Schiffrin, 2004).  Superoxide is known to quench NO because of its ability to 
transform it into ONOO
-
.  Peroxynitrite, a very weak vasodilator when compared to NO, has pro-
inflammatory properties which makes it pro-thrombotic (Szabo, 2003).  Decreased NO 
bioavailability may be secondary to its impaired synthesis.  Reactive oxygen species, as 
previously discussed, can cause endothelial cell death, leading to reduced expression of eNOS 
and therefore decreased synthesis of NO.   
Vascular tone is also modulated directly by ROS.  Somers and Harrison (1999) as well as 
Yada et al. (2003) described that H2O2 acts as an endothelium-derived relaxing factor, with 
evidence of pulmonary, coronary and mesenteric artery dilation.  Yet, spontaneously 
hypertensive rats have been demonstrated to have enhanced H2O2-mediated contraction of their 
aortic and mesenteric arteries (Gao & Lee, 2001).  Presently it remains unclear what the exact 
contraction/dilation effects of ROS are with respect to vascular physiological and 
pathophysiological conditions (Touyz & Schiffrin, 2004).  
1.1.5.4. Antioxidant Protection from Vascular Dysfunction and Remodelling 
Reactive oxygen species are continuously produced during aerobic metabolism.  The 
oxidative stress hypothesis of endothelial dysfunction is measured by the availability of 
protective antioxidants which prevent and/or limit vascular damage caused by ROS.  
Antioxidants provide a chemical, detoxification defense to ward off lipid peroxidation, NO 
inactivation, eNOS uncoupling and apoptosis of endothelial, VSM and myocardial cells.  
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Antioxidants are classified as either non-enzymatic or enzymatic.  The best known 
enzymatic antioxidant defense systems are superoxide dismutase (SOD), catalase and glutathione 
peroxidase (GPx).   Examples of non-enzymatic antioxidants include vitamin C, vitamin E and 
carotenoids, polyphenols and alpha-lipoic acid.   
1.1.5.4.1. Superoxide Dismutase 
Superoxide dismutase exists in three different mammalian isoforms: cytosolic and 
extracellular copper-zinc SOD (CuZn-SOD and EC-SOD) and manganese SOD (Mn-SOD), 
localized in the mitochondria (Faraci & Didion, 2004).  Each isoform catalyzes the dismutation 
of O2
-
 into H2O2 and molecular oxygen as per the following reaction where the metal (M) = Cu 
(n=1), Mn (n=2), Fe (n=2), and Ni (n=2): 
                                                       (1.8) 
                                      (1.9) 
 
 The redox metals contained within the center of the SOD isoform are the source of the 
catalytic action, reduced by one O2
-
 and oxidized back by the second O2
-
 (Faraci & Didion, 
2004). 
 Copper-Zinc-SOD is the predominant isoform of the enzyme expressed in high 
levels in all cells but importantly in blood vessels.  In mouse aortas, CU-Zn-SOD accounts for 
50% - 80% of total SOD activity (Guo, et al., 2001).  Relatively the same expression levels have 
been reported in human arteries (Guo, et al., 2001).  Consequences of Cu-Zn-SOD deficiencies 
include: increased levels of O2
-
 and peroxynitrite, impaired NO-mediated relaxation, increased 
arterial tone (Didion, et al.  2002).     
 Manganese-SOD, localized in the mitochondria, a known producer of O2
-
, is the 
first line of defense against oxidative stress.  Landmesser et al. (2001) found that Mn-SOD is 
found at higher levels in cerebral arteries compared with the aorta or carotid arteries.  Packer et 
al. (2002) reported that mice who do not express Mn-SOD die within weeks after birth.   
 The only extracellular isoform, EC-SOD, has an affinity for heparan sulfate 
proteoglycans on cellular surfaces, in the extracellular matrix and basement membranes to which 
it binds (Marklund, 1984).  Heparin treatment can elevate systemic levels of EC-SOD by 
releasing it from its tissue bound state.  EC-SOD is also found between the endothelium and 
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VSM, with its major source being the muscle since the endothelium has not been shown to 
express the enzyme (Fukai, et al. 2002).  A major function of EC-SOD is to protect NO diffusion 
from the endothelium to the vascular muscle (Oury, Day, & Crapo, 1996).  Interestingly, EC-
SOD deficiency has not been correlated with changes to BP, however EC-SOD deficient mice 
have greater arterial pressures than controls (Jung, et al., 2003).  There are some species 
differences for EC-SOD heparin-binding affinities.  For instance, mice and humans have very 
similar levels of EC-SOD that has a high affinity for heparin in both species (Stralin, et al., 
1995).  However, in rats, only low levels of EC-SOD have been detected in the vasculature, and 
what has been expressed does not bind to heparan sulfate under physiological conditions (Faraci 
& Didion, 2004).   
1.1.5.4.2. Catalase 
 Catalase is an important intracelluar H2O2 detoxifying antioxidant.  
Enzymatically, catalase converts H2O2 into molecular oxygen and water as per the following 
reaction: 
                                                                                (1.10) 
 
Systematically, in conjuction with SODs, catalase can effectively eliminate the H2O2 
remaining after O2
-
 dismutation.  In cases of limited glutathione levels or GPx activity, catalase 
is very effective at protecting cells from high-level oxidative stress (Wassmann, Wassmann, & 
Nickenig, 2004).   
1.1.5.4.3. Glutathione Peroxidase 
 Glutathione peroxidase is similar to catalase in its ability to scavenge and reduce 
H2O2.  It can also reduce lipid peroxides to water and lipid alcohols via the oxidation of 
glutathione (GSH) to glutathione disulfide (GSSG).  Thought to be a major defense for low-level 
oxidative stress, reduced expression of GPx or GSH levels are associated with increased OH
-
 and 
lipid peroxyl radicals (Wassmann, Wassmann, & Nickenig, 2004).  The reaction of the 
glutathione systems is as follows:  
                                                                     (1.11) 
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Reduced GSH, the most important regulator of the above reaction, is found in millimolar 
concentrations intracellularly (Parodi, De Maria, & Roubina, 2007).  The oxidized form of GSH, 
GSSG as per Parodi et al. (2007) represents less than 2% of the total intracellular glutathione 
pool.  The most desirable redox state for glutathionine is maintenance of higher levels of GSH 
relative to GSSG.  Changes to the redox state of GSH is compensated by a recycling event 
initiated by GSH reductase, using NADPH as a substrate converting GSSG back to GSH as per 
the following reaction: 
                                             (1.12) 
  Consequently the redox state of GSH affects other redox couples such as 
NADPH/NADP
+
 as well as NADH/NAD
+
 contributing to its known ability to act as a promoter 
of apoptosis (Parodi, De Maria, & Roubina, 2007). 
Glutathione, a tripeptide containing cysteine, glutamate and glycine residues has an 
affinity, much like any other thiol containing species, to undergo protein modification when 
exposed to oxidative stress (Kondo, Hirose, & Kageyama, 2009).  Their modification includes 
the formation of protein-disulfides (Pr-S-SG) called S-glutathionylation, a reaction between 
proteins and GSSG (Kondo, Hirose, & Kageyama, 2009).  This modification essentially reduces 
the availability for conversion of GSSG back to GSH, hindering again the redox state of the 
antioxidant.  Protein modification is reversible via glutaredoxin, reduced by the initial oxidation 
of GSH, known to play an important role in protecting vascular cells from apoptosis. 
1.1.5.4.4. Non-enzymatic Antioxidants 
Non-enzymatic antioxidants are rapidly becoming a source of significant pharmaceutical 
interest for the development of CV drugs which target the oxidative hypotheses, including 
polyphenols, vitamin C, vitamin E, carotenoids and alpha-lipoic acid.  The most important 
source of the aforementioned antioxidants is dietary.     
Vitamin C is water-soluble, found in blood and plasma, reacting as a major antioxidant, 
in reducing tocopherol radicals and thereby lipid peroxidation in vascular membranes (Fusco, et 
al., 2007).  Vitamin C also has the ability to regenerate vitamin E, a lipophilic moiety residing 
within lipoproteins and membranes.  Vitamin E is believed to significantly protect LDLs against 
oxidative modifications, contributing to its ability to prevent atheroscelerosis (Fusco, et al., 
2007).    
39 
 
Carotenoids are also lipophilic antioxidants, whose concentration is inversely related to 
the levels of isoprostanes, inflammation and atherosclerosis (Block, Dietrich, & Norkus, 2002).  
The most potent and most studied carotenoid is β-carotene, which is claimed to be able to quench 
singlet-oxygen radicals (Di Mascio, Murphy, & Sies, 1991).   
Polyphenols are available through many dietary sources including fruits and berries, 
broccoli and cabbage, red wine, chocolate and some teas.  In most studies, polyphenols are 
reported to have low bioavailability due in part to their rapid excretion (Williams, Spencer, & 
Rice-Evans, 2004).  However, their reported antioxidant effects include reduced vascular 
inflammation and levels of oxidized LDL which maintains interest in their potential application 
as protectors of CVD (Serafini, et al., 2000).   
Alpha-lipoic acid (ALA) is found at highest concentrations, per gram of dry weight in 
broccoli, spinach and tomatoes, and is accumulated in tissue when consumed (Ghibu, et al., 
2009).  The antioxidant effects of ALA are vast including its ability to scavenge the OH
·
, 
1
O2, 
HOCl and ONOO
-
 (Ghibu, et al., 2009).  Furthermore, ALA is a potent chelator of metal ions 
such as manganese, copper, iron and zinc (Suh, Moreau, & Heath, 2005).   
1.1.6. Homocysteine and Hypertension 
1.1.6.1. Homocysteine Metabolism and Reactivity 
Homocysteine (Hcy) is a non-protein, sulfhydryl-containing amino acid that is produced 
from the metabolism of methionine, an essential amino acid.  The metabolism of Hcy can be 
divided into three distinct pathways: (1) the remethylation of Hcy to methionine by the vitamin 
B12 dependent methionine synthase; (2) the transsulfuration pathway, converting Hcy to 
cystathionine and then cysteine via. vitamin B6 dependent cystathionine β-synthase (CBS) 
enzyme; (3) in the liver and kidneys, Hcy can be remethylated back to methionine by betaine-
homocysteine methyltransferase (Maron & Loscalzo, 2009).  Figure 2 illustrates the Hcy 
metabolic cycle.   
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Figure 2 The homocysteine metabolic cycle.  (Maron & Loscalzo, 2009), with Permission from 
Annual Reviews Inc. 
 
Several Hcy species have been identified in human plasma including albumin-(protein)-
bound, free circulating disulfides and sulfhydryl forms (Maron & Loscalzo, 2007).  However, 
total Hcy (tHcy) plasma concentrations are commonly reported in the literature as current 
analytical methodology involves the reduction of Hcy disulfide bonds, quantifying all forms as 
free tHcy (Maron & Loscalzo, 2009, Perla-Kajan, et al., 2007).  The American Heart Association 
released an advisory statement classifying tHcy plasma concentrations as follows: 5 – 15 µmol/L 
Hcy as normal, 16-30 µmol/L Hcy as moderate, 31-100 µmol/L Hcy as intermediately elevated 
and tHcy levels above 100 µmol/L as severely elevated concentrations (Malinow, et al., 1999).   
Jacobsen (1998) stated that oxidized Hcy chemical species made up 98-99% of the tHcy 
in human plasma, where 80-90% of those species are protein bound.  In a mouse model of hHcy, 
Eberhardt et al. (2000) found significant increased ROS accumulation, predominantly O2
-
 in 
aortic tissue as compared with controls.  In the literature, it is consistent that in vivo and in vitro 
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models treated with Hcy produce elevated amounts of ROS (Eberhardt, et al., 2000, Heydrick, et 
al., 2004, Postea, et al., 2006, Zhang, et al., 2000).   
There are several mechanisms by which Hcy may increase ROS in vascular tissue.  
Firstly, Hcy is thought to produce ROS when its oxidation rate becomes elevated.  Homocysteine 
contains a free-sulfhydryl group.  Such compounds are called “thiols”.  Thiols are highly 
susceptable to oxidation under aerobic conditions where they form disulfides and the ROS 
hydrogen peroxide according to the general reaction: 2 RSH + O2 ↔ RSSR + H2O2 (Weiss, 
2005).  The autooxidation of Hcy through this mechanism is known to form oxidized 
homocysteine (homocystine), and oxidizes other thiols such as gluathione and cysteine through 
mixed disulfide formation (Weiss, 2005).  However, recent evidence suggests that only a small 
fraction of oxidized Hcy in plasma results from direct oxidation, so this mechanism is unlikely a 
major source of Hcy derived ROS (Sengupta, et al., 2001).   
Homocysteine has been associated with increased ONOO
-
 formation through a 
mechanism which is thought to “uncouple” eNOS (Pritchard, et al., 1995) resulting in endothelial 
cell membrane lipid peroxidation.  Surprisingly, this mechanism has been demonstrated 
stereospecifically with L-Hcy but not D-isoforms (Heydrick, et al., 2004).  The suggestion that 
Hcy causes eNOS uncoupling implies that eNOS is the source for ROS such as O2
-
 and ONOO
-
.   
The vasculature is under oxidative stress when ROS accumulate because of an imbalance 
between ROS production and protection by anti-oxidants.  Homocysteine has been shown to 
inhibit the activity of cellular antioxidant enzymes including glutahione peroxidase (GPx-1) and 
SOD (Weiss, 2005).  Homocysteine, in vivo and in vitro, reduces the expression of GPx-1, 
subsequently preventing its ability to reduce and therefore detoxify H2O2 and lipid peroxides into 
their respective alcohols (Weiss, 2002).  Superoxide dismutase is the principle scavenger of O2
-
.  
It is thought Hcy may interfere with the binding of SOD to the extracellular surface of 
endothelial cells by causing alterations to endothelial heparan sulfate proteoglycans (Yamamoto, 
et al., 2000). 
Lastly, Hcy has been implicated in neutrophil activation of NADPH oxidases (Weiss, 
2005).  As previously discussed, the Nox enzymes are a significant source of O2
-
 production in 
the vasculature.  Therefore, Hcy activation of Nox enzymes may contribute a significant source 
of ROS.   
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1.1.6.2. Hyperhomocysteinemia 
Hyperhomocysteinemia, is defined as tHcy concentrations elevated above 15 µmol/L.  
Hyperhomocysteinemia has been strongly associated with the pathogenesis of CVD, and 
correspondingly has been identified as a contributing factor in four main disease mechanisms 
including thrombosis, vascular oxidative stress, apoptosis and cellular proliferation (Loscalzo, 
1996) (Lubos, et al., 2007, Rounds, et al., 1998, Welch, et al., 1998).   
1.1.6.2.1. Etiologies 
Genetic, nutritional and medical etiologies have been identified as causing marked 
elevations in plasma Hcy concentrations.  Inherited enzyme mutations, to 
methylenetetrahydrofolate reductase (MTHFR), essential for Hcy remethylation, as seen in up to 
40% of the U.S. population, can increase tHcy by 25% (Qi, et al., 2003).  The most common 
cause of severe hHcy are genetic mutations to the cysthathionine β-synthase (CBS) enzyme of 
the transsulfuration pathway.  These mutations are considered inborn errors of metabolism and 
are seen in 1:200,000 U.S. live births (Maron & Loscalzo, 2007).  However, due to the severe 
elevations of Hcy caused by the CBS mutation, premature death is a common result of associated 
thromboembolic events (Mudd, et al., 1995).   
Three crucial dietary vitamins are required to drive the Hcy metabolic cycle.  These 
vitamins are folic acid, vitamin B12 (cobalamin) and vitamin B6 (pyridoxal phosphate).  Since 
these vitamins are considered co-factors for Hcy metabolic enzymes, deficiencies in any of these 
vitamins are associated with hHcy (Brosnan, et al., 2004).   
In patients with end-stage renal disease, Robinson et al. (1996) noted that 85% of 
individuals had elevated Hcy levels as compared to normal controls.  Estrogen deficiencies and 
hypothyroidism have also been associated with hHcy (McCully, 2007) as have psoriasis and 
lymphoblastic leukemia (Welch & Loscalzo, 1998).  Additionally, smoking and certain 
medications increase Hcy concentrations by depleting folic acid or impairing the synthesis of 
vitamins B12 and B6 (Welch & Loscalzo, 1998).   
1.1.6.2.2. Oral Methionine Loading 
Both experimentally and diagnostically, methionine loading tests evaluate the function of 
a test subjects‟ homocysteine metabolism.  Hyperhomocysteinemia is diagnosed based on 
elevated fasting plasma homocysteine levels, 6 hours after oral methionine loading (de Jonge, et 
al., 2004).  Boger et al. (2000) demonstrated that when monkeys were fed a methionine rich diet, 
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the increase in their tHcy concentrations were associated with impaired NO-dependent carotid 
artery vasodilation.  Wanby et al. (2003) demonstrated that in humans, oral methionine loading 
was associated with acute elevations in plasma tHcy.  In the Wanby et al. (2003) study, patients 
were given 100 mg of L-methionine per kg of body weight in 200 mL of orange juice in the 
morning just after their baseline blood test.  The patients blood was sampled again 4 hours later 
(Wanby et al., 2003).  Results showed a significant increase in tHcy plasma concentrations (13.7 
µmol/L tHcy – baseline: 35.4 µmol/L tHcy – 4 hours after loading; p<0.001) (Wanby et al., 
2003).   
Elevated fasting plasma tHcy after oral methionine loading indicates a defect in the 
remethylation metabolic pathway, whereas elevated tHcy levels after loading indicate defective 
transsulfuration (de Jonge, et al., 2004).  To sustain an experimentally relevant hHcy plasma 
concentration in test subjects that have fully functional methionine metabolic cycles, a high 
methionine oral load must be sustained over time.  De Jonge et al. (2004) state that tHcy reaches 
its peak concentration 6 hours after methionine loading, which is the normal clinical time to test 
for hHcy.  Fasting plasma tHcy concentrations in healthy subjects, chronically dosed with high 
methionine, would definitively indicate whether or not overall baseline concentrations had risen.         
1.1.6.2.3. Epidemiology   
Hyperhomocysteinemia has been established as a risk factor for coronary artery disease 
(CAD), MI, stroke, venous thromboembolism and peripheral vascular disease through numerous 
epidemiological reports (Maron & Loscalzo, 2009).  A meta-analysis of 27 studies showed that 
there was an increased, incremental risk of CAD with every 5 µmol/L increase in tHcy 
concentrations (Boushey, et al., 1995).  Boushey et al. (1995) claimed that, hHcy was attributable 
for 10% of CAD risk in the population, and therefore 50,000 deaths from CAD could be 
eliminated by Hcy reduction.  Supporting these findings was the Homocysteine Studies‟ 
Collaboration meta-analysis, which reported a 19% reduction in the risk for stroke and 11% 
reduction in the risk for ischemic heart disease per 3 µmol/L tHcy reduction (Homocysteine 
Studies Collaboration, 2002).     
1.1.6.3. Homocysteine and Vascular Dysfunction 
Vascular dysfunction as it relates to the pathogenesis of hypertension is predominantly 
characterized by the health and well being of the vascular endothelium.  Endothelial dysfunction 
is predictive of CV pathologies, and is most commonly diagnosed when there is evidence of 
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impaired vasodilation (Cai & Harrison, 2000).  However, since BP is a product of TPR, other 
factors such as decreased lumen size due to atherosclerotic lesions or thrombosis, are other 
mechanisms by which Hcy may contribute to the pathogenesis of hypertension. 
1.1.6.3.1. Impaired Vasoreactivity 
Humans with hHcy have impaired endothelium-dependent vasodilation (Tawakol, et al., 
1997) (Chambers, et al., 1999).  Reactive oxygen species production in hHcy, quench NO 
bioavailability both in vivo and in vitro (Weiss, 2005).  The highly reactive O2
-
, produced 
intracellularly, is in a prime location to react with NO, also produced within the endothelial cell, 
to form ONOO
-
.  In cultured endothelial cells, Hcy alters vasoreactivity by decreasing the 
production and/or bioavailability of mediators such as ET-1, NO, and prostacyclin, a 
vasodilatory eicosanoid (Demuth, et al., 1999, Upchurch, et al., 1997, Wang & Vaziri, 1999).   
Another mechanism for hHcy inhibition of NO production is caused by asymmetric 
dimethylarginine (ADMA) (Austin, et al., 2004).  Asymmetric dimethylarginine is a bi-product 
of methioine metabolism (Figure 2), caused by increased S-adenosylmethionine-dependent 
methylation of protein residues, or by decreased hydrolyzation and subsequent renal excretion of 
ADMA (Vallance, 2001).  Plasma levels of ADMA rise rapidly after acute methionine loading in 
humans, correlated directly with impaired vasorelaxation (Boger, et al., 2000).  ADMA is a 
known eNOS inhibitor, and also promotes the uncoupling of eNOS, directly increasing vascular 
oxidative stress, again reducing the bioavailability of NO (Boger, 2003).  In hHcy monkeys, 
elevated plasma ADMA was associated with impaired relaxation of the carotid arteries (Boger, et 
al., 2000).  Also, in rat models and human subjects given oral methionine, elevated plasma 
ADMA was correlated with impaired endothelial function (Boger, et al. 2001) (Stuhlinger, et al., 
2003).  Elevated plasma ADMA is an emerging risk factor for hypertension, 
hypercholesterolemia, hHcy, diabetes mellitus and CVD(Boger, 2003).     
The expression of MCP-1 and IL-8 in human aortic endothelial cells, is also induced by 
Hcy (Podder, et al., 2001).  These inflammatory mediators significantly alter the vasoreactivity 
of pulmonary arteries (Podder, et al., 2001).  Zhang et al. (2007) showed that Hcy, in a dose-
dependent manner, decreased cyclic guanosine monophosphate levels, a second messenger 
normally increased by ACh to facilitate vasodilation, thereby inhibiting the endothelium‟s 
vasodilatory response to ACh.  
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1.1.6.3.2. Thrombosis 
Thrombosis, as induced by Hcy, is due to its procoagulant activity and its known ability 
to alter anticoagulant mechanisms (Lee & Prasad, 2002).  Thrombosis and subsequent occlusion 
of the carotid artery in hHcy mice happened 50% faster than in control mice (Wilson, et al., 
2004).  The endothelium plays a role in vascular homeostasis by maintaining balance between 
pro- and anti-thrombotic pathways (Thrambyrajah & Townsend, 2000).  Rogers (1998) described 
that the endothelium uses the following mechanisms to create an antithrombogenic surface: (1) 
production of tissue plasminogen activators (t-PA), which limits plug formation and fibrin 
deposition (2) inhibition of platelet activation by NO, prostacyclin and enzymes which cleave 
ATP; (3) regulation of heparan sulfate, thrombomodulin and protein C activity (Rogers, 1988).  
Homocysteine has been shown to disrupt all of these mechanisms, predisposing hHcy patients to 
thrombosis.   
Firstly, in cultured endothelial cells, Hcy forms disulfide bonds with a cysteine residue on 
the endothelial cell surface receptor for t-PA, blocking its binding, leading to decreased plasmin 
generation, promoting fibrin deposition and ultimately thrombosis (Hajjar, et al., 1998).  
Secondly, Hcy alters vasoreactivity and promotes thombogenesis by decreasing the production 
and/or bioavailability of mediators such as NO and prostacyclin.  Lastly, aortic thrombomodulin 
activity was decreased in hHcy monkeys fed a high-methionine diet, reducing the ability to 
activate protein C which limits its anti-thrombotic activity, anti-apoptotic and antiinflammatory 
activities (Lentz, et al., 1996).   
1.1.7. Heparin 
For many years heparin has been widely used in the treatment and prevention of both 
arterial and venous thrombosis.  Only recently has the focus shifted onto different forms of 
heparins, including low-molecular weight heparins (LMWH) and the use of different means of 
systemic delivery such as oral heparins.   
1.1.7.1. Chemistry 
Heparin and heparan sulfate belong to a family of glycosaminoglycans (HS-GAG) 
biosynthesized through the attachment of monosaccharides to a main core protein in the Golgi 
(Sasisekharan & Venkataraman, 2000).  Heparin is a highly sulfated polysaccharide commonly 
isolated from mast cells, while heparan sulfate is a less sulfated polysaccharide found on cellular 
surfaces, including endothelial cells and on the extracellular matrix (Sasisekharan & 
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Venkataraman, 2000).  HS-GAGs are characterized biochemically by a linear chain of anionic 
repeating units of uronic acid and glucosamine residues (Skidmore, Guimond, Rudd, Fernig, 
Turnbull, & Yates, 2008).  Heparin has a molecular weight of approximately 60-100 kDa, 750-
1000 kDa if the core protein is included (Li & Vlodavsky, 2009).   However, the heparin 
produced from mast cells undergoes degradation prior to being a completed molecule, as Li and 
Vlodavsky (2009) report with its final molecular weight of 5-30 kDa.  Low-molecular weight 
heparins are prepared commercially through further degradation or fractionation of the main 
heparin GAG chain with molecular weights less than 8 kDa (REF).   
1.1.7.2. Activity 
The main studied activity of HS-GAGs are as potent anticoagulants due to their 
polysaccharide sequence which specifically binds to antithrombin, inhibiting a variety of 
coagulation factors including factor Xa, and heparin cofactor II, a thrombin inhibitor.  Due to the 
high charge of HS-GAGs, they readily bind to proteins and the vascular wall.  Interactions 
between HS-GAGs and other vascular structures including enhanced protein-protein interactions, 
sequestering of protein ligands on endothelial cell surfaces and in the extracellular matrix, act as 
co-receptors for growth factors (Whitelock & Iozzo, 2005).  Furthermore, HS-GAGs protect 
proteins from degredation (Hashimoto, et al., 1997), mediates protein internalization (Gingis-
Velitski et al., 2004) and regulate protein membrane transport (Dowd, Clooney, & Nugent, 
1999).   
In addition to its anticoagulant properties, HS-GAGs have been shown to release EC-
SOD and inhibit platelet endoperoxide metabolite formation thereby reducing superoxide 
concentrations (Karlsson & Marklund, 1987), decrease the accumulation of vascular calcium 
(Vasdev, Prabhakaran, & Sampson, 1991), reduce ROS generation as related to the activation of 
prostaglandin and phospholipase biosynthesis.  Using xanthine and xanthine oxidase as ROS 
producers to cause in vitro endothelial cell damage, Hiebert and Liu (1990) demonstrated that 
heparin significantly increased cell viability and decreased lactate dehydrogenase release, thus 
reducing cellular oxidative injury.  Heparin treatment has also repeatedly been shown to lower 
BP, when administered daily to spontaneously hypertensive rats, characterized by a significant 
decrease in TPR and increases in CO (Mandal, et al., 1978).  Heparin‟s antihypertensive effect, 
excluding any effect on hematocrit, include increased endothelial-derived nitric-oxide 
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vasodilation and inhibition of ET-1 and consequently VSM cell contractility (Mandal, Lyden, & 
Saklayen, 1995).   
1.1.7.3. Administration 
Primarily, heparins are administered by intravenous or subcutaneous routes.  
Experimentally, oral heparin administration has also been shown as a viable alternative.  Jaques 
et al. (1991) and Hiebert et al. (1993) using a rat model, supported findings of Engelberg (1995) 
that oral heparin is absorbed.  Furthermore, the endothelium has been shown to be the target 
organ for orally administered heparin.  Hiebert et al. (1993) showed heparin, within 6 minutes of 
intragastric administration was detected in association with rat endothelium, and that oral 
heparins have antithrombotic activity in rats.  These results suggest that plasma concentrations of 
orally administered heparin would be dependent on its uptake and release by the endothelium.   
Interestingly, oral heparins have also been seen to have effects such as lowering BP in 
spontaneously hypertensive rats (Vasdev, et al., 1992).  
 
1.2. RATIONALE AND HYPOTHESIS 
Essential hypertension is an important modifiable risk factor for CVD whose specific 
causes are difficult to fully elucidate.  The difficulty arises due to the multi-factorial nature of BP 
control.  Firstly, BP is a product of both CO and TPR.  Therefore, changes to the reactivity of the 
vasculature and cardiac function can both significantly affect BP.  Since the most significant and 
immediate changes to BP arise through the vasoactivity of arterioles, which are considered the 
primary resistance vessels in the vasculature, studies about hypertension tend to focus on their 
relationship to TPR.  However, increases in BP due to changes in TPR can in concert cause 
adverse changes in cardiac structure and function.  For instance, increased arterial stiffness can 
lead to left ventricular dysfunction, such that subjects would show a marked increased in left-
ventricular end-diastolic pressure ultimately leading to ventricular hypertrophy and cardiac 
failure.  Therefore, full hemodynamic investigations are ultimately required to elucidate how and 
by what timeline essential hypertensive mechanisms affect BP.   
There has been an increasing body of evidence implicating hHcy as having a causal 
relationship to the development of hypertension (Rodrigo, et al., 2003) (Tyagi, et al., 2005) 
(Davis, et al., 2001) (Sutton-Tyrrell, et al., 1997).  The exact mechanism by which hHcy is 
causal to hypertension is unknown but in numerous studies it has been shown to limit the 
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bioavailability of NO (Boger, et al., 2001), increase smooth muscle cell proliferation and impair 
vascular elasticity by reducing elastin/collagen ratios (Stehouwer & van Guldener, 2003) and 
furthermore is deleterious to endothelial cells causing endothelial dysfunction (Zhang, et al., 
2000).  Each of these proposed mechanisms correspond to increases in TPR and the development 
of hypertension.   
Hyperhomocysteinemia has also been shown to cause adverse cardiac remodelling and 
heart failure in association with hypertension (Joseph, et al., 2003) (Sundstrom, et al., 2004) 
(Bokhari, et al., 2005) (Devi, et al., 2006).  Joseph et al. (2003) claim that hHcy induces left 
ventricular hypertrophy, myocardial fibrosis and stiffness.  The consequences of cardiac 
remodelling are impaired systolic and diastolic function, such as low LV ejection volumes 
(Cesari, et al., 2004).  However, there is limited hemodynamic evidence available that 
comprehensively describes the consequences of hHcy cardiac remodelling.   
All of the aforementioned CV effects of hHcy are based on an oxidative hypothesis 
implicating Hcy thiol auto-oxidation, eNOS uncoupling, activation of Nox enzymes and 
antioxidant inhbition of GPx-1 and SOD as being contributing factors to its association with 
increased levels of ROS.  Voutilainen et al. (1999) clearly demonstrated that hHcy is positively 
associated with increased oxidative stress, supported by evidence of increased F2-isoprostane 
levels, a specific marker of lipid peroxidation.  Futhermore, vitamic C administration, used as an 
anti-oxidant prevents Hcy dependent endothelial dysfunction in terms of NO inactivation, 
supporting the view that increased oxidative stress is integral in the pathogenic mechanism of 
hHcy (Kanani, et al., 1999). 
  The oxidative hypothesis describing Hcy‟s causal relationship to hypertension is the key 
factor that is essential for targeting potential therapeutics.  Heparin has been increasingly 
described as having antioxidant activity, which affords protection to the endothelium from 
oxidative stress.  It has been suggested that heparin acts as an antioxidant by facilitating the 
release of SOD from the endothelium surface to act in the plasma as an ROS scavenger 
(Karlsson & Marklund, 1987), and that heparin decreases normal ROS generation by inhibiting 
prostaglandin and phopholipase biosynthesis (Vasdev, Prabhakaran, & Sampson, 1991).  Hiebert 
and Liu (1990 and 1994) demonstrated specifically that heparin or dextran sulfate, a compound 
very similar to heparin, protects endothelial cells in vitro from ROS damage generated by 
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xanthine and xanthine oxidase.  However, there is no published data which shows that heparin 
affords antioxidant like protection to endothelial cells from Hcy generated ROS production.         
Based on the above background knowledge it is hypothesized that elevated levels of 
plasma homocysteine will cause oxidative stress leading to endothelial cell dysfunction, 
resulting in the development of hypertension and that heparin administration will 
attenuate these effects. 
All of the potential pathological mechanisms by which Hcy may have a causal 
relationship to hypertension are correlated to it being an inducer of oxidative stress in the CV 
system.  The controversy over the specific mechanism which contributes to Hcy induced 
hypertension is confounded by a lack of hemodynamic information that can both structurally and 
chronologically differentiate between pathological events.  Therefore, a full hemodynamic 
evaluation of an animal model of hHcy could provide a comprehensive overview of vascular and 
cardiac function in relation to total plasma levels of Hcy.  Furthermore, evidence of CV 
oxidative stress should be associated with hemodynamic changes.  Total oxidative stress can be 
indirectly quantitated by measuring serum malondialdehyde (MDA), a product of lipid 
peroxidation related to lipid membrane damage.  As oxidative stress is postulated to correspond 
directly with Hcy mediated increases in BP, MDA measurements taken in systems (1) which 
provide BP control, (2) organs which produce a significant amount of antioxidant, and (3) large 
blood vessels which receive a significant volume of blood under high pressure would provide a 
holistic evaluation of important body systems which has not been studied previously.  Further 
evaluation of GSH concentrations in select tissues and plasma could provide an indication of 
possible thiol oxidation and mixed disulfide formation between GSH and Hcy, or its depletion 
via the detoxification of ROS.  While MDA suggests oxidative stress via lipid peroxidation, ROS 
are also known to promote cell death by apoptosis.  Since endothelial cells are integral in BP 
control, evaluation of their apoptosis would provide further evidence of vascular dysfunction.  
Lastly, because heparin has been suggested to have antioxidant activity, its delivery into an in 
vivo model of hHCy should attenuate CV oxidative stress and any correlated hemodynamic 
changes. 
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1.3. OBJECTIVES 
Therefore the specific objectives of this study are to: 
1. Develop an in vivo animal model of hHcy by providing a high-methionine diet, 
demonstrated by measuring fasting total plasma Hcy concentrations. 
2. Evaluate the correlation between increasing plasma levels of Hcy to the hemodynamics of 
anesthetized animals.  
3. Determine if Hcy has a causal role in the development of hypertension and if heparin 
attenuates its effects. 
4. Determine whether Hcy induces oxidative stress by measuring serum and tissue MDA 
and plasma and tissue GSH concentrations and whether heparin attenuates its effects. 
5. Determine whether Hcy induces endothelial cell apoptosis and whether heparin attenuates 
its effects. 
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2.0. MATERIALS AND METHODS 
2.1. MATERIALS 
L-cysteine, DL-homocysteine, L-glutathione reduced, L-methionine, D-penicillamine, 
5,5‟-dithiobis-2-nitrobenzoic acid (DTNB), dithiothreitol (DTT), propidium iodide (PI), hoescht 
33258, tetra ethoxy propane (TEP), sodium dodecyl sulfate (SDS), glacial acetic acid (HAc), 
triton-X-100 (Tx), sulfosalicylic acid, and ethylene diamine tetra acetic acid (EDTA) were 
obtained from Sigma Chemical Company, St. Louis, MO, USA.  Bio-Rad protein assay was 
acquired from Bio-Rad, Hercules, CA, USA.  DeadEnd Fluorometric TUNEL System was 
obtained from Promega, Madison, WI, USA.  Thiobarbituric acid (TBA) was purchased through 
Helixx Technologies, Scarborough, ON, Canada.  Halocarbon Products Corporation, River Edge, 
NJ, USA provided Halothane and Baxter Corporation, Toronto, ON, Canada provided AErrane 
(isoflurane, USP) for anesthetic use.  All other chemicals are of reagent grade and were obtained 
from VWR International Inc., West Chester, PA, USA.  Homocysteine reagent pack for use with 
the Abbott IMx Instrument for the detection of total homocysteine in plasma was obtained from 
Abbott Laboratories, Abbott Park, IL, USA. 
2.2. METHODS 
2.2.1. Study Design 
2.2.1.1. High Methionine Diet Induced Changes in Fasting Plasma Homocysteine Levels and 
Hemodynamic Parameters 
This study was designed to investigate the effect of a high methionine diet on fasting 
plasma Hcy levels and hemodynamic parameters in male Wistar Kyoto (WKY) rats.  The study 
included 4 diet treatment groups at 2, 4, 6 and 8 weeks exposure, as well as 2 age-matched 
groups at 2 and 8 weeks fed a control rat diet (n = 5 – 6 per group).   
2.2.1.2. Hemodynamic Responses to Different Inhalation Anesthetics 
This study was designed to investigate if the type of inhalation anesthetic used during 
surgery produced any differences in the hemodynamic parameters of male Sprague Dawley (SD) 
rats fed a high methionine diet for 2 or 4-weeks, including 2 week age-matched controls (n = 5 – 
6 per group). 
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2.2.1.3. Effect of Oral Heparin on Homocysteine Induced Changes to Hemodynamic 
Parameters, Lipid Peroxidation, Reduced Glutathione Concentrations and Endothelial 
Cell Apoptosis 
This study was designed to evaluate the effect of oral heparin treatment (1 mg/kg/48 
hours) on the hemodynamics, lipid peroxidation status, reduced glutathione (GSH) 
concentrations and endothelial cell apoptosis in male WKY rats with elevated fasting plasma 
homocysteine levels (n=5 per group).  
2.2.1.4. Definition of Variables 
The following variables, used throughout this work and are defined as follows: 
 Hyperhomocysteinemia (hHcy) – significantly elevated fasting plasma Hcy levels 
compared to control. 
 Hypertension – significantly elevated arterial blood pressure compared to control. 
 Oxidative stress – significantly lowered GSH concentrations and/or increased 
malondialdehyde levels.  
2.2.2. Diet Model of Hyperhomocysteinemia 
Male WKY rats were fed a modified diet to induce hHcy.  Rats were fed a diet of normal 
rat chow ad libitium, which already contains an essential 0.33% methionine to which an 
additional 1.7% w/w L-methionine was added for a final concentration of 2.03% methionine.  
The rats were separated into experimental groups of 2, 4, and 8 weeks exposure.  Control rats 
were age matched to the 2 and 8 week exposure group.  Body mass was recorded for each 
experimental animal prior to surgery. 
2.2.3. Hemodynamic Investigation 
2.2.3.1. Surgery and anesthesia 
At the end of each diet or control period the rats were anesthetized with isoflurane or 
halothane at 5.0% / L O2(g) to induce, and 2.0% / L O2(g) for maintenance of surgical anesthesia.  
To perform hemodynamic studies, a Millar MikroTip Pressure Catheter was positioned directly 
at the site of pressure measurement in either the LV or outside of the aortic arch in the right 
common carotid artery.  The MikroTip catheter was appropriate for insertion into the rat carotid 
artery as the transducer size was 2 French and the wire thread through the vasculature measures 
at 1.5 French.  The pressure catheter was inserted through the right common carotid artery and 
53 
 
advanced into the LV.  The pressure catheter was allowed to normalize for 30 minutes in the LV 
at which point it was retracted into the carotid artery where it was stabilized for 15 minutes until 
the end of the hemodynamic measurement.   
Once the catheter was removed from the animal, arterial blood was collected from a 
cannula placed into the left common carotid artery.  A total of 7 ml of blood was drawn into 
vacutainers appropriate for future assay.  For assays requiring plasma, 5 ml of blood was 
collected on ice in EDTA tubes.  These tubes were divided into 3 ml of plasma for HPLC 
analysis and 2 ml for Hcy determinations.  For the MDA assay, the remaining 2 ml of arterial 
blood was collected in a serum collection tube.  Following bleeding, the animal was sacrificed 
and the mesentery, first order mesenteric artery branching directly off of the aorta, the aorta, 
renal artery, kidney and heart were rapidly excised, gently cleaned of blood and debris and stored 
appropriately based on the assay they were collected for.   
2.2.3.2. Data collection 
Data was acquired on a Biopac Data Acquisition system and all hemodynamic 
measurements were made assessing the data on AcqKnowledge software.  Left ventricular (LV) 
hemodynamics were assessed during the last 5 minute segment of the 30 minute normalization 
period.  Left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure 
(LVEDP), left ventricular developed pressure (LVDP) and the myocardial index of ventricular 
contraction (+dp/dt) and relaxation (-dp/dt) were assessed.  Both the rate of contraction and 
relaxation were assessed as the maximal slope of the LV pressure waveform either during the 
rising/contraction or falling/relaxation phase.  The LVSP was determined as the maximum 
pressure reached during ventricular ejection and the LVEDP was assessed as the pressure 
immediately following atrial contraction and ventricular filling.  The LVDP was the difference 
between the maximum and minimum pressures recorded from the LV.   
Arterial pressures were recorded and analyzed with AcqKnowledge software.  Arterial 
pressure was recorded in the last 5 minute recording segment during the 15 minute stabilization 
period when the pressure tip was in the common carotid artery.  Diastolic pressure (DP) was seen 
as the minimum pressure of the arterial waveform.  Systolic pressure (SP) was recorded as the 
maximum pressure of the arterial waveform.  Pulse pressure (PP) was calculated as the 
difference between systolic and diastolic pressures, and mean arterial pressure (MAP) was 
calculated as DP + 1/3 PP.   
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2.2.4. Oral Heparin Administration 
Unfractionated bovine lung heparin was dissolved in water at a concentration of 5 mg/ml.  
The dosage of oral heparin was 1 mg/kg/48hrs for 8 weeks.  Heparin was given by oral gavage 
using a steel needle with a blunted end, 7.5 cm in length, to which a 1 ml syringe was attached.  
Control animals were given 0.4 ml saline by oral gavage every 48 hours.    
2.2.5. Detection of Apoptotic Endothelial Cells 
2.2.5.1. Tissue collection, preservation and storage 
Endothelial cells were assessed for apoptosis in the first order mesentery artery, renal 
artery and the aortic arch.  After the tissues were removed they were fixed for 24 hours in 10% 
buffered formalin, then cryoprotected by dehydrating the tissue in 30% sucrose solution for a 
minimum of 72 hours.  The tissue was then embedded in optimal cutting temperature (OCT) 
medium and fast frozen in liquid nitrogen.  Frozen samples were kept at -20ºC until they were 
cut by a cryostat and mounted on permafrost slides (VWR).  Slides with tissues were kept at -
20ºC until stained. 
2.2.5.2. TUNEL staining protocol 
TUNEL staining procedure was carried out following the manufacturer‟s specifications 
from Promega‟s DeadEnd Flurometric TUNEL system.  In brief, slides with tissues were 
washed twice with phosphate buffered saline (PBS) at pH 7.4, after which the tissues were 
incubated for 8-10 minutes in 20 µg/ml proteinase K solution.  After an additional wash with 
PBS, tissues were fixed in 4% paraformaldehyde.  To detect apoptosis tissue sections were 
exposed to 25 µl of equilibration buffer for 5-10 minutes.  Positive controls were prepared by 
fragmenting chromosomal DNA with DNase 1 for 10 minutes, which exposes multiple 3‟-OH 
DNA ends for labeling by the TUNEL method.  Fluorescence labeling of apoptotic EC was 
accomplished by incubating all tissue sections, except the negative controls, with rTDT 
incubation buffer for 1 hour in a humidified chamber.  Negative controls were treated in the 
same fashion except the incubation buffer used for treatment was void of the rTDT enzyme.  
Immersing the tissue sections in an inorganic sodium chloride/sodium citrate solution for 15 
minutes terminated the reaction.  After washing several times in PBS, the propidium iodide (PI) 
nuclei stain was added to tissue sections and incubated at room temperature in the dark for 15 
minutes.   
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Samples were analyzed using a fluorescence microscope with a standard fluorescein filter 
set to view the TUNEL green fluorescence at 520 ± 20 nm and the red fluorescence of the PI 
nuclei stain at >620 nm.  The nuclear stain fluoresces red, and the TUNEL stain fluoresced 
green, therefore when overlaid cells are seen to fluoresce yellow, and were counted as apoptotic 
ECs.  Cells that failed to fluoresce yellow when images were overlaid, but still displayed the red 
nuclear stain were counted as non-apoptotic ECs.    Slides were mounted with antifade and 
sealed with coverslips for storage at 4ºC until images were taken.  All yellow cells, identified on 
the lumen side of the basal lamina were considered positive for apoptotic endothelial cells.  
Positive stained apoptotic endothelial cells were counted and expressed as % apoptotic 
EC/tissue/animal group. 
2.2.6. High Performance Liquid Chromatography Assay of Sulfhydryl Amino Acids 
Ellman‟s reagent, 5-5‟-dithiobis(2-nitrobenzoic acid) (DTNB) is prevalently used for the 
detection of thiol groups as it reacts with these groups to give a mixed disulfide which can be 
quantified by its UV absorbance (1).  Combining the effects of DTNB with precise UV detection 
by high performance liquid chromatography (HPLC), permits for the chromatographic separation 
of the derivatized thiols, thus allowing for quantitative, sensitive and precise measurements of 
free reduced sulfhydryl concentrations in biological matrices.  Dithiothreitol (DTT) was used via 
HPLC chromatographic separation in the same fashion as DTNB.  
2.2.6.1. Instrumentation 
Chromatographic analysis was performed with a Hitachi D-7000 HPLC system which 
was composed of a L7400 UV detector, L7200 auto-sampler, L7100 pump and water bath.  Data 
was collected digitally with the Hitachi model D7000 HSM chromatography data station 
software. 
2.2.6.2. Preparation of reagents 
Mobile phase A was prepared from a stock solution of 0.5 M KH2PO4 adjusted to pH 
3.89 with orthophosphoric acid, double distilled water (ddH2O) and HPLC grade methanol.  The 
final composition of the mobile phase was 12.5% methanol (v/v), 100 mM KH2PO4 at a final pH 
of 3.89.  The mobile phase was filtered with a nylon membrane filter with a pore size of 0.45.  
Mobile phase B was used to elute excess DTNB and DTT from the column comprised of 40% 
HPLC grade methanol (v/v), 100 mM KH2PO4, pH 3.89 and filtered as described above.  Mobile 
phases were stored at 4ºC between uses. 
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A 10 mM stock solution of DTNB was prepared by dissolving 396 mg of DTNB in 100 
ml of 0.5 M KH2PO4, pH 7.2, stored at 4ºC and used within a month.  A 10 mM stock solution of 
DTT was prepared by dissolving 15.4 mg of DTT in 10 ml of distilled water, which was 
refrigerated and used within 2 weeks.  A solution of 5% (w/v) sulfosalicyclic acid (SSA) 
containing 0.2 mM EDTA was prepared for use with blanks, standards and samples.  A solution 
of 9% SSA containing 0.2 mM EDTA was prepared for acidifying and thus stabilizing 
sulfhydryls in plasma samples.  A 7 M ortho-phosphoric acid solution was prepared by mixing 
equal volumes of 85% (w/v) H3PO4 and water.   
2.2.6.3. Standards 
Calibrators and internal standards were made up in the 5% SSA solution containing 0.2 
mM EDTA from 100 mM stock solutions of each compound.  The calibrating compounds 
consisted of cysteine, glutathione and homocysteine, with an internal standard of penicillamine.  
The high calibrator consisted of 25 µM cysteine, 100 µM glutathione and 45 µM homocysteine.  
The low calibrator consisted of 2.5 µM cysteine, 10 µM glutathione and 4.5 µM homocysteine.  
The internal standard was prepared as a stock solution of 100 mM.  
2.2.6.4. Derivatization and sample preparation 
Samples used for the assay of sulfhydryl amino acids and peptides included plasma, 
kidney, liver, and left ventricular tissue.  Equal volumes of plasma and 9% sulfosalicyclic acid 
containing 0.2 mM EDTA provided plasma antioxidant stabilization.  The protein precipitate was 
removed by microcentrifugation for 5 minutes and the supernatant was removed and stored at -
80ºC until assayed.  Tissue samples were washed and quick frozen in liquid nitrogen 
immediately after being excised.  Frozen tissues were then processed in a frozen state in a mikro-
dismembrator and reconstituted 1:30 with 5% SSA containing 0.2 mM EDTA.  The reconstituted 
tissue samples were sonicated at 40 hertz twice for 5 seconds, then once for 10 seconds.  The 
samples were then centrifuged at 12,000 rpm for 20 minutes at 4ºC, after which the supernatant 
was collected and kept on ice until assayed or stored at -80ºC for up to one week.   
The reaction mixtures for the determination of free reduced sulfhydryls consisted of 250 
µL of TRIS buffer, pH 8.9, 65 µL of standard/sample, 10 µL of internal standard, 10 µL of 
ddH2O and 175 µL of DTNB.  Once all reagents and samples were added to the tubes, the 
mixture was allowed to sit for 5 minutes while the DTNB reacts with the proteins.   The reaction 
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mixture was then re-acidified by adding 23 µL of 7 M H3PO4 dropwise while mixing to prevent 
protein precipitation.  The derivatives were stable for at least 28 hours at room temperature. 
The reaction mixture for the analysis of total sulfhydryls and reduced disulfides consisted 
of 250 µL of TRIS buffer, pH 8.9, 65 µL of standard/sample, 10 µL of internal standard, 175 µL 
of DTNB and 10 µL of DTT.  The reaction mixture was incubated for 5 min and acidified as 
described for the reduced sulfhydryls.  Once both reaction mixtures were ready, 130 µL was 
loaded into vials in duplicate and placed into the auto-sampler for injection onto the HPLC.   
2.2.6.5. Chromatography 
Chromatography of the sulfhydryl-DTNB and –DTT derivatives were accomplished 
using isocratic elution on a Supelco LC-18T column (150 x 4.6 mm, 3 µm) at 37ºC using a 
waterbath.  The mobile phase A was run at a flow rate of 0.9 ml/min.  Sulfhydryl-derivatives 
were detected by UV absorbance at 345 nm.  After 10 minutes of isocratic elution the mobile 
phase was switched to mobile phase B and ran for 8 minutes to elute excess DTNB or DTT 
reagent from the column.  The column was then equilibrated for 7 minutes with mobile phase A 
before ejection of the next sample.  Injection volume for each sample/standard was 50 µL.   
2.2.6.6. Protein determination  
Total protein concentrations were determined by the Bradford assay (1976) using 
reagents supplied by Bio-Rad and bovine serum albumin (BSA) as a standard.  In a 1 mL 
disposable cuvette 20 μL of supernatant or serum samples were diluted to a total volume of 800 
μL with distilled water (ddH2O).  Then 200 μL of Bio-Rad reagent was added to achieve a final 
volume of 1 mL, which was incubated at room temperature for 10 minutes.  Following 
incubation, the absorbance was read at 595 nm in a spectrophotometer. 
2.2.7. Malondialdehyde (MDA) Assay 
The amount of membrane lipid peroxidation was determined using a spectrophotometeric 
method adapted from Ohkawa, Ohishi and Yagi (1979).  This method measures the interaction 
between thiobarbituric acid (TBA) and a breakdown product of lipid peroxidation, 
malondialdehyde (MDA).   
2.2.7.1. Tissue and serum preparation 
Rat tissues (kidney, liver, LV, mesentery and aorta) and serum samples were assayed for 
MDA concentrations.  Tissues samples were rapidly homogenized in a phosphate buffer solution 
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immediately following their excise.  The homogenates were centrifuged at 4ºC, at 3000 rpm for 
10 minutes, and the resultant supernatant was collected and stored at -80ºC until assayed.   
For serum samples, 2 ml of arterial blood were collected in labeled serum vacutainer 
tubes.  The blood was stored at 4ºC, left to clot for no more than 6 hours, and then centrifuged at 
3000 rpm for 15 min.  Serum was pipetted into labeled Eppendorf tubes and stored at -80ºC until 
assayed.  
2.2.7.2. Reagent preparation 
A 100 µM stock solution of MDA standard of tetraethoxypropane (TEP) was prepared by 
adding 6 µL of TEP to 250 ml of ddH2O.  The resultant stock solution was then diluted to a 10 
µM working standard prior to assay by diluting 0.1 mL of the stock standard to 0.9 mL of 
ddH2O.  The MDA standard was stored under refrigeration for up to one week. 
A solution of 8.1% (w/v) sodium dodecyl sulphate (SDS) was prepared by dissolving 8.1 
g of SDS in 100 mL of ddH2O.  The SDS solution was stored at room temperature. 
The solution of 0.67% (w/v) thiobarbituric acid (TBA) was prepared by dissolving 3.35 g 
of TBA in 40 mL of 2 M sodium hydroxide and pH was corrected to 5.9 with 0.1 M NaOH.  The 
solution was then brought up to a 500 mL volume with ddH2O. 
Glacial acetic acid (HAc) was diluted with ddH2O 1:4 in a fume hood, to make a 20% 
solution, and pH corrected to 3.4 with 0.1 M NaOH. 
The 15:1 butanol/pyridine solution was prepared in a fume hood by combining 50 mL of 
pyridine with 750 mL of butanol. 
2.2.7.3. Reaction and detection methods 
The reaction mixture contained 50:50, 20% HAc, pH 3.4: 0.67% (w/v) TBA.  Tissue 
supernatant and serum samples of 100 μL were placed into glass test tubes mixed with 3 mL of 
reaction mixture and 200 μL of 8.1% (w/v) SDS and brought to 1 mL volume with 700 μL 
ddH2O.  Test tubes were incubated in a glycol bath at 98ºC for one hour.  After heating, 1.0 mL 
of ddH2O was added to cool the reaction mixture, and 5.0 mL of butanol pyridine (15:1) was 
added to all tubes.  Tubes were then capped and vortexed for 10 seconds each.  The vortexed 
tubes were centrifuged at 3000 rpm for 15 minutes.  The top layer was removed and read in a 
P2000 fluorometer at an excitation of 515 nm and emission of 553 nm.  Concentrations of serum 
MDA were expressed as nmol/L, while tissue MDA was expressed as nM/mg protein, as 
compared to standards of 10 μmol/L tetraethoxypropane.  
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2.2.8. Fasting Plasma Homocysteine Determination 
2.2.8.1. Animal Fasting 
All animals were fasted overnight, between 8 – 14 hours prior to surgery and bleeding, 
from either control or high-methionine diet depending on the experimental group.   
2.2.8.2. Plasma preparation 
Arterial blood was drawn and collected in EDTA vacutainer tubes on ice.  Tubes were 
kept on ice and transported to blood chemistry laboratory at the Royal University Hospital in 
Saskatoon, Saskatchewan for the assay of total homocysteine concentrations.   
2.2.8.3. Assay for the detection of Homocysteine in plasma 
 An Abbott IMx instrument utilizing fluorescence polarization (FPIA) technology 
was used to quantify total plasma homocysteine concentrations.  A minimum of 50 µL of plasma 
was required to run the assay.  The basic properties of the assay involve the reduction of 
homocysteine, mixed disulfides, and protein bound forms of homocysteine in the sample to form 
free homocysteine under the influence of the enzyme dithiothreitol (DTT).  The total free Hcy is 
then transformed to S-adenosyl-L-homocysteine (SAH) by the enzyme SAH hydrolase and 
residual adenosine.  Both the SAH form of homocysteine and the labeled S-adenosyl-L-cysteine 
fluorescein tracer, acting as antigens, compete for sites on an Anti-S-adenosyl-L-homocysteine 
mouse monoclonal antibody molecule (anti-S-adenosyl-L-homocysteine mouse monoclonal 
antibody, S-adenosyl-L-cysteine fluorescein tracer and SAH hydrolase are all contained in the 
homocysteine reagent pack provide by Abbott Laboratories).  The polarization from the 
fluorescein-antigen conjugate was determined by its rate of rotation during the lifetime of the 
excited state in solution.  The binding of the antigen to the antibody therefore changed the 
polarization of the compound.  Lastly, the intensity of the polarization was measured by the 
FPIA optical assembly and related to the known antigen concentration (Shipchandler et al. 
1995).  
2.2.9. Statistical Methods 
Results were expressed as mean ± standard error of the mean (SEM).  The data were tested 
by paired Student‟s t-tests.  The difference was considered significant is p was less than 0.05. 
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3.0. RESULTS 
3.1. CREATING A RAT MODEL WITH ELEVATED FASTING PLASMA 
HOMOCYSTEINE 
Plasma total homocysteine concentrations measured in fasted WKY rats for control and 
high-methionine diet (MD) (5/group) are shown in Figure 3.  Homocysteine concentrations were 
similar for the 2 and 8 week control rats and were 4.32  0.16 and 4.93  0.24 mol/L 
respectively. 
At 2 weeks of MD exposure, mean total plasma homocysteine concentrations were 5.52  
0.29 mol/L and were significantly elevated compared to their age-matched controls (p=0.01), 
but not compared to the 8 week control group.  After 4 and 8 weeks of MD exposure, plasma 
homocysteine levels were 5.89  0.4 and 7.22  0.24 mol/L respectively.  Both exposure groups 
had significantly elevated homocysteine levels compared to the 2 week control rats (p<0.05).  
The homocysteine levels in the 8 week MD group were also significantly elevated compared to 
their age-matched controls (p=0.01).  
A linear-regression analysis between total fasting plasma homocysteine and the duration 
of MD exposure is shown in Figure 4.  Homocysteine concentrations beginning at 4.5  0.01 
mol/L increased linearly up to 7.2  0.58 mol/L at 8 weeks MD exposure.  As shown by the 
coefficient of determination (r² = 0.9098), 90% of the variance seen in homocysteine levels is 
due to the duration of exposure to MD.  However, the observed changes in Hcy levels between 2, 
4 and 8 weeks MD exposure groups failed to reach significance by student t-tests. 
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Figure 3  Plasma total homocysteine concentrations in fasted male WKY rats fed a modified diet 
containing 2% methionine for up to 8 weeks.  Homocysteine levels were significantly increased 
by 2 weeks on the modified diet and remained elevated for the duration of diet exposure.  Data is 
expressed as mean ± SE (n = 4 – 5).  * p<0.05 vs. 2 week control; † p<0.05 vs. 8 week control.    
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Figure 4   Linear regression analysis of fasting total plasma homocysteine concentrations 
contained in a 95% confidence interval (dotted lines) vs. duration of MD exposure in WKY rats 
(n = 4 – 5).  Homocysteine concentrations increase linearly with duration of MD exposure (r2 = 
0.9098).   
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3.2. EFFECT OF HALOTHANE OR ISOFLURANE ANESTHETIC ON 
HEMODYNAMICS IN SPRAGUE DAWLEY RATS ON A HIGH METHIONINE 
DIET FOR UP TO 4 WEEKS  
Since supplies of halothane were discontinued, the effect of different anesthetics on the 
hemodynamics of male SD rats was investigated.  Groups were halothane and isoflurane 
anesthetic in control diet groups, 2 week MD exposure groups and 4 week MD exposure groups.  
The following hemodynamic parameters: left ventricular systolic pressure, left ventricular end-
diastolic pressure, left ventricular developed pressure, myocardial indices of contractility and 
relaxation, arterial systolic pressure, diastolic pressure and mean arterial pressure.   
3.2.1. Left ventricular systolic pressure (LVSP) 
The effect of anesthetic and MD exposure on LVSP is shown in Figure 5.  LVSP is 
significantly elevated (p=0.014) in the isoflurane control (104.96  2.73 mmHg) compared to the 
halothane control group (94.37  1.46 mmHg).  The reverse was seen at the 2-week diet 
exposure period where there was a trend towards an increase in LVSP in the halothane group 
where the 2-week halothane group LVSP was 105.75  2.59 mmHg compared to in the 2-week 
isoflurane diet group 94.82  3.98 mmHg (p=0.050).  Increased exposure periods to the MD 
increased LVSP in the halothane anesthetized rats only.  The 2-week diet exposure group, 
anesthetized with halothane, had significantly higher LVSP than their anesthetic control 
(p=0.0065) as did the 4-week diet exposure halothane group (116.87  5.02 mmHg), (p=0.0077).  
The LVSP in the 4-week diet exposed halothane group (109.28  2.96 mmHg) was significantly 
greater than the 2-week isoflurane diet group (p=0.0074), but not the 4-week isoflurane diet 
group (p=0.23).  
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Figure 5 Left ventricular systolic pressure in control or MD exposed SD rats for 2 and 4 weeks 
anesthetized with halothane or isoflurane.  Isoflurane control LVSP was significantly elevated as 
compared to halothane controls (p=0.014).  LVSP was significantly elevated in the 2-week and 
4-week halothane MD exposed groups compared to halothane controls.  The 4-week MD group 
with halothane anesthetic was also found to be significantly elevated above the 2-week 
isoflurane MD exposed group.  Data is expressed as mean ± SE (n = 5 – 6). * p=0.0141 vs. 
halothane control. ** p<0.01 vs. halothane control.  † p=0.0074 vs. I2. 
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3.2.2. Left ventricular end-diastolic pressure (LVEDP) 
The effect of anesthetic and MD exposure on left ventricular end-diastolic pressure is 
shown in Figure 6.  There was no significant change in LVEDP seen with anesthetic use or with 
diet exposure between all groups.   The LVEDPs in halothane control, 2-week and 4-week high 
methionine exposure groups were 15.65  2.63, 14.77  1.31 and 18.85  3.26 mmHg 
respectively.  In isoflurane control, 2-week and 4-week high methionine exposure groups, 
LVEDPs were 8.78  3.37, 11.20  1.30 and 11.53  4.08 mmHg respectively.       
3.2.3. Left ventricular developed pressure (LVDP) 
The effect of anesthetic and MD exposure on left ventricular developed pressure is shown 
in Figure 7.  LVDP were 83.25  3.23 and 101.4  4.62 mmHg for the halothane and isoflurane 
controls respectively, and were significantly higher with isoflurane treatment (p = 0.02).  At 4 
weeks of MD exposure, LVDP for the halothane and isoflurane groups were 97.67  3.39 and 
107.60  1.06 mmHg respectively and were significantly higher with isoflurane treatment 
(p=0.038).  The LVDP in the 4 week halothane MD exposed group was significantly elevated vs. 
its anesthetic control (p=0.013). 
Within the isoflurane groups there was no significant differences observed in LVSP.  
There were also no differences observed between the 2 weeks MD exposure groups and any 
other MD or anesthetic groups.        
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Figure 6  Left ventricular end-diastolic pressure (LVEDP) in control or MD exposed SD rats for 
2 and 4 weeks anesthetized with halothane or isoflurane.  There was no significant change in 
LVEDP measured between any of the anesthetic or diet exposure groups.  Data is expressed as 
mean ± SE (n = 5 – 6).       
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Figure 7   Left ventricular developed pressure (LVDP) in control or MD exposed SD rats for 2 
and 4 weeks and anesthetized with halothane or isoflurane.  LVDP was measured as the 
maximum LV pressure – minimum LV pressure.  Both the isoflurane control and 4 week 
isoflurane MD exposed rats had significantly higher LVDP than their respective matched 
halothane control and 4 week MD exposed rats.  Data is expressed as mean ± SE (n = 5 – 6). * 
p<0.05. 
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3.2.4. Myocardial index of contractility (+ dp/dt) and relaxation (- dp/dt) 
The effect of anesthetic and MD exposure on the myocardial index of contractility is 
shown in Figure 8.  Halothane anesthesia resulted in significantly lower + dp/dt compared to 
isoflurane anesthesia.  The + dp/dt for halothane vs. isoflurane groups was respectively 4119  
273 and 6885  371 mmHg/sec, (p=0.0095) in the control groups, 4711  300 and 6624  372 
mmHg/sec, (p=0.017) in the 2 week diet groups and 5090  225 and 8076  341 mmHg/sec, 
(p=0.0043) in the 4 week diet group.  
 The effect of anesthetic and MD exposure on the myocardial index of relaxation 
is also shown in Figure 8.  No significant change in – dp/dt was observed between matched 
anesthetic groups.  The – dp/dt in control halothane and isoflurane was 3627  491 and 4299  
396 mmHg/sec respectively.   In the 2 week diet treated groups, halothane and isoflurane groups 
the – dp/dt was 4356  382 and 4376  467 mmHg/sec respectively and in the 4 week diet group 
4894  270 and 5459  193 mmHg/sec respectively.  At 4 weeks of MD exposure, - dp/dt was 
significantly increased in each anesthetic group vs. their controls with p values of p=0.035 and 
p=0.046 for the halothane and isoflurane groups respectively.       
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Figure 8  Myocardial index of contractility (+dp/dt)  and relaxation (-dp/dt) in control or MD 
exposed SD rats for 2-4 weeks anesthetized with halothane or isoflurane.  All of the isoflurane 
anesthetized animals had significantly higher +dp/dt than their respective matched halothane 
groups.  The 4-week MD groups -dp/dt were significantly elevated as compared to their matched 
anesthetic control. Data is expressed as mean ± SE; (n = 5 – 6).  – dp/dt: * p=0.035 vs. halothane 
control, † p=0.046 vs. isoflurane control.  +dp/dt: * p<0.05; ** p<0.01 
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3.2.5. Systolic Arterial Pressure (SP) 
The effect of different anesthetics and MD exposure on systolic arterial pressure (SP) is 
shown in Figure 9.  No significant changes were observed in SP between halothane and 
isoflurane anesthetic controls (97.77  1.17 and 98.90  5.54 mmHg, p=0.85 respectively), and 
2-week diet exposure groups (104.4  3.10 and 107.2  3.97 mmHg, p=0.43 respectively).  The 
SP of the 4-week halothane MD group (118.9  4.12 mmHg) was significantly elevated 
compared to its anesthetic control (p=0.0078), the isoflurane control (p=0.02) and the 4-week 
diet isoflurane group (106.6  2.3 mmHg; p=0.041).  There was a trend towards a significant 
increase in SP in the 2-week MD halothane group compared to its anesthetic control (p=0.052). 
3.2.6. Diastolic Arterial Pressure (DP) 
The effect of different anesthetics and MD exposure on diastolic arterial pressure is 
shown in Figure 9.  In the control groups, halothane treatment DP (81.52  3.59 mmHg) was 
significantly higher (p=0.02) than isoflurane (67.65  3.64 mmHg).  Anesthetic treatment had no 
significant effect on DP between either the halothane or isoflurane 2-week (79.97  2.54 and 
73.07  4.84 mmHg respectively, p=0.39) or 4-week diet groups (88.33  4.83 and 75.33  2.69 
mmHg respectively, p=0.065).  Diet treatment also produced no change between 2 and 4 week 
isoflurane (p=0.48 and p=0.09) and halothane (p=0.48 and p=0.24) MD groups vs. their controls.   
3.2.7. Mean Arterial Pressure (MAP) 
The effect of different anesthetics and MD exposure on mean arterial pressure is shown 
in Figure 9.  There was a significant increase in MAP in the halothane control group, 84.89  
1.76 mmHg vs. the isoflurane control group, 74.62  3.05 mmHg, p=0.027.  There was no 
change observed between the halothane and isoflurane 2-week diet exposure groups MAP (85.52 
 1.08 and 86.87  3.79 mmHg respectively).  The 4-week isoflurane diet exposure group MAP, 
85.76  2.55 mmHg was significantly elevated compared to its anesthetic control (p=0.023).  
There was a trend towards an increase in MAP with increased diet exposure as the 4-week 
halothane diet group MAP, 96.99  5.10 mmHg was elevated, compared to 84.89 ± 1.76 mmHg 
in the halothane control (p=0.066).       
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Figure 9   Arterial systolic pressure (SP), diastolic pressure (DP) and mean arterial pressure 
(MAP) measured in control or MD exposed SD rats for 2 and 4 weeks anesthetized with 
halothane or isoflurane.  The DP in halothane anesthetized controls was significantly higher than 
the isoflurane anesthetized controls (* p=0.02).  The SP in the 4 week MD halothane group was 
significantly higher than its anesthetic control (** p=0.008), the isoflurane control (* p=0.019) 
and the 4-week isoflurane diet exposure group (* p=0.04).  The MAP in the halothane 
anesthetized control was significantly higher than the isoflurane anesthetized controls (* 
p=0.027).  MAP was also significantly elevated in the 4-week isoflurane diet exposure group vs. 
its anesthetic control (* p=0.023).  Data is expressed as mean ± SE, n = 5 – 6.    
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3.3. HEMODYNAMICS OF RATS WITH ELEVATED PLASMA HOMOCYSTEINE 
LEVELS 
A hemodynamic investigation was made on the effect of MD exposure in male WKY rats 
for up to 8 weeks, including 2-week and 8-week age-matched controls measured under isoflurane 
anesthetic.  Hemodynamic parameters are divided into LVSP, LVEDP, LVDP, myocardial 
indices of contractility and relaxation, SP, DP and MAP.   
3.3.1. Left ventricular systolic pressure (LVSP) 
The effect of MD exposure on LVSP is shown in Figure 10.  LVSP was significantly 
elevated by 6 weeks of MD feeding (115.2  1.48 mmHg, p=0.037) and remained significantly 
elevated at 8-weeks of MD exposure (124.7  5.0 mmHg, p=0.0086) compared to the 2-week 
control (98.86  5.1 mmHg).  The 4-week diet group (109.3  2.96 mmHg) had a significantly 
higher LVSP than the 2-week diet group (p=0.0194), as did the 6-week (p=0.003) and 8-week 
(p=0.0016) diet groups.  As well, the 8-week diet group had a significantly higher LVSP than the 
4-week diet group (p=0.0385).  The 8-week high methionine group was the only group found to 
have significantly elevated LVSP compared to the 8-week control group (110  5.21 mmHg, 
p=0.0243).   
3.3.2. Left ventricular end-diastolic pressure (LVEDP) 
The effect of MD exposure on LVEDP is shown in Figure 11.  LVEDP was significantly 
elevated in the 8-week MD group (20.06  2.96 mmHg) compared to age-matched control (6.36 
 1.61 mmHg, p=0.0067)), as well as the 2-week diet (11.2  1.3 mmHg, p=0.0409) and 6-week 
diet groups (9.9  1.46 mmHg, p=0.0277).  The LVEDP for the 2-week control, 10.58  3.68 
mmHg, and 4-week diet group, 11.53  4.08 mmHg were not significantly different than any 
other group.  Also the LVEDP in the 8-week control group was significantly elevated compared 
to the 2-week diet exposure groups (p=0.048).       
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Figure 10  Left ventricular systolic pressure (LVSP) measured in male WKY rats fed a high 
methionine diet.  Rats were divided into groups exposed to a high (2%) methionine diet (MD) for 
2, 4, 6 and 8 weeks as well as 2 and 8 week age-matched WKY rats fed a control diet.  LVSP 
was significantly elevated compared to the 2-week control group by 6 weeks of MD feeding.  
LVSP in the 8-week MD group was significantly elevated compared to the 2-week control, as 
well as the 2, 4-week diet groups and the 8-week control group. The 6-week diet group was also 
significantly elevated compared to the 2-week diet group.  The 4-week diet group also had a 
significantly higher LVSP than the 2-week diet group.  Data is expressed as mean ± SE, n = 5 – 
6. *: p=0.0086 vs. 2-week control; p=0.0016 vs. 2-week MD; p=0.0243 vs. 8-week control.  **: 
p=0.0369 vs. 2-week control; p=0.003 vs. 2-week MD. †: p=0.0194 vs. 2-week MD. 
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Figure 11  Left ventricular end-diastolic pressure (LVEDP) measured in male WKY rats fed a 
high methionine diet.  Rats were divided into groups exposed to a high (2%) methionine diet 
(MD) for 2, 4, 6 and 8 weeks as well as 2 and 8 week age-matched WKY rats fed a control diet.    
LVEDP was significantly elevated in the 8 week MD compared to its age-matched control, and 
the 2-week and 6-week MD groups.  The 8-week control group had a significantly lower LVEDP 
than the 2-week MD group.  Data is expressed as mean ± SE, n = 5 – 6.  † p<0.05 vs. 2 and 6-
week MD; ‡ p=0.0067 vs. 8-week control; * p=0.0478 vs. 2-week MD. 
75 
 
 
3.3.3. Left ventricular developed pressure (LVDP) 
The effect of MD exposure on LVDP is shown in Figure 12.  The 4, 6 and 8-week diet 
groups and the 8-week control group all had significantly higher LVDP (100.3  1.46, 105.3  
1.3, 104.6  4.71 and 103.6  3.68 mmHg respectively), than the 2-week diet exposure group 
(86.6  2.01 mmHg) (p<0.01).  The 6-week diet group also had a significantly higher LVDP than 
the 4-week diet group and 2-week control LVDP (93.8  4.13 mmHg) (p<0.05).     
3.3.4. Myocardial index of contractility (+dp/dt) and relaxation (- dp/dt) 
The effect of MD exposure on the myocardial index of contractility (+dp/dt) is shown in 
Figure 13.  The + dp/dt was significantly elevated after 4 and 6 weeks of MD exposure (8076 ± 
340 and 8867 ± 328 mmHg/sec respectively) compared to the 2 week control group (6149 ± 791 
mmHg/sec, p=0.016 vs. 4 week MD and p=0.0043 vs. 6 week MD) and the 2 week MD group 
(6031 ± 666 mmHg/sec, p=0.0087 vs. 4 week MD and p=0.0022 vs. 6 week MD).  After 8 weeks 
of MD exposure +dp/dt significantly decreased (7009 ± 506 mmHg/sec) compared to the 6 week 
diet exposure group (p=0.018) as well as the 8 week control group (8831 ± 160 mmHg/sec, 
p=0.026).  The +dp/dt was also significantly elevated in the 8 week control group compared to 2 
week controls (p=0.016). 
The effect of MD exposure on the myocardial index of relaxation (-dp/dt) is shown in 
Figure 14.  The -dp/dt in the 4 and 6 week MD exposure groups (5459 ± 193 and 6525 ± 463 
mmHg/sec,  respectively) was significantly higher than the 2 week control group (4299 ± 396 
mmHg/sec; p=0.0317 vs. 4 week MD and p=0.0081 vs. 6 week MD).  The 8 week control group 
–dp/dt (5854 ± 451 mmHg/sec) was significantly elevated compared to the 2 week controls 
(p=0.0360).  Exposure for 6 weeks on the MD showed significantly increased -dp/dt compared to 
2 weeks MD (4376 ± 467 mmHg/sec, p=0.0360). 
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Figure 12  Left ventricular developed pressure (LVDP) measured in male WKY rats fed a high 
methionine diet.  Rats were divided into groups exposed to a high (2%) methionine diet (MD) for 
2, 4, 6 and 8 weeks as well as 2 and 8 week age-matched WKY rats fed a control diet.  The 
LVDP in the 2-week MD group was significantly less than the 4, 6 and 8-week MD groups as 
well as the 8 week control group.  The 6-week MD group also had significantly higher LVDP 
than the 2 week control and 4-week MD groups.  Data is expressed as mean ± SE, n = 5 – 6. **: 
p=0.0079 vs. 4 and 8-week MD; p=0.0043 vs. 6-week MD; p=0.0067 vs. 8-week control.  *: 
p=0.0452 vs. 2-week control; p=0.035 vs. 4-week MD. 
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Figure 13  Myocardial index of contractility (+dp/dt) measured in male WKY rats fed a high 
methionine diet.  Rats are divided into groups exposed to MD for 2, 4, 6 and 8 weeks as well as 2 
and 8 week age-matched WKY rats fed a control diet.  The +dp/dt was significantly elevated in 
the 8 week compared to the 2 week control groups.  The +dp/dt was also significantly elevated in 
the 4 and 6 week MD groups compared to the 2-week control and the 2 week MD group.  At 8 
weeks MD exposure, + dp/dt decreased significantly compared to the 6 week MD group and the 
8 week control group.    Data is expressed as mean ± SE.  *: p=0.016 vs. 2 week control, 
p=0.0087 vs. 2 week MD; **: p=0.0043 vs. 2 week control, p=0.0022 vs. 2 week MD; †: 
p=0.0179 vs. 6 week MD; ‡: p=0.016 vs. 2 week control.   
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Figure 14  Myocardial index of relaxation (-dp/dt) measured in male WKY rats fed a high 
methionine diet.  Rats are divided into groups exposed to MD for 2, 4, 6 and 8 weeks as well as 2 
and 8 week age-matched WKY rats fed a control diet.  The –dp/dt for the 8 week controls was 
significantly higher than the 2 week controls.  Also, the – dp/dt was significantly elevated in the 
4 and 6 week MD groups compared to the 2 week controls.  The 6 week but not the 4 week MD 
group – dp/dt was significantly greater than the 2 week MD group.  Data is expressed as mean ± 
SE.   *: p=0.036 vs. 2 week control; **: p=0.0081vs. 2 week control; †: p=0.036 vs. 2 week MD; 
‡: p=0.032 vs. 2 week control.   
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3.3.5. Arterial Pressure 
 The effects of MD exposure SP, DP and MAP are shown in Figure 15.  All 
measures of arterial pressure (MAP, SP and DP) were significantly elevated in the 8 week MD 
group (107 ± 5.2, 126 ± 6.0, and 97.2 ± 5.0 mmHg, respectively) compared to all other groups, 
except SP in the 6 week MD group.  Data and p values were: 2 week control group, MAP: 78.1 ± 
4.2 mmHg, p=0.0027; SP: 98.9 ± 5.5 mmHg, p=0.0094; DP: 67.7 ± 3.6 mmHg, p=0.0020; the 2 
week MD group, MAP: 82.9 ± 5.0 mmHg, p=0.011; SP: 103 ± 5.6 mmHg, p=0.019; DP: 73.1 ± 
4.8 mmHg, p=0.0084; and the 4 week MD group, MAP: 85.8 ± 2.5 mmHg, p=0.015; SP: 107 ± 
2.4 mmHg, p=0.026; DP: 74.3 ± 2.7 mmHg, p=0.0082.  MAP and DP of the 6 week MD group 
(MAP: 91.0 ± 2.4 mmHg, p=0.0387; DP: 81.0 ± 3.0 mmHg, p=0.0318) were significantly 
different than the 8 week MD group.  The arterial pressures of the 8 week control group (MAP: 
88.9 ± 3.7 mmHg, p=0.0257; SP: 107 ± 4.2 mmHg, p=0.0324; DP: 79.8 ± 3.4 mmHg, p=0.0238) 
were also significantly different than the 8 week MD group. 
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Figure 15   Systolic pressure (SP), diastolic pressure (DP) and mean arterial pressure (MAP) 
measured in male WKY rats fed a high methionine diet.  Rats are divided into groups exposed to 
MD for 2, 4, 6 and 8 weeks as well as 2 and 8 week age-matched WKY rats fed a control diet.  
All arterial pressures of the 8-week MD rats were significantly elevated compared to all groups, 
except SP in the 6 week MD group (p=0.062).  Data is expressed as mean ± SE.  n = 5 – 6. * p < 
0.05 vs. all groups; except SP in the 6 week MD. 
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3.4. EFFECT OF ORAL HEPARIN ON HEMODYNAMICS AND FASTING PLASMA 
HOMOCYSTEINE CONCENTRATIONS IN HIGH METHIONINE DIET FED 
WISTAR KYOTO RATS FOR 8 WEEKS  
The WKY rats were divided into a MD exposed group, MD plus oral heparin 
(1mg/kg/48hr) group for 8 weeks and age-matched controls.  Hemodynamic measurements were 
performed under isoflurane anesthesia.   
3.4.1. Fasting Plasma Homocysteine Levels 
The effect of oral heparin treatment in WKY rats fed MD on total fasting plasma 
homocysteine concentrations is shown in Figure 16.  Fasting plasma homocysteine 
concentrations were significantly elevated after 8 weeks of MD feeding (7.17  0.46 mol/L) 
compared to their age-matched control (5.46  0.36 mol/L, p=0.0097).  Homocysteine 
concentrations remained elevated in the oral heparin treated MD group (7.02  0.40 mol/L) 
compared to the normal diet age-matched controls (p=0.0170).  Oral heparin treatment had no 
effect on fasting plasma homocysteine concentrations in rats fed the MD.  
The effect of oral heparin treatment in WKY rats fed MD on total body mass was 
recorded prior to surgery as shown in Figure 17.  There were no differences observed in total 
body mass between the control (309 ± 9.6 g) and MD diet groups with or without oral heparin 
treatment (301 ± 9.9 g; 315 ± 5.4 g) respectively, suggesting that each animal was fed and 
consumed relatively the same amount of the MD.   
3.4.2. Left Ventricular Systolic Pressure (LVSP) 
The effect of oral heparin treatment on LVSP of MD fed WKY rats is shown in Figure 
18.  LVSP was significantly elevated in the MD group (122.6  3.2 mmHg) compared to the age-
matched control (112.3  2.9 mmHg, p=0.0315).  There was no significant difference observed 
in LVSP between the oral heparin treated group (119.9  3.2 mmHg) and all other groups, 
suggesting oral heparin treatment attenuated the increase seen in LVSP by MD feeding. 
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 Figure 16  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on plasma total 
homocysteine concentrations in male WKY rats fed a 2% methionine diet (MD) for 8 weeks.  
Homocysteine levels were significantly elevated in MD fed rats after 8 weeks and remained 
elevated in the MD plus oral heparin group compared to age-matched controls.  Data is 
expressed as mean  SE (n = 5).  * p=0.0107; ** p=0.0097 vs. control. 
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Figure 17  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on body mass in male 
WKY rats fed a 2% methionine diet (MD) for 8 weeks.  There were no differences in body mass 
observed between the groups.  Data is expressed as mean  SE (n = 5).  
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Figure 18  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on left ventricular 
systolic pressure (LVSP) in male WKY rats fed a 2% methionine diet (MD) for 8 weeks.  LVSP 
was significantly elevated in the MD group compared to controls.  Data is expressed as mean  
SE (n = 5).  *: p=0.0315 vs. control. 
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3.4.3. Left Ventricular End-Diastolic Pressure (LVEDP) 
The effect of oral heparin on LVEDP of MD fed WKY rats including age-matched 
controls is shown in Figure 19.  LVEDP was significantly elevated in the MD group (14.23  2.5 
mmHg) compared to age-matched controls (7.13  1.11 mmHg, p=0.0214).  There was no 
significant difference observed in LVEDP between the oral heparin group (8.42  1.91 mmHg) 
and all other groups, suggesting oral heparin treatment attenuated the increase seen in LVEDP by 
MD feeding.   
3.4.4. Left Ventricular Developed Pressure (LVDP) 
The effect of oral heparin on LVSP of MD fed WKY rats including age-matched controls 
on LVDP is shown in Figure 20.  In the 8 week heparin treated group exposed to a MD, LVDP 
was significantly elevated (111.4 ± 1.2 mmHg) as compared to its age-matched control (105.2 ± 
2.2 mmHg, p=0.0284).  There was no change observed in LVDP in the 8 week MD group (108.4 
± 3.1 mmHg) compared to controls. 
3.4.5. Myocardial Indices of Contractility (+dp/dt) and Relaxation (-dp/dt) 
The effect of oral heparin treatment on + dp/dt and – dp/dt is shown in Figure 21.  There 
was no significant change in + dp/dt or – dp/dt seen with MD exposure or heparin treatment.  
The +dp/dt and – dp/dt were 7898 ± 357 and 6035 ± 314 mmHg/sec respectively, in the MD 
exposure group, 8647 ± 314 and 6455 ±160 mmHg/sec respectively, in the diet exposure group 
combined with oral heparin treatment, and 8387 ± 202 and 6339 ± 117 mmHg/sec respectively in 
the age-matched control group. 
86 
 
Control MD MD+H
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
*
p = 0.021 vs. Control
p = 0.086 vs. MD+H
MD vs. C p = 0.0214
L
V
E
D
P
 (
m
m
H
g
)
 
 
Figure 19 Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on left ventricular 
end-diastolic pressure (LVEDP) measured in male WKY rats fed a 2% methionine diet (MD) for 
8 weeks.  LVEDP was significantly elevated in the MD group as compared to controls.  No 
increase was seen in LVEDP in the heparin treated MD group, which was similar to control 
values.  Data is expressed as mean ± SE (n = 5).  *: p = 0.0214 vs. control.     
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Figure 20 Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on left ventricular 
developed pressure (LVDP) measured in male WKY rats fed a 2% methionine diet (MD) for 8 
weeks.  LVDP was significantly elevated in the MD plus oral heparin group compared to 
controls.  There was no significant change in LVDP in the MD fed rats compared to other 
groups.  Data is expressed as mean ± SE (n = 5).  *: p<0.05 vs. control.   
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Figure 21 Effect of oral heparin (1 mg/kg/48hours), given by gavage, on myocardial indicies 
of contractility (+ dp/dt) and relaxation (- dp/dt) measured in male WKY rats fed a 2% 
methionine diet (MD) for 8 weeks.  No significant difference was observed between any of the 
groups.  Data is expressed as mean ± SE (n = 5). 
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3.4.6. Left Ventricular Mass and Volume 
The mass and volume of the LV was measured following the hemodynamic 
investigations, results are shown in Figure 22.  There were no differences observed in the LV 
mass (control: 0.74 ± 0.07 g; MD: 0.69 ± 0.02 g; MD+H: 0.73 ± 0.006 g) or volume (control: 
0.58 ± 0.12 mL; MD: 0.85 ± 0.10 mL; MD+H: 0.83 ± 0.04 mL) between any of the groups.  
There was a trend towards increased LV volume in the MD fed rats (p=0.086, control vs. MD).       
3.4.7. Arterial Pressures 
The effect of oral heparin treatment on SP, DP and MAP of MD fed WKY rats is shown 
in Figure 23.  All measures of arterial pressure, SP, DP and MAP were significantly elevated in 
the MD exposed group (119.9 ± 3.92 mmHg; 90.33 ± 3.51 mmHg; 97.67 ± 2.91 mmHg, 
respectively) compared to age-matched controls (107.8 ± 2.507 mmHg, p=0.020; 79.24 ± 2.081 
mmHg, p=0.017; 88.77 ± 2.182 mmHg, p=0.028; respectively).  There was no difference in 
arterial pressures between the MD plus oral heparin group (SP: 114.7 ± 3.3 mmHg; DP: 83.4 ± 
2.4 mmHg; MAP: 93.82 ± 2.7 mmHg) vs. controls or the MD alone group.  
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Figure 22 Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on LV mass and 
volume measured in male WKY rats fed a 2% methionine diet (MD) for 8 weeks.  There were no 
differences observed between the LV mass or volume in any of the groups.  Data is expressed as 
mean ± SE (n = 5). p=0.086 MD vs. C. 
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Figure 23 Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on mean arterial 
pressure (MAP, systolic pressure (SP) and diastolic pressure (DP) measured in male WKY rats 
fed a 2% methionine diet (MD) for 8 weeks.  All measures of arterial pressure are significantly 
elevated in the rats exposed to MD for 8 weeks compared to their age-matched control.  There 
were no differences observed between MD plus oral heparin arterial pressures and the other 
groups.  Data is expressed as mean ± SE (n = 5).  *: p<0.05 MD vs. Control. 
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3.5. EFFECT OF ORAL HEPARIN TREATMENT ON MD FED WKY RATS FOR 8 
WEEKS ON MALONDIALDEHYDE (MDA) CONCENTRATIONS  
3.5.1. Serum MDA 
The effect of oral heparin treatment in MD fed male WKY rats on serum MDA 
concentrations is shown in Figure 24 and Table 1.  Neither MD exposure nor oral heparin 
treatment exposure had any significant effect on serum MDA concentrations.   
3.5.2. Liver MDA 
The effect of oral heparin treatment in MD fed male WKY rats on liver MDA 
concentrations is shown in Figure 25 and Table 1.  Oral heparin treatment significantly decreased 
liver MDA concentrations compared to the MD group (p=0.0317).  There was no difference in 
liver MDA concentrations between the control group (4.179 ± 1.1 nmol/mg protein) and other 
groups. 
3.5.3. Kidney MDA 
The effect of oral heparin treatment in MD fed male WKY rats on kidney MDA 
concentrations is shown in Figure 26 and Table 1.  Exposure to a MD for 8 weeks produced a 
significant decrease in kidney MDA levels compared to the control group (p=0.0159).  Oral 
heparin treatment had no significant effect on kidney MDA levels compared to other groups. 
3.5.4. Mesentery MDA 
The effect of oral heparin treatment in MD fed male WKY rats on mesentery MDA 
concentrations is shown in Figure 27 and Table 1.  There was no significant difference observed 
in mesentery MDA concentrations between groups.   
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Figure 24  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on malondialdehyde 
(MDA) concentration measured in serum samples from male WKY rats fed a 2% methionine diet 
(MD) for 8 weeks.  No significant differences were observed between groups.  Data is expressed 
as mean ± SE (n=5). 
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Table 1:  Effect of oral heparin (1 mg/kg/48hours), given by gavage, on malondialdehyde 
(MDA) concentration measured in serum, liver, kidney, first-order mesentery, descending 
thoracic aortic and left ventricle samples from male WKY rats fed a high methionine diet (MD) 
for 8 weeks.   
 [MDA] 
nmol/ml 
 
[MDA] nmol/mg protein 
 Serum Liver Kidney Mesentery Aorta Left Ventricle 
Control 20.16 ± 3.2 4.179 ± 1.1 3.263 ± 0.66 1.869 ± 0.71 5.801 ± 1.7 0.7720 ± 0.22 
MD 25.47 ± 8.0 5.100 ± 0.96 1.586 ± 0.12† 0.5654 ± 0.10 1.990 ± 0.68 0.2810 ± 0.06 
MD+H 24.49 ± 5.9 2.423 ± 0.28* 2.287 ± 0.73 0.5910 ± 0.15 2.420 ± 0.44 0.5930 ± 0.14 
MD: Methionine Diet; MD+H Methionine Diet + Oral Heparin Treatment.  Data is expressed as 
mean ± SEM.  * p=0.0317 vs. MD. † p=0.0159 vs. Control. 
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Figure 25  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on malondialdehyde 
(MDA) concentration measured in liver samples from male WKY rats fed a 2% methionine diet 
(MD) for 8 weeks.  The rats exposed to MD had significantly higher MDA levels than diet 
exposed rats treated with oral heparin.  Data is expressed as mean ± SE (n=5).  *: p=0.0317 vs. 
MD+H. 
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Figure 26  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on malondialdehyde 
(MDA) concentration measured in kidney samples from male WKY rats fed a 2% methionine 
diet (MD) for 8 weeks.  Rats exposed to a MD for 8 weeks had significantly lower MDA levels 
compared to controls.  Data is expressed as mean ± SE (n=5).  *: p=0.0179 vs. control. 
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Figure 27  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on malondialdehyde 
(MDA) concentration measured in first-order mesentery samples from male WKY rats fed a 2% 
methionine diet (MD) for 8 weeks.  No significant differences were observed between groups.  
Data is expressed as mean ± SE (n=5). 
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3.5.5. Aorta MDA 
The effect of oral heparin treatment in MD fed male WKY rats on aorta MDA 
concentrations is shown in Figure 28 and Table 1.  There was a trend towards a decrease in 
MDA concentrations in the MD group with and without heparin treatment.  However, this 
difference compared to control failed to reach significance (p=0.095 for MD and p=0.31 for 
MD+H).    
3.5.6. Left ventricle MDA 
The effect of oral heparin treatment in MD fed male WKY rats on LV MDA 
concentrations is shown in Figure 29 and Table 1.  There were no significant differences 
observed in LV MDA between all groups.  There was a trend towards a decrease in LV MDA 
concentrations in the MD exposure without heparin treatment compared to control (p=0.095).  
Oral heparin appeared to reverse the effect of MD on MDA levels, by returning values close to 
control.   
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Figure 28  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on malondialdehyde 
(MDA) concentration measured in descending thoracic aortic samples from male WKY rats fed a 
2% methionine diet (MD) for 8 weeks.  No significant differences were observed between 
groups.  Data is expressed as mean ± SE (n=5). 
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Figure 29  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on malondialdehyde 
(MDA) concentration measured in Left Ventricle samples from male WKY rats fed a 2% 
methionine diet (MD) for 8 weeks.  No significant differences were observed between groups.  
Data is expressed as mean ± SE (n=5). 
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3.6. EFFECT OF ORAL HEPARIN TREATMENT ON MD FED WKY RATS FOR 8 
WEEKS ON GLUTATHIONE CONCENTRATIONS 
Total reduced fraction of glutathione (GSH) measured by HPLC to determine the effects 
of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% methionine diet 
(MD) for 8 weeks.  GSH was measured in plasma samples as well as liver, kidney and left 
ventricular tissue samples for each group. 
3.6.1. Plasma GSH 
The effect of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% 
methionine diet (MD), on total plasma GSH concentrations is shown in Figure 30 and Table 2.  
The plasma GSH concentrations in the MD group were significantly lower than the control group 
(p=0.016).  MD+H plasma GSH concentrations did not differ from control and MD groups 
(p=0.16 and p=0.41 respectively).  
3.6.2. Liver GSH 
The effect of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% 
methionine diet (MD), on liver GSH concentrations is shown in Figure 31 and Table 2.  Liver 
GSH concentrations were not significantly different between groups (control vs. MD: p=0.62; 
control vs. MD+H: p=0.70; MD vs. MD+H: p=0.87). 
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Table 2:  The effect of oral heparin treatment (H) (1/mg/kg/48hrs) given by gavage, in male 
WKY rats fed a high methionine diet (MD) for 8 weeks on reduced glutathione (GSH) 
concentrations in plasma, liver, kidney, and LV samples. 
 
 [GSH] µmol/l [GSH] µmol/mg protein 
Plasma Liver Kidney Left Ventricle 
Control 4.239 ± 0.94 0.02786 ± 0.0029 0.01690 ± 0.0016 0.02074 ± 0.0050 
MD 0.5896 ± 0.59† 0.02460 ± 0.0025 0.01830 ± 0.0025 0.01353 ± 0.0016  
MD+H 1.817 ± 1.2 0.02880 ± 0.0036 0.03438 ± 0.0073 0.02288 ± 0.0023*  
MD: Methionine Diet; MD+H: Methionine Diet + Oral Heparin Treatment.  Data is 
expressed as mean ± SEM.  (n = 5). * p=0.0150 vs. MD. † p=0.016 vs. control.   
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Figure 30  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on GSH 
concentrations in plasma samples from male WKY rats fed a 2% methionine diet (MD) for 8 
weeks.  Plasma GSH concentration in the MD group were significantly lower than the control 
group (p=0.016 vs. control).  Data is expressed as mean ± SE (n = 5). 
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Figure 31  Effect of oral heparin (H) (1 mg/kg/48hours), given by gavage, on GSH 
concentrations in liver, kidney and left ventricle tissue samples from male WKY rats fed a 2% 
methionine diet (MD) for 8 weeks.  There was no significant difference in GSH concentrations 
between groups in either the liver or kidney tissue analysis.  However, the oral heparin treated 
MD group had significantly higher LV GSH concentrations compared to MD only group.  Data 
is expressed ± SE (n = 5).  * p=0.0150.     
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3.6.3. Kidney GSH 
The effect of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% 
methionine diet (MD), on kidney GSH concentrations is shown in Figure 31 and Table 2.  There 
was a trend of increasing kidney GSH concentrations in the oral heparin treated MD group, 
which failed to reach significance when compared to the control and MD group (p=0.078; 
p=0.10, respectively).  Difference in kidney GSH concentrations were also non-significant when 
the MD and MD+H groups were compared (p=0.65). 
3.6.4. Left ventricle GSH 
The effect of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% 
methionine diet (MD), on left ventricle GSH concentrations is shown in Figure 31 and Table 2.  
The oral heparin treated group had significantly higher LV GSH values than the MD group 
(p=0.015).  The LV GSH concentrations in the control group were not significantly different 
compared to the other groups (vs. MD: p=0.14; vs. MD+H: p=0.86).   
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3.7. EFFECT OF ORAL HEPARIN TREATMENT OF MD FED WKY RATS FOR 8 
WEEKS ON ENDOTHELIAL CELL APOPTOSIS MEASURED BY TUNEL 
STAIN 
The percent of apoptotic endothelial cells (ECs) as measured by fluorescent TUNEL stain 
was measured to determine the effect of oral heparin (1mg/kg/48hr) given by gavage, in male 
WKY rats fed a 2% methionine diet (MD) for 8 weeks.  Apoptotic ECs were measured in aorta, 
renal artery and superior mesenteric artery samples for each group.  
3.7.1. Apoptotic Aortic ECs 
The effect of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% 
methionine diet (MD) for 8 weeks, on EC apoptosis in the aorta is shown in Figures 32 and 35 
and representative TUNEL stains shown in Figures 36 – 38.  The percent of apoptotic aortic ECs 
were significantly higher in the MD group (17.04 ± 3.74%) compared to controls (6.08 ± 3.24%, 
p=0.036).  The heparin treatment group percent aortic apoptotic ECs were not significantly 
different from either group (13.38 ± 4.38%).  Interestingly, there was a trend towards a higher 
percent apoptotic ECs in the aorta in the MD group compared to the renal artery (p=0.075).  
3.7.2.  Apoptotic Renal Artery ECs 
The effect of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% 
methionine diet (MD) for 8 weeks, on EC apoptosis in the renal artery is shown in Figures 33 
and 35 and representative TUNEL stains shown in Figures 39 – 41.  There was no significant 
difference in the percent of apoptotic renal artery ECs between the groups (Control: 5.86 ± 
2.15%; MD: 7.81 ± 3.25%; MD+H: 10.59 ± 3.55%). 
3.7.3. Apoptotic Mesenteric Artery ECs 
The effect of oral heparin (1mg/kg/48hr) given by gavage, in male WKY rats fed a 2% 
methionine diet (MD) for 8 weeks, on EC apoptosis in the superior mesenteric artery is shown in 
Figures 34 and 35 and representative TUNEL stains shown in Figures 42 – 44.  The percent of 
apoptotic EC in the mesenteric artery was significantly elevated in the MD group (17.99 ± 
1.90%) as compared with controls (7.43 ± 1.62%, p=0.0003).  Heparin treatment significantly 
reduced the percent apoptotic EC in MD treated mesenteric artery (7.31 ± 1.17%, p=0.0001) to 
values very similar to control (p=0.95).  Interestingly, the percent apoptotic ECs in the MD group 
mesenteric artery were significantly higher than the MD renal artery (p=0.014). 
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Table 3:  The total number and % of apoptotic endothelial cells counted in aorta, superior 
mesenteric artery and renal artery tissue samples of male WKY rats fed a high methionine diet 
(MD) for 8 weeks and treated with oral heparin (H) (1/mg/kg/48hrs) given by gavage.  
     
Aorta            Mesenteric Artery           Renal Artery 
 Total # of 
cells 
counted 
% Apoptotic 
Total # of 
cells 
counted 
% Apoptotic 
Total # of 
cells 
counted 
% Apoptotic 
Control 100 6.08 ± 3.24 397 7.43 ± 1.62 389 5.86 ± 2.15 
MD 161 17.04 ± 3.74
 
344 17.99 ± 1.90  359 7.81 ± 3.25  
MD+H 69 13.38 ± 4.38 446 7.31 ± 1.17 327 10.59 ± 3.55 
MD: Methionine Diet; MD+H: Methionine Diet + Oral Heparin Treatment.  Data is expressed as 
mean ± SEM.  (n = 10 – 15).   
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Figure 32 Percent apoptotic aortic ECs from male WKY rats fed MD for 8 weeks, including 
age-matched controls and oral heparin treated (H) (1 mg/kg/48hours) MD rats (MD+H).  Percent 
of apoptotic cells were significantly higher in the MD group (17.04 ± 3.74%) compared to 
controls (6.08 ± 3.24%).  There was no difference between MD+H values and the other groups.  
Data is expressed as mean ± SE (n=15).  *: p=0.036 vs. control. 
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Figure 33 Percent apoptotic renal artery ECs from male WKY rats fed MD for 8 weeks, 
including age-matched controls and oral heparin treated (H) (1 mg/kg/48hours) MD rats 
(MD+H).  There were no significant differences between the groups. Data is expressed as mean 
± SE (n=15). 
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Figure 34 Percent apoptotic mesenteric artery ECs from male WKY rats fed MD for 8 weeks, 
including age-matched controls and oral heparin treated (H) (1 mg/kg/48hours) MD rats 
(MD+H).  The percent of apoptotic ECs were significantly higher in the MD treated group 
(17.99 ± 1.90%) compared to controls and the heparin treated group (7.43 ± 1.62, p=0.0003; 7.31 
± 1.18%, p=0.0001, respectively).  Data is expressed as mean ± SE (n=15).  **: p<0.001 vs. 
control and MD+H. 
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Figure 35 Percent apoptotic ECs comparison between the male WKY rats fed MD for 8 weeks, 
controls and oral heparin treated (1 mg/kg/48hours) MD rats (MD+H).  The percent of apoptotic 
ECs were significantly higher in the mesenteric artery of the MD treated group (17.99 ± 1.90%) 
compared to the renal artery in the MD group (7.82 ± 3.25%, p=0.014).  There was a trend for 
that the aorta had a higher percentage of apoptotic ECs in the MD group (17.04 ± 3.74%) 
compared to the renal artery, yet this difference is non-significant (p=0.075).  Data is expressed 
as mean ± SE (n=15).  *: p=0.014 vs. Renal Artery. 
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Figure 36  Control Aorta; 20x magnification 
 
 
 
 
 Figure 37  MD Aorta; 20x magnification 
 
Aortic Endothelial Cells with 
Positive PI nuclei stain 
Internal Elastic Lamina 
Aortic Endothelial Cells with 
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Figure 38  MD+H Aorta; 20x magnification      
 
Figures 35 – 38  Representative TUNEL double-stained images of aortas dissected from male 
WKY rats fed MD for 8 weeks, controls and oral heparin treated (1 mg/kg/48hours) MD rats 
(MD+H).  Images for TUNEL staining have an overlay of green fluorescence from the TUNEL 
stain with red fluorescence from PI.  Image is at 20x magnification.  Endothelial cells were 
counted as all cells above the internal elastic lamina with a positive PI nuclei stain.  TUNEL-
positive endothelial cells were counted as all cells in the overlaid image, above the internal 
elastic lamina which appear yellow.  Percent apoptotic aortic endothelial cells were quantified in 
ratio as number of TUNEL-positive endothelial cells: number of endothelial cells.    
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Figure 39  Control Renal Artery; 20x magnification 
 
 
 
Figure 40  MD Renal Artery; 20x magnification 
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Figure 41  MD+H Renal Artery; 20x magnification 
 
Figures  39 – 41   Representative TUNEL double-stained images of renal arteries dissected from 
male WKY rats fed MD for 8 weeks, controls and oral heparin treated (1 mg/kg/48hours) MD 
rats (MD+H).  Images for TUNEL staining have an overlay of green fluorescence from the 
TUNEL stain with red fluorescence from PI.  Image is at 20x magnification.  Endothelial cells 
were counted as all cells above the internal elastic lamina with a positive PI nuclei stain.  
TUNEL-positive endothelial cells were counted as all cells in the overlaid image, above the 
internal elastic lamina which appear yellow.  Percent apoptotic aortic endothelial cells were 
quantified in ratio as number of TUNEL-positive endothelial cells: number of endothelial cells.    
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Figure 42  Control Superior Mesenteric Artery; 20x magnification 
 
 
 
Figure 43  MD Superior Mesenteric Artery; 20x magnification 
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Figure 44  MD+H Superior Mesenteric Artery; 20x magnification 
 
Figures 42 – 44  Representative TUNEL double-stained images of the superior mesenteric 
arteries dissected from male WKY rats fed MD for 8 weeks, controls and oral heparin treated (1 
mg/kg/48hours) MD rats (MD+H).  Images for TUNEL staining have an overlay of green 
fluorescence from the TUNEL stain with red fluorescence from PI.  Image is at 20x 
magnification.  Endothelial cells were counted as all cells above the internal elastic lamina with a 
positive PI nuclei stain.  TUNEL-positive endothelial cells were counted as all cells in the 
overlaid image, above the internal elastic lamina which appear yellow.  Percent apoptotic aortic 
endothelial cells were quantified in ratio as number of TUNEL-positive endothelial cells: number 
of endothelial cells.    
118 
 
 
4.0. DISCUSSION 
The results of the present study suggest that hHcy has a causal relationship in the 
development of hypertension and furthermore, if untreated could lead to the onset of heart 
failure.  At the cellular level, Hcy appears to exert its hypertensive pathological role by altering 
EC function.  Indirectly Hcy has been implicated in the pathogenesis of hypertension by 
increasing oxidative stress.  These studies focus primarily on Hcy impaired endothelium-
dependent vasodilation (Chambers, Obeid, & Kooner, 1999).  Homocysteine is thought to cause 
endothelial dysfunction and impair vasoreactivity by several means: (1) by generating ROS 
which quench NO bioavailability (Weiss, 2005), causing EC lipid peroxidation (Kaul, Zadeh, & 
Shah, 2006) and apoptosis (REF); (2) by causing eNOS uncoupling through the production of 
ADMA (Austin, Lentz, & Werstuck, 2004); (3) by increasing EC inflammatory mediators such 
as MCP-1 and IL-8 (Podder, et al. 2001) and (4) by altering the production and/or bioavailability 
of other vasoreactive mediators such as ET-1 and prostacyclin (Demuth, et al., 1999).  There is 
also the view that the relationship between elevated Hcy and the development of hypertension is 
confounded by many other variables which dismiss Hcy causal association.  Impaired renal 
function is shown to increase both BP and elevated Hcy levels (Stehouwer & van Guldener, 
2003).  Sutton-Tyrrell et al. (1997) demonstrated that the causal association between Hcy levels 
and hypertension was independent of renal failure, by excluding patients with impaired renal 
function from their correlations.  Smoking and alcohol consumption are known causes of 
essential hypertension but are not related to Hcy levels (Lim & Cassano, 2002).  Changes in 
renal function and dietary/lifestyle factors could also have an association with hHcy and the 
development of hypertension.  Yet, when vitamins B12 and B6 are administered as an agent to 
lower Hcy levels, BP also decreases, independently of any further changes in renal function or 
lifestyle factors (van Dijk, et al., 2001).             
 
4.1. HIGH-METHIONINE DIET INDUCED INCREASES IN FASTING PLASMA 
HOMOCYSTEINE LEVELS 
Robin et al. (2004) demonstrated that a methionine-enriched diet induced mild hHcy and 
hypertension in rats.  The standard rat diet that was fed to the control animals in this study 
contained a base concentration of 0.33% (w/w) L-methionine.  After feeding the animals ad 
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litium an additional 1.7% (w/w) L-methionine for 2 weeks, Hcy fasting plasma concentrations 
were approximately 1.5 fold higher than age-matched controls (5.52 ± 0.29 µmol/L vs. 4.32  
0.16 µmol/L) and by 8 weeks of feeding, they remained significantly elevated as compared to 
age-matched controls (7.22 ± 0.24 µmol/L vs. 4.93  0.24 mol/L).  These results are very 
similar to the Hcy concentrations measured by Robin et al. (2003) which found non-fasting Hcy 
levels were elevated 2-3 fold, compared to controls, when feeding WKY rats a 1.45% DL-
methionine diet for 10 weeks.  The rats in the present study were fasted for at least 8 hours, 
overnight to exclude any methionine loading effects on plasma Hcy concentrations.  Oral 
methionine loading will produce an acute rise in plasma Hcy by 2 hours, with a peak Hcy 
response at 8 hours and return to baseline by 24 hours post loading (Chambers, Obeid, & 
Kooner, 1999).  The fasting plasma Hcy concentrations in this report therefore represent overall 
basal levels that the rats develop throughout the study.  These levels are lower than those 
normally associated with hHcy (> 15 µmol/L) but are significantly higher than controls.  The 
significant increase in fasting plasma Hcy concentrations provides an evidence based approach 
for making experimental conclusions associated with Hcy activity.   
The linear regression of methionine diet exposure to fasting plasma Hcy concentrations 
indicates that the prolonged feeding of a MD diet would progressively increase plasma Hcy 
concentrations.  Zhang et al. (2004) found that SD rats fed an additional 1% DL-methionine in 
their diet for 14 weeks also had fasting plasma Hcy concentrations 2-3 fold higher than control.  
The trend is that a diet rich in methionine affects Hcy metabolism.  In a study by Rowling et al. 
(2002), high L-methionine diet supplementation between 0.5 to 1% (w/w), up-regulated hepatic 
glycine N-methyltransferase, which regulates the ratio of SAM:SAH, causing continued 
methionine conversion into Hcy.  Long-term feeding of MD may be responsible for up-
regulating the conversion of Hcy back to its precursor methionine or to cysteine, explaining the 
mild response seen in this study (Zhang, et al., 2004).  Use of a high-methionine diet is a reliable 
and affordable experimental means of increasing fasting plasma Hcy levels by 2 weeks of 
feeding.   
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4.2. HEMODYNAMIC RESPONSE TO DIFFERENT INHALATION ANESTHETICS 
The initial studies were conducted using halothane as the inhalation anesthetic to 
maintain surgical anesthesia during hemodynamic recordings in rats.  Halothane was 
discontinued, due to its associated hepatotoxicity and was not available for subsequent studies.  
The anesthetic was changed to isoflurane, which is resistant to biodegradation and tissue uptake 
(0.17% of isoflurane appears as urinary metabolites), explaining its minimal toxicity (Eger, 
1984).  Since hemodynamic measurements had been conducted on both halothane and isoflurane 
anesthetized animals, a comparison was necessary to evaluate if the results differed due to the 
anesthetic used.  We found that, control animals under isoflurane vs. halothane anesthetic had 
significantly higher LVSP and LVDP.  There was no change in isoflurane arterial pressures 
when controls or MD treated rats were compared and it is known that isoflurane does not 
increase myocardial contractility (Nathan & Odin, 2007).  Also, Eger (1984) suggests that 
isoflurane decreases TPR and thus arterial pressures, confounding the results of this study, where 
increased afterload/LVSP was shown in the isoflurane group.  Rivenes et al. (2001) showed that 
isoflurane produced no significant change in either ejection fractions or shortening fractions of 
the LV, both expected to be only mildly affected by increased afterload, as measured by 
echocardiograph.  Whereas, halothane caused a significant decrease in both ejection and 
shortening fractions of the LV, attributed to its negative inotropic effects (Rivenes, et al., 2001).   
Control animals anesthetized with halothane were shown, in this study, to have markedly 
higher MAP and DP than the isoflurane anesthetized controls.  In contrast, Rivenes, et al. (2001) 
compared MAP under both halothane and isoflurane and found the most significant depression in 
the halothane group.  Their results were further corroborated by a decrease in vascular resistance 
during both halothane and isoflurane treatment (Rivenes, et al., 2001).    The increase seen in the 
halothane group MAP in this study is believed to be a direct reflection of the marked increase in 
DP.  Increased arterial DP should correspondingly increase afterload, and therefore LVSP.  
Given the claim by Dale and Brown (1987), that myocardial depression and cardiac arrhythmias 
are the major CV disadvantages of using halothane and that it is known that halothane is a 
negative ionotropic agent, it is presumable that halothane caused a marked increase in afterload, 
seen as an increase in arterial DP, and also reduced myocardial contractility, impairing the 
reactivity of the LV pressure-volume loops, resulting in decreased LVDP and LVSP.   
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Isoflurane also caused a significant elevation in the rate of myocardial contractility in 
control rats as compared to those anesthetized with halothane.  It is known that halothane has a 
greater negative inotropic effect than isoflurane and furthermore has been demonstrated to 
preserve HR, opposed to isoflurane which has positive chronotropic effects (Rivenes, et al., 
2001).  Furthermore, isoflurane has also been demonstrated to increase both myocardial 
excitability and intraventricular conduction, both with the potential to increase HR (Nathan & 
Odin, 2007).  An increase in the rate of contractility can also increase HR, suggesting the results 
of this study are in accord with those of Nathan and Odin (2007). 
Lastly, the effect of MD on isoflurane and halothane hemodynamic measurements were 
very different.  The LVSP increase seen in control animal under isoflurane anesthetic was 
reversed with MD treatment such that the animals on the MD under halothane had significantly 
higher LVSP than their matched isoflurane counterparts, but had no effect on LVDP or LVEDP.  
Furthermore, the MD diet had no effect on rate of myocardial contractility in either anesthetic 
group compared to controls.  However, at 4 weeks MD exposure, the rate of myocardial 
relaxation was increased in both the isoflurane and halothane groups compared to their 
respective anesthetic controls.  Other studies have shown that prolonged hHcy causes structural 
changes to the LV eventually resulting in impaired diastolic and systolic function corroborated 
by low LV ejection fractions (Cesari, et al., 2004).  Reduced LV ejection causes an increased 
preload, which by the LV pressure-volume loops should result in more forceful ventricular 
contraction as to improve systolic function.  Increased LVSP in response to Hcy dependent 
decreases in ejection fractions, were reflected as an increase in arterial SP seen in the halothane 
group after 4 weeks MD exposure.  The relationship between short term hHcy and LV systolic 
function is not well described in the literature.  At 4 weeks of MD exposure, changes to the 
myocardium and vasculature may be in their infancy, requiring this study to investigate extended 
periods of elevated plasma Hcy levels.   
 The effects of halothane and isoflurane anesthesia on hemodynamic parameters of male 
WKY rata are not comparative.  Halothane produces a marked decrease in the myocardial index 
of contractility demonstrated by a significantly increased LVSP and LVDP, known to be caused 
by its associated negative inotropic effects.  Isoflurane is a current inhalation anesthetic of choice 
as it does not produce the same level of LV depression as compared to the discontinued 
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Halothane.  Therefore, the results of this study are not comparable and isoflurane is 
recommended for further studies.       
 
4.3. HEMODYNAMICS OF RATS WITH ELEVATED PLASMA HOMOCYSTEINE 
By 8 weeks of feeding MD to WKY rats, all measures of arterial pressure were 
significantly elevated, as were LVSP and LVEDP, all marked by a sudden decrease in the rate of 
myocardial contractility.  Very similar to the findings of Robin et al. (2003), MD increased the 
systolic pressure of WKY rats.  Robin et al. (2003) found that systolic pressures in WKY rats, as 
measured by tail-cuff, were significantly elevated by 5 weeks of MD and were sustained until the 
end of the study at 10 weeks.  The baseline systolic BP attained by their group was between 100 
– 110 mmHg, similar to this study measured under isoflurane anesthesia where systolic BP was 
98.9 – 107 mmHg.  Hcy dependent increases in SP were higher measured by tail-cuff by Robin 
et al. (2003) (>140 mmHg) than this study (126 mmHg).  Other studies have also found a 
correlation between MD exposure and elevations in arterial BP.  Rolland et al. (1995) observed 
both systolic and diasolic hypertension in minipigs fed a methionine-rich diet for 4 months.  In 
human patients, elevations in total Hcy plasma concentrations either have a strong, independent 
association with systolic hypertension (Sutton-Tyrrell, et al., 1997) or they are associated with 
elevated MAP and DP (Fiorina, et al., 1998).  Supporting all findings is the documented 
evidence that hHcy increases TPR and BP by causing endothelial injury and dysfunction and 
modifying vascular wall compliance through structural changes (Huang, et al., 2008).  
Interestingly, due to the complexity of CV regulation and the development of essential 
hypertension, the effects of MD on LV pressures may be caused by or causal to the overall 
increases seen in arterial pressure.  This study showed that LVSP increased incrementally with 
prolonged exposure to MD.  Since the literature available regarding LV pressure responses to 
hHcy are very limited, physiological explainations corroborated by the hemodynamic 
measurements in this study will be discussed using LV pressure-volume loops.  It is well 
documented that prolonged hHcy leads to left ventricular systolic and diastolic failure (Cesari, et 
al., 2004) (Bokhar, et al., 2005) (Devi, et al., 2006), but the progressional development of such 
failure has yet been elucidated.   
The progressive increase in LVSP, seen in the MD treated rats for 8 weeks is correlated 
with increased MAP, SP and DP.  As per LV pressure-volume loops, increased arterial pressure 
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is equal to an increase in afterload.  Increased afterload, if inotropy is constant, may cause an 
increase in LVSP and end-systolic volume, being consequential to a decrease in SV, and a small 
increase in end-diastolic volume.  At 8 weeks of MD exposure LVEDP was significanly elevated 
in association with the marked increase in LVSP.  Van der Velde, et al. (1991), using aortic 
impedance as a model of increased afterload in canines, proved that examining end-systolic 
pressure-volume relationships which include an increased rate of myocardial contraction and 
stroke work compared to end-diastolic volumes are sensitive enough to be intrepreted as 
increased LV contractility.  Therefore the results of the present study may indicate the 
development of heart failure because even as LVSP increases in response to higher afterload, 
LVEDP also increases higher than would expected, corresponding to increased preload and 
therefore compromised LV ejection.  However, further changes in +/- dP/dt would corroborate 
these findings.  Preload is defined as the greatest pressure reached in the ventricle during 
diastolic filling and is determined by venous return, atrial systolic pressures, and ejection 
fractions, the amount of blood ejected from the previous ventricular systole (Greenway & Lautt, 
1986).  Given the results of van der Velde et al. (1991), if these markers of LV function were 
also correlated to increase inotropy, and LVEDP is elevated, then the LV ejection fraction is 
likely signficantly reduced.  Futhermore, LVDP was unchanged at 8 weeks MD exposure as 
compared to control animals in this study.  The LVDP is the maximal pressure achieved in the 
LV during systole, equal to the LVSP substracted by the LV diastolic pressure.  The increase in 
LVEDP, explained by a decrease in ejection fraction and incomplete LV emptying would 
correspondigly increase LV diastolic pressure.  Also given the increase seen in LVSP, the overall 
LVDP is offset by the increase of both parameters simultaneously.  Cesari et al. (2005) showed 
that hHcy was inversely related to LV ejection fractions and associated most strongly in arterial 
hypertensive patients  The results of this study show that arterial hypertension in hHcy may 
either unmask or favor the onset of low LV ejection and predispose the animals to subsequent 
heart failure.   
Another indication of the development of hHcy induced heart failure are the changes seen 
in the myocardial indicies of contractility and relaxation.  At 4 and 6 weeks MD exposure – dp/dt 
and + dp/dt increased significantly from the young control group.  However, at 8 weeks MD, – 
dp/dt and + dp/dt decreased.  The trend appear to indicate an increase in myocardial contractility 
and relaxation up to the point of increased arterial pressures and premature cardiac failure, which 
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may coincide with 8 weeks of MD exposure in this study.  Devi et al. (2006) showed + dp/dt and 
– dp/dt were signficantly lower in rats after 10 weeks of MD feeding.  Rosenberger et al. (2010) 
demonstrated that mice fed a Hcy-enriched diet for 12 weeks had significantly reduced LV 
shortening, indicating a decrease in contractility and  relaxation of cardiomyocytes.  Moreover, 
Rosenberger et al. (2010) also showed that the mice referred to previously had significantly 
prolonged QRS complexes which are related to atrioventricular conduction delay and can result 
in marked end-diastolic volume or preload increases.  The QRS complex is related to the time it 
takes for action potential conduction through the ventricle, and begins when the heart is in atrial 
systole and isovolumetric contraction, just prior to the opening of the aortic valve and ventricular 
systole.  In this study, these results were replicated with respect to increased LVEDP which also 
occupies the same time frame as the QRS complex.  This effect can be compensated for by 
increasing HR, which should restore CO despite ventricular failure.  Furthermore, the significant 
decrease in + dp/dt at 8 weeks MD is also confirmed by Rosenberger et al. (2010) such that when 
corrected for HR, the QT interval of hHCy mice was also significantly prolonged, indicating 
decreased myocardial conductivity.  The QT interval begins during atrial systole and ends at the 
end of ventricular contraction.  Therefore, any disturbance seen in + dp/dt may be attributed to 
changes during this period of time.  A prolonged QT interval is very dangerous as it can quickly 
result in ventricular fibrillation which causes sudden death if not treated (Morita, Wu, & Zipes, 
2008).    However, the decrease in myocardial relaxtion may be due to altered calcium 
management or to a direct myocyte effect caused by Hcy (Perreault, et al., 1990).  The results of 
this study are in accord with others with respect to impaired myocardial conductivity and 
generation of myocyte contractility again predicting resultant cardiac failure after prolonged 
hHcy, in association with elevated arterial and LV pressures.   
The most interesting aspect of the results of this study are the changes seen in + dp/dt and 
LVSP prior to detectable increases in arterial BP.  At 4 and 6 weeks of MD exposure, the LV 
appears to be reacting to increased preload.  The developed pressure in the ventricle is higher at 6 
weeks of MD and the rate of myocardial contractility increases up to 6 weeks as well.  These 
results indicate that as per the Frank-Starling Law of the Heart and its associated LV pressure-
volume loops, as LV SV increases, so does CO and arterial pressure.  So at 8 weeks MD, arterial 
pressures are signficantly elevated, potentially caused by cardiac responses not by changes to the 
vasculature. 
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At 8 weeks of MD feeding, detrimental changes to LV hemodynamics were becoming 
apparent.  It is expected that the myocardial indices of contractility and relaxation should have 
been more responsive to the changes seen in LVEDP and LVSP, however, it is believed that if 
the study was continued into longer exposure periods, the development of heart failure would be 
even more evident.  Furthermore, arterial blood pressure was significantly elevated, which as 
defined indicates the animal were hypertensive.  The following studies elucidate whether the 
development of hypertension was due to changes in the vasculature, increased TPR, or if the 
developing changes to LV hemodynamics caused reflective BP increases, and by what 
mechanism oral heparin was able to attenuate some of the effects.     
 
4.4. EFFECT OF ORAL HEPARIN TREATMENT ON THE HEMODYNAMICS OF 
RATS WITH ELEVATED PLASMA HOMOCYSTEINE 
Heparin was orally administered to WKY rats in conjunction with MD feeding for 8 
weeks.  Hemodynamic measurements were collected under isoflurane anesthesia at the end of the 
8 week cycle in heparin plus MD exposed rats, MD only exposed rats and controls.  Firstly, 
heparin treatment did not effect fasting plasma Hcy concentrations.  Total fasting plasma Hcy 
concentrations were elevated in both the MD and MD plus heparin treated rats as compared to 
controls.  Blood samples for the determination of fasting total Hcy concentrations were collected 
in cooled vials containing EDTA, a common laboratory anticoagulant which irreversilbly binds 
calcium ions, a crucial element of the coagulation cascade, then centrifuged to permit testing of 
plasma fractions.  Nybo et al.,  (1972) demonstrated that after accounting for plasma dilution due 
to erythrocyte water loss, NaF/Heparin use as an anticoagulant for blood collection with the 
purpose of determining total plasma Hcy, produced identical results as those sample collected 
with EDTA.  The results of this study and Nybo et al., (1972) both indicate that heparin has no 
metabolic or catabolic effect on Hcy.  Therefore, as heparin treatment does not affect Hcy levels, 
its use in the present study can be associated as that of an agent which affects in vivo 
hemodynamic and biochemical results independent of elevated plasma Hcy levels.   
The results of this heparin study utilized different WKY rats than those from the effects 
of Hcy alone study previously discussed.  Validating the results of the previous section, the 
hemodynamic measurements of 8 week MD and control WKY rats were reproduced almost 
identically in this heparin study.  The most notable hemodynamic events seen in this study were 
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that all measures of arterial pressure were significantly elevated by 8 weeks of MD feeding, as 
were LVSP and LVEDP compared to control.  Interestingly, heparin appears to have attenuated 
the increases seen in all of the aforementioned pressures.  It was previously discussed that the 
hemodynamics of the 8 week MD fed rats indicated changes to (1) a presumed increase in TPR, 
with respect to increased ventricular afterload/LVSP; (2) increased arterial pressures, with 
respect to the increase in venticular preload/LVEDP; (3) reduced ejection fraction, again with 
respect to increased preload/LVEDP; (4) and the onset of heart failure with respect to decreased 
+ dp/dt.  It is plausible that the increase in afterload/LVSP and subsequent increase in LVEDP 
and arterial pressures of rats fed MD in this study is attributed to an increase in TPR as caused by 
endothelial dysfunction, inhibited by heparin. 
The hypertensive effects of hHcy are strongly correlated to increased TPR and 
endothelial dysfunction (Chambers, Obeid, & Kooner, 1999).  Chambers et al., (1999) have 
shown that increments of 2 – 3 µmol/L plasma Hcy, similar to the increases seen in this study, 
attained by low-dose oral methionine feeding was enough to induce endothelial dysfunction.  
The increase in arterial pressures at 8 weeks of MD feeding are likely correlated to the increases 
seen in both preload/LVEDP and afterload/LVSP.  The ability of heparin to prevent the previous 
hemodynamic increases may be intrinsically linked to its ability to protect against endothelial 
cell death and dysfunction (Hiebert & Liu, 1990) and consequently increases in TPR and BP.  
Hyperhomocysteinemia dependent endothelial dysfunction is characterized by reduced eNOS 
activity (Lee, et al., 2004).  Reduced eNOS expression is associated with impaired endothelium 
dependent vasodilation, and thus is correlated with increased TPR.  Heparan sulfate 
proteoglycans (HSPGs) due to their high negative charge, serve as an important anchor for many 
external molecules on the cellular surface, making them an integral partner in the recruitement 
and activation of signaling pathways (Bishop, Schuksz, & Esko, 2007).  Ramella et al. (2010) 
demonstrated that vasostatin 1, a vasodilating and cardiac stabilizer during sympathetic stress 
responses, requires HSPGs to anchor and endocytose into endothelial cells where it initiates 
eNOS activation.  Their observations were further confirmed, as treatement with heparinase 
completely prevented vasostatin 1 endocytosis into endothelial cells (Ramella, et al., 2010).  If 
heparin increased NO production, it is reasonable that levels of S-nitrosohomocysteine would 
also increase.  Adducts between NO and Hcy have been shown to actually stabilize NO, 
enhancing its vasodilatory effects 16 fold over S-nitrosocysteine (Gow, Cobb, & Stamler, 2001).     
127 
 
Another potential mediator of Hcy dependent increases in LVSP, LVEDP and arterial 
pressures is endothelin-1 (ET-1), a very potent vasoconstrictor and potential mediator of cardiac 
hypertrophy (Kedzierski & Yanagisawa, 2001).  Endothelial dysfunction has been observed with 
respect to increased levels of ET-1 in hHcy demonstrated by significanly impaired endothelium-
dependent vasodilation, independent of oxidative stress (Tousoulis, et al., 2010).  Tousoulis et al. 
(2008) further indicated that the Hcy dependent rise in ET-1 levels was associated with fasting 
plasma total Hcy levels, and not with acute-methionine loading and transient plasma Hcy 
increases.  Heparin has several demonstrated effects on ET-1.  In cultured bovine endothelial 
cells, heparin suppressed ET-1 release (Imai, Hirata, & Marumoand, 1993).  Kuwahara-
Watanabe et al. (2005) further described that heparin suppresses the gene expression of ET-1 at 
the level of transcription.  Heparin and HSPGs are again noted to act as important anchors on the 
endothelial surface facilitating the binding of another key factor known to regulate BP through 
ET-1.  Heparin-binding epidermal growth factor (HB-EGF) has been described as having a 
plethora of protective effects, especially concerning organ microcirculation.  Zhou, Brigstock 
and Besner (2009) demonstrated that HB-EGF increases pressure-induced vasodilation and 
reduces ET-1 vasoconstriction in adult rat mesenteric arterioles.  Endothelin has very different 
effects depending on which receptor it is bound.  The ETA receptors are found in VSM and 
illicits vasoconstriction when activated.  The ETB receptors are located on endothelial cells, and 
cause the release of NO and subsequent vasodlation when bound by ET-1.  Interestingly, heparin 
not only affects ET-1 release and synthesis, it also has effects on its receptor expression.  For 
instance, in a rat model of cyclosporin nephropathy, heparin decreased ET-1 BP response in the 
left carotid artery by over 20% (Bennett, et al., 1997).  The study by Zhou et al. 2009, 
demonstrated that HS-EGF upregulates ETB receptor expression. 
The most widely accepted hypothesis explaining the relationship between hHcy and the 
development of hypertension is that Hcy increases oxidative stress which is directly responsible 
for causing endothelial dysfunction.  However, this hypothesis continues to be debated.  For 
instance, Chao et al., (2000) showed that increases in Hcy concentrations, induced by methionine 
treatment, reduced endothelium-dependent vasodilation in the absence of increased oxidative 
stress.  However, other studies have shown that elevated Hcy levels reduce endothelium-
dependent vasodilation in association with increased superoxide production as well as increased 
protein nitrosylation, a biomarker for peroxinitrite formation (Li, et al., 2002).  The evidence is 
128 
 
varied, but the oxidative stress hypothesis for hHcy could explain increases in arterial BP and 
increased TPR, affecting LVSP and LVEDP.  Some of the results of increased  oxidative stress 
in hHcy includes the reduced bioavailability of NO in a superoxide dependent manner producing 
peroxinitrite (Heydrick, et al., 2004), lipid peroxidation of endothelial cells (Loscalzo, 1996) and 
redox sensitive apoptosis of endothelial cells (Mercie, et al., 2000) both causing cell death and an 
assocated reduction in NO availability.  Ross et al., (1992) believe that heparin and heparan 
sulfates have direct antioxidant functions.  Firstly, heparin is known to release EC-SOD from 
endothelial cell surfaces in humans and mice (Karlsson & Marklund, 1987), but these effects on 
EC-SOD in rats is limited since EC-SOD has a significantly lower heparin affinity (Faraci & 
Didion, 2004).  The difference exists due to the lack of an amino acid, crucial for protein subunit 
interactions (Marklund, 1984).  Because the rat essentially lacks heparin associated EC-SOD, 
this effect of heparin is excluded as a mechanism of antioxidant protection.  However, heparin 
and other GAGs because of their charge, may structurally make them reserviors for cations 
preventing their participation in ROS reactions (Grant, Long, & Williamson, 1987).  Iron 
(Fe
3(2)+
) catalyzes the Haber-Weiss reaction, which is a significant source of the hydroxyl radical, 
a known promoter of lipid peroxidation (Minotti & Aust, 1989).  Halvorsen et al. (1996) have 
shown that low concentrations of Hcy (< 6µmol/L) promotes cation catalyzed LDL oxidation, 
whereas high concentrations of Hcy were protective in vitro.  Other studies have shown a pro-
oxidant effect of thiols in systems containing free Fe
2+
 (Lynch & Frei, 1997), and also an 
antioxidant effect in systems containing free Fe
3+
 (Lynch, Campione and Moore, 2000).  In a 
histochemical study by Garcia-Segura (1977), it was shown that Fe
2+
 and Fe
3+
 readily bound to 
heparin-related GAGs, replacing Ca
2+
 from heparan sulphate.  It is not clear whether iron bound 
to heparin is unable to participate in Haber-Weiss type reactions.  However, the relatively low 
pH that surrounds a polyanion such as heparin, enables acidic oxidation without ROS production 
as per the following equation (Ross, Long, & Williamson, 1992):  
                                                         
(4.1) 
There is accumulating evidence which indicates that antioxidants prevent endothelial 
dysfunction in hHcy.  Vitamin C, an ROS scavenger was shown to prevent NO inactivation by 
superoxide (Kanani, et al., 1999), and potentiate ACh-induced vasodilation (Virdis, et al., 2001) 
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in hHcy.  The antioxidant melatonin has also been shown to reduce Hcy dependent contraction 
on the human umbilical artery, thus decreasing TPR (Okatani, Wakatsuki, & Reiter, 2000).  All 
of this evidence indicates that if heparin were to act as an antioxidant in the assumed pro-oxidant 
vascular atmosphere of hHcy, then it may be responsible for inhibiting  endothelial dysfunction, 
shown by decreased LVSP, LVEDP and arterial pressures.   
Systemic characterization of heart failure includes mechanisms of cardiomyocyte stress 
such as apoptosis, ischemic injury, and inflammatory reactions (Kitahara, et al., 2010).  
Moreover, hHcy has been chracterized as causing LV hypertrophy, myocardial fibrosis and 
coronary remodelling, subsequent to the cardiomyocyte stressors listed previously (Joseph, 
Washington, & Joseph, 2003).  Heparin has been decribed as a protective agent against all three 
proposed cardiomyocyte stressors and therefore against end-stage LV dysfunction remodelling as 
associated with hHcy.  Since it is not exactly known which happens first, vascular or cardiac 
dysfunction, all of the aforementioned theories are useful when evaluating the CV effects of 
heparin on hHcy. 
A high-methionine diet signficantly increased LVSP and LVEDP by 8 weeks in this 
study and heparin treatment mildly attentuated the increase.  The LV of the heart will 
hypertrophy as an adaptive response, when overloaded with increasing pressure and volume to 
preserve its function (Yajima, et al., 2005).  Left ventricular hypertrophy is a strong predictor of 
CV morbidity and mortality in arterial hypertensive patients (Levy, et al., 1990).  Plasma Hcy 
levels are independently associated with LV mass, wall thickness in the Framingham Heart 
Study (2004).  The remodelling changes seen in hHcy hearts are correlated with increased 
collagen deposition and myocardial fibrosis, as seen in rats fed MD for 10 weeks (Devi, et al., 
2006).  If the structural changes in the LV were progressive up to 8 weeks of MD feeding, then 
heparin‟s ability to prevent the increases seen in LVSP and LVEDP may be related to protecting 
the LV from hHcy dependent remodelling.  Yajima et al. (2005) found that when heparin and 
fibroblast growth factor-2 (FGF-2), a heparin-binding protein that induces angiogenesis, are 
injected into the myocardium of rats with heart failure, that myocardial shortening and therefore 
LV ejection fraction, as well as the heart-to-body weight ratio were significantly improved.  
Brain natriuretic peptide (BNP) is a sensitive marker for heart failure, secreted in response to 
increased ventricular wall tension reflecting changes in ventricular function another marker of 
heart failure (Yasuda, et al., 1999).  Atrial natriuretic peptide (ANP) is released only during LV 
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hypertrophy in rats (Yajima, et al., 2005).  Yasuda et al. (1999) and Yajima et al. (2005) 
demonstrated that heparin treatment decreases BNP alone or both ANP and BNP respectively.  
Furthermore, Yajima et al. (2005) correlate heparin and FGF-2 activity, known to release NO 
and be anti-apoptotic, as being responsible for normalizing systolic LV wall stress and 
decreasing myocardial stiffness, allowing for greater muscle contraction at a given preload 
(Matsubara, et al., 1998).  These results indicate that heparin may have prevented an increase in 
LVEDP and LVSP by inhibiting or retarding the progressive remodelling of the LV cause by 
elevated plasma Hcy levels.   
Another finding of this study was a significant increase in LVDP in MD fed rats treated 
with heparin as compared to controls, but the increase in LVDP in the diet group alone failed to 
be significant.  The developed pressure of the LV is an indication of the relative increases to both 
LVSP and LV diastolic pressure.  Because LVSP and LVEDP were both significantly elevated in 
the MD group, this offset any increase in LVDP explained by reduced ejection fraction, 
incomplete LV emptying and therefore increased diastolic pressure.  In the heparin group 
however, the small increase in LVSP (119.9 mmHg) as compared to control (112.3 mmHg) was 
likely exacerbated by a presumable decrease in LV diastolic pressure, resulting in a significantly 
elevated LVDP (111.4 mmHg) compared to controls.  The diastolic pressure in the heparin group 
could be related to an overall improvement in systolic and diastolic function if indeed LV 
hypertrophy and fibrosis were inhibited.   
Lastly, there were no significant changes seen in the myocardial indicies of contraction or 
relaxation in this heparin study.  In the earlier study, MD feeding by 8 weeks signficantly 
decreased + dp/dt compared to controls.  The trend is similar in this study however insignificant.  
Additionally, heparin appears to increase + dp/dt back to control levels, again insignificantly.  As 
previously discussed, the negative changes seen in + dp/dt are likely correlated to the onset of 
heart failure in the MD fed rats.     
Because oral heparin treatement was able to attenuate the development of hypertension in 
the MD fed rats, and it is known to be endothelium protective, it is believed that the 
homocysteine induces changes in hemodynamic parameters is caused by endothelial dysfunction 
and subsequently increased TPR.  Changes seen to the hemodynamic parameters of the LV were 
consequential of the initiating increases in arterial BP.  Prolonged investigation of the diet model 
used in these experiements would reveal the development of heart failure, seen as further 
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compromised LV ejection fractions and increased LVEDP and changes in the myocardial indices 
of contractility and relaxation. 
 
4.5. ELEVATED PLASMA HOMOCYSTEINE AND LIPID PEROXIDATION 
Malondialdyhyde (MDA) is a product of lipid metabolism and is used as an experimental 
biomarker of oxidative stress.  Domagala et al., (1997), Hcy levels are positively correlated with 
MDA levels.  However, in their study, the lowest concentration of Hcy tested in conjunction with 
MDA levels was > 30 µmol/L and MDA levels were maximal at 1 mmol/L, which is beyond 
realistic physiological concentrations (Domagala, Libura, & Szczeklik, 1997).  In a simliar study, 
Ventura et al. (2000) found that only acute increases in plasma Hcy after methionine loading 
caused significant increased MDA levels.  The peak oxidative damage seen by Ventura et al. 
(2000) occurred eight hours post-methionine load.  Heydrick et al. (2004) measuring isoprostane 
levels as a marker of lipid peroxidation, showed that Hcy dose dependently increased total 
isoprostanes with a discernable effect at 50 µmol/L Hcy, and significant observations at 300 
µmol/L Hcy.  Weiss et al. (2003) indicate that in a stereospecific manner, only the L-isoform but 
not the D-isoform of Hcy increases total isoprostane levels in endothelial cell cultures.  Weiss et 
al. (2003) have also shown that loading endothelial cell cultures with catalase had no effect on 
lipid peroxidation, excluding the role of hydrogen peroxide in the process.  Dudman et al. (1991) 
and Wall et al. (1980) both show that hHcy induces hydrogen peroxide dependent oxidative 
damage to endothelial cell cultures.   
Many of the previous findings were made at non-physiological levels of plasma Hcy, 
rendering them unrealistic for comparison with this study.  The results of the present study were 
performed in fasted animals, with significantly lower total plasma Hcy concentrations than peak 
levels, seen eight hours after methionine loading (Chambers, Obeid, & Kooner, 1999).  Also at 
this time it is entirely probable that MDA was already removed from the serum or tissue samples 
either by oxidation, or by forming protein adducts (Farmer & Davoine, 2007).  Rat tissue MDA 
levels reported in the literature range from 0.3 – 10 nmol/mg (Ataie, et al., 2010) (Kiziler, et al., 
2008), which are in agreement with this study.  High-methionine diet feeding did not appear to 
signficantly increase MDA concentrations in serum, LV, kidney, mesentery or aortic samples in 
this study.  However, there is a trend towards decreased tissue MDA levels in the MD and MD 
plus heparin group as compared to control tissues.  There are several explainations for this trend.  
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Firstly, the trend may be due to physiological and heparin dependent detoxification and 
elimination of free Hcy from the blood.  Total plasma Hcy concentrations comprised of 
approximately 80% protein bound Hcy and 2% free Hcy (Jakubowski, 2004).  The free fraction 
of Hcy is the most biologically active form.  Given the already very low concentrations of Hcy in 
this study after fasting, the residual free fraction of Hcy would be very minimal.  Furthermore, 
the free fraction of Hcy is readily available for sequestration into further protein adducts, Hcy-
thiolactone, or even S-nitrosohomocysteine.  S-nitrosohomocysteine is an adduct between NO 
and Hcy, which may be a detoxifying mechanism for protection against endothelial cell lipid 
peroxidation.  Fu et al. (2002) claim that endothelial cells will increase NO production 
facilitating the formation of the adduct, thereby reducing the bioavailability of Hcy.  Heparin 
would further potentiate this effect as it is shown to anchor vasostatin-1, encouraging eNOS 
activation (Ramella, et al. 2010).   S-nitrosohomocysteine has been shown to be protective in 
many ways against Hcy toxicity including the prevention of endothelial cell apoptosis and the 
proliferation of VSM cells (Stamle, et al., 1993).  Similarily, Lee et al. (2005) have shown that 
the NO donor, s-nitroso-N-acetylpenicillamine (SNAP) increases NO levels in vitro forming S-
nitrosohomocysteine, thereby inhibiting ROS generation of Hcy sulfhydryl groups and 
furthermore inhibited Hcy dependent MDA increases.  Therefore, it is reasonable that due to the 
reduced bioavailability of free Hcy, either by fasting or adduct formation, that MDA levels 
should be similar to controls, which were seen in this study. 
High-methionine diet feeding signficanly increased MDA levels in liver samples 
compared to heparin treatment and signficantly decreased levels in kidney samples compared to 
controls.  Hepatic uptake of Hcy happens readily and therefore may act as a sink for Hcy.  The 
increase seen in liver MDA is likely related to its overall exposure to Hcy.  Heparin, acting to 
encourage Hcy adduct formation reducing its bioavailability, may have attenuated the increase in 
MDA levels. The significant decrease of MDA levels seen in the kidneys of the MD group as 
compared to controls, and insignificant decrease compared to the heparin treated group, may be 
due in part to the generation of thiol antioxidants, inhibiting lipid peroxidation.  The kidneys are 
capable of Hcy transsulfuration, producing cysteine and GSH.  N-acetylcysteine, a derivative of 
L-cysteine, has been suggested to be a very powerful antioxidant, alone or by acting as a 
precursor for GSH (Han, et al., 1997).  Zembron-Lacny et al. (2009) have shown that N-
acetylcysteine markedly decreases lipid peroxidation measured in healthy, male subjects.  If 
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kidney exposure to elevated levels of Hcy increased its transsulfuration into cysteine, then it is 
likely that N-acetylcysteine levels may increase protecting the organ from lipid peroxidation.  
However, the aforementioned rationales are purely speculative.  Therefore this study finds that 
there was no clear association between MDA and Hcy levels, and therefore the potential 
antioxidant effect of heparin could not be corroborated.                  
It should also be noted that the serum MDA results seen in this study are unusually high 
(20 – 30 nmol/ml) compared with the results of other studies using much higher Hcy 
concentrations (0.5 – 2 nmol/ml) (Domagala, Libura, & Szczeklik, 1997) (Ventura, et al., 2000).  
The marked increase in serum MDA levels as compared to similar studies is likely from sample 
contamination due to partial red blood cell (RBC) hemolysis.  The serum samples collected for 
the MDA assay were drawn through a small gauge cannula inserted into the femoral artery after 
the hemodynamic study.  The serum samples withdrawn from the collection tubes after 
centrifugation had a notable red colour, likely caused by RBC hemolysis during sampling.  RBC 
are sensitive to membrane lipid peroxidation and the oxidation of hemoglobin (Melchiorri, 
Reiter, & Sewerynek, 1995).  When RBCs are present in serum samples at very low levels, 1 x 
10
8
 RBC/ml, MDA concentrations increase significantly (Hooser, et al., 2000).  Therefore, the 
results of this study are not suitable for comparison with others.  However, because the literature 
thus far indicates that signficant MDA levels in serum are attained only with moderate to severe 
hHcy levels, the probability of seeing any positive association was very unlikely.  In conclusion, 
there was no direct evidence indicating that increased fasting plasma homocysteine levels caused 
increases in lipid peroxidation by measuring MDA levels. 
 
4.6. ELEVATED PLASMA HOMOCYSTEINE AND GLUTATHIONE 
Hempel (1998) suggested that hHcy sensitizes endothelial cells to oxidative stress by 
reducing glutathione levels.  Chern et al. (2001) have also shown that folate-deficient human 
hepatoma cells had suppresed intracellular GSH content.  Prolonged exposure to MD 
significantly decreased plasma GSH levels as compared to control.  There also appears to be a 
trend towards heparin restoring plasma GSH levels.  The concentration of reduced glutathione 
(GSH) in control plasma samples measured in this study were 4.24 ±0.94 µmol/L, which are in 
accord with other findings that report a range from 2.14 – 6.37 µmol/L GSH in healthy human 
plasma (Mansoor, Svardal, & Ueland, 1992).  The redox ratio of GSH to oxidized glutathione 
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(GSSG) is an important indicator of oxidative stress.  In its reduced state, GSH readily acts as a 
proton donor to detoxify hydrogen peroxide.  The redox activity of GSH is dependent on 
glutathione peroxidase (GPx) which catalyzes the conversion of reduced GSH to GSSG.  A 
decrease in GSH levels can therefore be indicative of increased ROS scavenging.  However, this 
rationale would be more conclusive if GSSG levels were available for comparison.  More 
commonly, studies indicate that hHcy reduces the function and expression of GPx, hindering the 
glutathione cycle thereby increasing oxidative stress (Lubos, Loscalzo and Handy, 2007) (Robin 
et al., 2004) (Jakubowski, 2004).  Inhibition of GPx is associated with free Hcy concentrations of 
1 – 5 µmol/L  (Chen, et al., 2000).  The free Hcy concentrations in this study were maximally 
estimated at 0.2  µmol/L, based on the estimation of free Hcy being approximately 2% of the 
total fraction, making GPx inhibition unlikely.  Regardless of the mechanism, the significant 
decrease seen in plasma GSH levels in MD fed rats is convincing of increased Hcy induced 
oxidative stress.   
Furthermore, it is very interesting that heparin appears to be attenuating the decrease in 
GSH levels.  In the LV, we found that GSH concentrations were significantly elevated in the 
heparin treated group as compared with the MD fed rats.  Additionally, in the kidney, there was a 
non-significant trend towards an increase in GSH concentrations in the heparin treated group as 
compared to the MD and control rats.  Singh et al., (2008) reported LV GSH concentrations of 
hHcy rats equal to 0.30 µmol/mg protein, which are similar to the findings in this study.  They 
have also shown that mast cell stabilizers prevent cellular heparin release and changes in 
intracellular LV GSH concentrations (Singh, Singh, and Balakumar, 2008).  There is a lot of new 
interest in the role of the multidrug resistance protein (MRP1) in the regulation and transport of 
GSH.  Multidrug resistance proteins function as ATP dependent anion export pumps (Ballatori, 
Krance, Marchan, & Hammond, 2009).  The substrate specificity of MRP1 for GSH compared to 
GSSG is approximately 1:100, indicating that GSSG is preferentially exported by MRP1 after 
GSH oxidation (Leier, et al., 1994).  Angelini et al. (2007) have shown that unfractionated 
heparin treatment in human leukocytes enhances glutathione export via MRP, in an non-
oxidative environment.  This could explain the increased serum GSH concentrations in the 
heparin treated group.  The results of this study indicate that elevated Hcy levels induced 
oxidative stress, and since it is not believed that GPx activity was reduced, then GSSG levels 
would increase, as would their export in the presence of heparin.  In this scenario, GSH levels 
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would decrease initially because of ROS detoxification, however, synthesis of new GSH would 
ensue, given the higher levels of Hcy.  As per Chang (2007), MRP1 expression is high in the 
kidneys, cardiac muscle and erythrocytes, again potentially corresponding to the elevated GSH 
concentrations seen with heparin treatment in those areas.   
Oral heparin treatment attenuated the decreases seen in GSH concentrations most tissues 
caused by elevated fasting plasma Hcy levels.  This suggests that heparin can either ameliorate 
tissue antioxidant status by detoxifying ROS directly or by encouraging antioxidant formation.  
Both mechanisms would be endothelium protective in a pro-oxidant atmosphere, suggested to be 
the pathological mechanism of hHcy.    
 
4.7. ELEVATED PLASMA HOMOCYSTEINE AND ENDOTHELIAL CELL 
APOPTOSIS 
  It is widely accepted that hHcy causes endothelial cell dysfunction, and recently it is 
believed to be partially associated with Hcy induced endothelial cell apoptosis.  Endothelial 
function is dependent on a balance between pro- and anti-apoptotic signals, and disruptions to 
this system causes the pathogenesis of vascular disease (Stefanec, 2000).  Lee et al. (2005) have 
shown that Hcy-mediated cell death of human umbilical vein endothelial cells displayed typical 
apoptotic features which included nuclear fragmentation and chromatin condensation, and that 
co-treatment of apoptosis inhibitors decreased the appearance of the classic morphological 
changes, confirming that Hcy caused endothelial cell apoptosis.  In the this study, elevated total 
Hcy concentrations significantly increased the percent of apoptotic endothelial cells in the aorta 
and superior mesenteric artery of MD fed rats.  Additionally, heparin treatment significantly 
prevented the apoptosis of mesenteric endothelial cells and appeared to decrease the number of 
apoptotic aortic endothelial cells in the current study.  Firstly, apoptosis can be triggered by 
physical (radiation, mechanical damage), chemical (ROS, pharmaceuticals) or biological 
(receptor-mediated) signals  (Freyssinet, et al., 1999).  It was predicted, as per the oxidative 
hypothesis for hHcy, that increased oxidative stress would induce endothelial cell apoptosis in 
MD fed rats.  The TUNEL stain used to detect positive apoptotic cells, does not discriminate 
between effectors involved in the apoptosis process.  However, many other studies have chosen 
to measure apoptosis by way of its associated effectors such as the caspases, cytochrome C of the 
Bcl-2/Bax family of apoptotic proteins  (Freyssinet, et al., 1999).  In a method similar to that of 
136 
 
Chern et al. (2001), this study shows that in conjunction with increased cellular apoptosis are 
decreased levels of GSH, implicating oxidative stress as the primary mediator of Hcy dependent 
apoptosis.  In the model by Chern et al. (2001), increased Hcy concentrations induced apoptosis 
in a process dependent on hydrogen peroxide formation.  Their study indicated that hydrogen 
peroxide activated nuclear transcription factor kappa B, which facilitates the expression of pro-
apoptotic genes  (Chern, et al., 2001).  Lee et al. (2005) also demonstrated that Hcy, in an ROS 
dependent manner, causes caspase-induced apoptosis in endothelial cells.   
It was seen that the most significant decreases in GSH concentration, due to elevated Hcy 
levels were in the LV and plasma.  Correspondingly, the amount of apoptotic endothelial cells in 
the aortic tissue of MD fed rats was significantly elevated.  These results indicate that the redox 
capacity of the plasma and LV were compromised by decreased GSH, and the aorta, already 
under high-mechanical stress, would be the first site to encounter increased ROS, thereby having 
a greater risk for ROS dependent endothelial cell apoptosis.  The superior mesenteric artery 
branches off of the abdominal aorta, prior to the renal artery.  Similarily to the aorta, the superior 
mesenteric artery would be the second tissue, investigated in this study, to be exposed to 
increased ROS coming from the LV and plasma, thereby explaining its significant number of 
apoptotic endothelial cells.  Lastly, there was no difference in the percent of apoptotic 
endothelial cells between all treatment and control groups in the renal artery, also branching off 
of the abdominal aorta, inferior to the mesenteric artery.  Correspondingly, the GSH levels 
measured in the kidneys were unchanged by MD feeding, and thus the redox potential of this 
tissue, was not compromised and therefore likely not subjected to oxidative stress induced 
endothelial cell apoptosis. 
  There is a wealth of evidence indicating that NO mediates apoptosis.  Firstly, low levels 
of endogenous NO production have been shown to prevent oxidative stress induced endothelial 
cell apoptosis through s-nitrosylation (Kwon, et al., 2001).  Furthermore, Lee et al. (2005) 
confirmed that endogenous NO production interacts with Hcy to form S-nitrosohomocysteine, 
suppressing ROS formation and apoptosis treated with 1 mmol/L Hcy.  Lee et al. (2005) 
attributed 50% of NO-dependent inhibition of apoptosis to only a 25% ratio between S-
nitrosohomocysteine and Hcy.  This result indicates that the concentration of NO in the 
endothelium can be directly correlated with the pro-apoptotic, pathogenic activity of Hcy.  
Heparin has already been discussed in detail pertaining to its ability to increase NO production 
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through cell-surface facilitated transport of vasoactive substances.  Therefore, heparin treatment 
may have increased NO production in the endothelium of the aorta and superior mesenteric bed 
protecting against apoptosis by either sequestering Hcy through the formation or S-
nitrosohomocysteine, or by direct action on pro-apoptotic effectors such as the caspases or NF-
кB. 
Elevated plasma Hcy levels caused endothelial dysfunction by increasing the amount of 
apoptotic endothelial cell death in vascular tissue samples.  This evidence further corroborates 
the conclusion that changes in the hemodynamics of rats with increased Hcy levels were seen 
because of increased oxidative stress which was deleterious to the endothelium, causing 
increased TPR and arterial BP, overtime possibly leading to heart failure, seen in this study as 
increasing LVEDP and subsequent LVSP. 
 
5.0. CONCLUSION 
The results of the present study suggest that (i) a high methionine diet fed to male WKY 
rats significantly elevates plasma Hcy levels by 2 weeks of feeding.  (ii) The hemodynamics of 
animals anesthetized with halothane versus isoflurane are significantly different, and therefore 
the results from each are considered inappropriate for comparison.  (iii) Elevated plasma Hcy 
increase arterial blood pressures as well as LVEDP and LVSP.  The increase in LVSP may 
reflect the development of hypertension as per an increase in afterload.  The large increase in 
LVEDP reflects a highly significant change in LV preload and/or a decrease in the myocardial 
index of contractility.  The changes seen in LVEDP suggests that elevated plasma Hcy levels 
may lead to heart failure.  Oral heparin treatment reversed the elevation in arterial blood pressure 
caused by elevated plasma Hcy levels, suggesting its possible role as a treatment for 
hypertension.  Furthermore, LVEDP elevation by elevated plasma Hcy was substantially reduced 
with oral heparin treatment.  This result indicates that oral heparin may prevent the onset of 
hypertension by protecting the endothelium thus decreasing the LV workload.  (iv) There was no 
clear association of elevated plasma Hcy levels causing increased lipid peroxidation with respect 
to MDA levels.  However, the significant decrease seen in plasma GSH concentrations 
associated with MD feeding indicates that there is a positive correlation between elevated plasma 
Hcy and oxidative stress.  Oral heparin treatment was seen to attenuate the decrease in GSH 
levels suggesting that it may have antioxidant activity.   (v) Elevated Hcy levels were positively 
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correlated with increased endothelial cell apoptosis, yet was suppressed by oral heparin 
treatment.    
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